<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Macrolides versus placebo for chronic asthma - Undela, K - 2021 | Cochrane Library</title> <meta content="Macrolides versus placebo for chronic asthma - Undela, K - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002997.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Macrolides versus placebo for chronic asthma - Undela, K - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002997.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002997.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Macrolides versus placebo for chronic asthma" name="citation_title"/> <meta content="Krishna Undela" name="citation_author"/> <meta content="National Institute of Pharmaceutical Education and Research Guwahati" name="citation_author_institution"/> <meta content="Lucy Goldsmith" name="citation_author"/> <meta content="St George's, University of London" name="citation_author_institution"/> <meta content="Kayleigh M Kew" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Giovanni Ferrara" name="citation_author"/> <meta content="University of Alberta and Alberta Health Services" name="citation_author_institution"/> <meta content="ferrara@ualberta.ca" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD002997.pub5" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/11/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002997.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002997.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002997.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti-Bacterial Agents [adverse effects]; *Asthma [drug therapy]; Disease Progression; Macrolides [therapeutic use]; *Quality of Life" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002997.pub5&amp;doi=10.1002/14651858.CD002997.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002997.pub5&amp;doi=10.1002/14651858.CD002997.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002997.pub5&amp;doi=10.1002/14651858.CD002997.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002997.pub5&amp;doi=10.1002/14651858.CD002997.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002997.pub5&amp;doi=10.1002/14651858.CD002997.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002997.pub5&amp;doi=10.1002/14651858.CD002997.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002997.pub5&amp;doi=10.1002/14651858.CD002997.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002997.pub5&amp;doi=10.1002/14651858.CD002997.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002997.pub5&amp;doi=10.1002/14651858.CD002997.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002997.pub5&amp;doi=10.1002/14651858.CD002997.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002997.pub5&amp;doi=10.1002/14651858.CD002997.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002997.pub5&amp;doi=10.1002/14651858.CD002997.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002997.pub5&amp;doi=10.1002/14651858.CD002997.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002997.pub5&amp;doi=10.1002/14651858.CD002997.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002997.pub5&amp;doi=10.1002/14651858.CD002997.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002997.pub5&amp;doi=10.1002/14651858.CD002997.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002997.pub5&amp;doi=10.1002/14651858.CD002997.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002997.pub5&amp;doi=10.1002/14651858.CD002997.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002997.pub5&amp;doi=10.1002/14651858.CD002997.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002997.pub5&amp;doi=10.1002/14651858.CD002997.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002997.pub5&amp;doi=10.1002/14651858.CD002997.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002997.pub5&amp;doi=10.1002/14651858.CD002997.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002997.pub5&amp;doi=10.1002/14651858.CD002997.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="IYhCEbRn";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002997\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002997\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002997\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002997\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","de","zh_HANT","th","ms","hr","fa","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002997.pub5",title:"Macrolides versus placebo for chronic asthma",firstPublishedDate:"Nov 22, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IYhCEbRn&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002997.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002997.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002997.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002997.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002997.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002997.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002997.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002997.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002997.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002997.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3539 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002997.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002997.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002997.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002997.pub5/full#CD002997-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002997.pub5/full#CD002997-sec-0078"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002997.pub5/full#CD002997-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002997.pub5/full#CD002997-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002997.pub5/full#CD002997-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002997.pub5/full#CD002997-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002997.pub5/full#CD002997-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002997.pub5/full#CD002997-sec-0072"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002997.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002997.pub5/appendices#CD002997-sec-0083"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002997.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002997.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/supinfo/CD002997StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/supinfo/CD002997StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002997.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002997.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002997.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002997.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002997.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002997.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Macrolides versus placebo for chronic asthma</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002997.pub5/information#CD002997-cr-0004">Krishna Undela</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002997.pub5/information#CD002997-cr-0005">Lucy Goldsmith</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002997.pub5/information#CD002997-cr-0006">Kayleigh M Kew</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002997.pub5/information#CD002997-cr-0007"><i class="icon corresponding-author fa fa-envelope"></i>Giovanni Ferrara</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/information/en#CD002997-sec-0103">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 November 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002997.pub5">https://doi.org/10.1002/14651858.CD002997.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002997-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002997-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002997-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002997-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002997-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD002997-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002997-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002997-abs-0001" lang="en"> <section id="CD002997-sec-0001"> <h3 class="title" id="CD002997-sec-0001">Background</h3> <p>Asthma is a chronic disease in which inflammation of the airways causes symptomatic wheezing, coughing and difficult breathing. Macrolides are antibiotics with antimicrobial and anti‐inflammatory activities that have been explored for the long‐term control of asthma symptoms. </p> </section> <section id="CD002997-sec-0002"> <h3 class="title" id="CD002997-sec-0002">Objectives</h3> <p>To assess the effects of macrolides compared with placebo for managing chronic asthma.</p> </section> <section id="CD002997-sec-0003"> <h3 class="title" id="CD002997-sec-0003">Search methods</h3> <p>We searched the Cochrane Airways Group Specialised Register up to March 2021. We also manually searched bibliographies of previously published reviews and conference proceedings and contacted study authors. We included records published in any language in the search. </p> </section> <section id="CD002997-sec-0004"> <h3 class="title" id="CD002997-sec-0004">Selection criteria</h3> <p>We included randomised controlled clinical trials (RCTs) involving both children and adults with asthma treated with macrolides versus placebo for four or more weeks. Primary outcomes were exacerbation requiring hospitalisation, severe exacerbations (exacerbations requiring emergency department (ED) visits or systemic steroids, or both), symptom scales, asthma control questionnaire (ACQ, score from 0 totally controlled, to 6 severely uncontrolled), Asthma Quality of Life Questionnaire (AQLQ, with score from 1 to 7 with higher scores indicating better QoL), rescue medication puffs per day, morning and evening peak expiratory flow (PEF; litres per minutes), forced expiratory volume in one second (FEV<sub>1</sub>; litres), bronchial hyperresponsiveness, and oral corticosteroid dose. Secondary outcomes were adverse events (including mortality), withdrawal, blood eosinophils, sputum eosinophils, eosinophil cationic protein (ECP) in serum, and ECP in sputum. </p> </section> <section id="CD002997-sec-0005"> <h3 class="title" id="CD002997-sec-0005">Data collection and analysis</h3> <p>Two review authors independently examined all records identified in the searches then reviewed the full text of all potentially relevant articles before extracting data in duplicate from all included studies. As per protocol, we used a fixed‐effect model. We conducted a sensitivity analysis for analyses with high heterogeneity (I<sup>2</sup> greater than 30%). GRADE was used to assess the certainty of the body of evidence. </p> </section> <section id="CD002997-sec-0006"> <h3 class="title" id="CD002997-sec-0006">Main results</h3> <p>Twenty‐five studies met the inclusion criteria, randomising 1973 participants to receive macrolide or placebo for at least four weeks. Most of the included studies reported data from adults (mean age 21 to 61 years) with persistent or severe asthma, while four studies included children. All participants were recruited in outpatient settings. Inclusion criteria, interventions and outcomes were highly variable. </p> <p>The evidence suggests macrolides probably deliver a moderately sized reduction in exacerbations requiring hospitalisations compared to placebo (odds ratio (OR) 0.47, 95% confidence interval (CI) 0.20 to 1.12; studies = 2, participants = 529; moderate‐certainty evidence). Macrolides probably reduce exacerbations requiring ED visits and/or treatment with systemic steroids (rate ratio (RaR) 0.65, 95% CI 0.53 to 0.80; studies = 4, participants = 640; moderate‐certainty evidence). Macrolides may reduce symptoms (as measured on symptom scales) (standardised mean difference (SMD) −0.46, 95% CI −0.81 to −0.11; studies = 4, participants = 136 ; very low‐certainty evidence). Macrolides may result in a little improvement in ACQ (SMD −0.17, 95% CI −0.31 to −0.03; studies = 5, participants = 773; low‐certainty evidence). Macrolides may have little to no effect on AQLQ (mean difference (MD) 0.24, 95% CI 0.12 to 0.35; studies = 6, participants = 802; very low‐certainty evidence). For both the ACQ and the AQLQ the suggested effect of macrolides versus placebo did not reach a minimal clinically important difference (MCID, 0.5 for ACQ and AQLQ) (ACQ: low‐certainty evidence; AQLQ: very low‐certainty evidence). Due to high heterogeneity (I<sup>2</sup> &gt; 30%), we conducted sensitivity analyses on the above results, which reduced the size of the suggested effects by reducing the weighting on the large, high quality studies.  </p> <p>Macrolides may result in a small effect compared to placebo in reducing need for rescue medication (MD −0.43 puffs/day, 95% CI −0.81 to −0.04; studies = 4, participants = 314; low‐certainty evidence). Macrolides may increase FEV<sub>1</sub>, but the effect is almost certainly below a level discernible to patients (MD 0.04 L, 95% CI 0 to 0.08; studies = 10, participants = 1046; low‐certainty evidence). It was not possible to pool outcomes for non‐specific bronchial hyperresponsiveness or lowest tolerated oral corticosteroid dose (in people requiring oral corticosteroids at baseline). There was no evidence of a difference in severe adverse events (including mortality), although less than half of the studies reported the outcome (OR 0.80, 95% CI 0.49 to 1.31; studies = 8, participants = 854; low‐certainty evidence). Reporting of specific adverse effects was too inconsistent across studies for a meaningful analysis. </p> </section> <section id="CD002997-sec-0007"> <h3 class="title" id="CD002997-sec-0007">Authors' conclusions</h3> <p>Existing evidence suggests an effect of macrolides compared with placebo on the rate of exacerbations requiring hospitalisation. Macrolides probably reduce severe exacerbations (requiring ED visit and/or treatment with systemic steroids) and may reduce symptoms. However, we cannot rule out the possibility of other benefits or harms because the evidence is of very low quality due to heterogeneity among patients and interventions, imprecision and reporting biases. The results were mostly driven by a well‐designed, well powered RCT, indicating that azithromycin may reduce exacerbation rate and improve symptom scores in severe asthma. </p> <p>The review highlights the need for researchers to report outcomes accurately and according to standard definitions. Macrolides can reduce exacerbation rate in people with severe asthma. Future trials could evaluate if this effect is sustained across all the severe asthma phenotypes, the comparison with newer biological drugs, whether effects persist or wane after treatment cessation and whether effects are associated with infection biomarkers. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002997-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002997-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD002997-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD002997-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002997-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002997-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD002997-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD002997-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD002997-abs-0013">Polski</a> </li> <li class="section-language"> <a class="" href="full/th#CD002997-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002997-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD002997-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002997-abs-0002" lang="en"> <h3>Should macrolides be used for chronic asthma?</h3> <p><b>Main point:</b> the existing evidence suggests a benefit of macrolides compared to placebo for reducing exacerbations requiring hospitalisation and severe exacerbations (defined as exacerbations requiring emergency department visit/treatment with systemic steroids). The effect of macrolides on other relevant clinical outcomes such as symptom scales and lung function is still unclear. </p> <p><b>Background</b> </p> <p>Asthma is a chronic disease in which inflammation of the airways leads to coughing, wheezing and breathing problems. There are probably different reasons for this inflammation and why it persists, and these may require different treatments. Infection in the lungs may be one cause, and macrolides are a type of antibiotic that may be used long term as a way of improving symptoms for these people. </p> <p><b>How we answered the question</b> </p> <p>We looked for studies on adults or children with asthma who were either given a macrolide or placebo (pretend treatment) for at least four weeks to see if it improved their symptoms and made it less likely for them to have an asthma attack, often referred to as an 'exacerbation'. We carried out our most recent search for studies in March 2021. After finding all the relevant studies, we collected information about asthma attacks requiring hospital admission, asthma attacks that needed to be treated with oral steroids, symptom scores, asthma control, quality of life, several measures of lung function, the need for rescue inhalers, serious side effects and measures of asthma activity in blood and sputum (mucous). </p> <p><b>What we found</b> </p> <p>We found 25 studies, including two new ones that had been published since the last search was done in 2015. Overall, almost 2000 people received either macrolides or placebo. There were many problems in the way studies were described and how well they reported data, which made us consider the overall evidence to be low quality, undermining our confidence in most of the results. The studies were quite different from each other, for example in the severity of people's asthma, the type of macrolide they were given and the length of the treatment period. </p> <p>Our review showed that macrolides were better than placebo in reducing exacerbations and may have benefits for some people in improving asthma symptoms, asthma control, asthma quality of life and some measures of lung function, but how much benefit and for whom are uncertain. Based on one well conducted study, the macrolide azithromycin may have some benefit for people with severe asthma, but overall the findings of this review do not support the use of macrolides for all asthma of any grade or severity. There were no reports of serious side effects of macrolides, but 16 studies did not report whether any occurred. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002997-sec-0078" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002997-sec-0078"></div> <h3 class="title" id="CD002997-sec-0079">Implications for practice</h3> <section id="CD002997-sec-0079"> <p>Existing evidence suggests an effect of macrolides compared with placebo on the rate of exacerbations requiring hospitalisation. Macrolides probably reduce exacerbations requiring emergency department visit/treatment with systemic steroids and may reduce symptoms. Based on one well‐designed and powered randomised controlled trial, azithromycin may reduce exacerbation rate and improve symptom scales in people with severe asthma but overall we cannot rule out the possibility of other benefits or harms because the evidence is of low certainty due to heterogeneity among participants and interventions, imprecision and reporting biases (<a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a>). </p> </section> <h3 class="title" id="CD002997-sec-0080">Implications for research</h3> <section id="CD002997-sec-0080"> <p>The review highlights the need for researchers to report clinically relevant outcomes accurately and completely using guideline definitions of exacerbations, validated symptoms and quality of life scales, as well as international scales for adverse effects. The review and meta‐analysis showed that macrolides can lead to a reduction of exacerbation rate and future trials could evaluate if this effect is sustained across all the severe asthma phenotypes and in comparison with newer biological drugs, whether effects persist or wane after treatment cessation, and are associated with infection biomarkers. Trials with prespecified subgroup analyses by asthma severity or phenotype would usefully contribute to the literature. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002997-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002997-sec-0008"></div> <div class="table" id="CD002997-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Macrolides compared to placebo for chronic asthma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Macrolide versus placebo for chronic asthma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with chronic asthma<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> macrolide </p> <p>Drugs used were clarithromycin, azithromycin, roxithromycin and troleandomycin. Macrolide was given once or twice daily in most studies for 4–52 weeks (median 8 weeks).<br/><b>Comparison:</b> placebo </p> <p>Treatment durations were calculated as weighted means of the studies included in each analysis. </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes<sup>a</sup> </b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed comparator risk**</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Macrolide</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbation requiring hospitalisation</b> </p> <p>Weighted mean study duration: 45 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> <p>(13 to 68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.47</b> </p> <p>(0.20 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>529</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe exacerbations (requiring ED visits or systemic steroids, or both)</b> </p> <p>Number of people having ≥ 1 exacerbations requiring an ED visit or systemic steroids, or both. </p> <p>Classification varied across studies.</p> <p>Weighted mean study duration: 35 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>410 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>311 per 1000<br/>(269 to 357) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rate ratio 0.65</b><br/>(0.53 to 0.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>640<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma symptoms – symptom scales (various scales; lower score = better)</b> </p> <p>Weighted mean study duration: 10 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean change in symptom scales in the intervention group compared to the control group was a reduction; <b>0.46 SD lower</b> (0.81 SD lower to 0.11 SD lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>e,f,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The SMD is a Cohen's effect size and can be interpreted as moderate (&lt; 0.4 = small, 0.40–0.70 = moderate, &gt; 0.70 = large). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma control (Asthma Control Questionnaire)</b> </p> <p>Scored 0–6 (lower scores indicate improvement in asthma control)</p> <p>Weighted mean study duration: 34 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean change in asthma control in the intervention group compared to the mean change in control group was a greater reduction;<b>0.17 SD lower</b> (0.31 SD lower to 0.03 SD lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>773<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>d,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The SMD is a Cohen's effect size and can be interpreted as small.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma quality of life (AQLQ)</b> </p> <p>Scored 1–7 (higher scores indicate improvement in quality of life)</p> <p>Weighted mean study duration: 35 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change on the AQLQ scale in the control group was an increase from baseline; <b>0.31 points higher</b>** </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in AQLQ in the intervention group compared to the mean change in the control group was an increase; <b>0.24 points higher</b> (0.12 higher to 0.35 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>802<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>c,d,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID: 0.5 points</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rescue medication (puffs/day)</b> </p> <p>Weighted mean study duration: 17 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rescue medication use in the control group was <b>1.08</b> puffs/day** </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in rescue medication puffs/day in the intervention group compared to the mean change in the control group was reduction; <b>0.43 fewer puffs</b> (0.81 fewer to 0.04 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>314<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>d,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (L)</b> </p> <p>Weighted mean study duration: 28 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean FEV<sub>1</sub> in the control group was <b>2.49</b> L** </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> (L) the intervention group compared to the control group was an increase; <b>0.04 L higher</b> (0 L to 0.08 L higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1046<br/>(10 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>h,i,j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Although there is no universally accepted MCID for FEV<sub>1</sub> in asthma, variability within a single testing session can be up to 0.12 L (data from a mixed pool of respiratory patients; <a href="./references#CD002997-bbs2-0068" title="EnrightPL , BeckKC , SherrillDL . Repeatability of spirometry in 18,000 adult patients. American Journal of Respiratory and Critical Care Medicine2004;169:235-8. [DOI: 10.1164/rccm.200204-347OC]">Enright 2004</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>(including mortality)</p> <p>Weighted mean study duration: 16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>93 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 1000<br/>(50 to 118) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.80</b><br/>(0.49 to 1.31) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>854<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>i,k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>**Assumed risk for continuous outcomes were calculated as weighted means of the scores in the control group. Note: <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a> could not be included in the rescue medication or quality of life calculations because they reported only mean difference between groups; <a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a> was not included in the FEV<sub>1</sub> calculation because it was the only change score; <a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a> was not included in the asthma control or quality of life calculations because it was the only study reporting absolute endpoint scores rather than change from baseline. </p> <p><b>AQLQ:</b> Asthma Quality of Life Questionnaire; <b>CI:</b> confidence interval; <b>ED:</b> emergency department; <b>FEV<sub>1</sub>:</b> forced expiratory volume in one second; <b>MCID:</b> minimal clinically important difference; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>SD:</b> standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE domains: study limitations, consistency of effect, imprecision, indirectness and publication bias. GRADE Working Group grades of evidence (<a href="./references#CD002997-bbs2-0101" title="Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). In: Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Schünemann 2021</a>).<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Two primary outcomes (morning and evening peak expiratory flow) are not presented. Bronchial hyperresponsiveness could not be pooled in a meta‐analysis and is described narratively in the review. Studies did not report lowest tolerated oral corticosteroid dose well and there were no data to analyse.<br/><sup>b</sup>Downgraded one level for indirectness due to differences in the recruited populations and in the criteria used to define 'severe exacerbations'.<br/><sup>c</sup>Downgraded one level for imprecision as among the included studies, one reported an important benefit of macrolide and another possible benefit of placebo.<br/><sup>d</sup>Downgraded one level due to uncertainties with randomisation procedures and high risk of attrition bias in some studies included in the analysis.<br/><sup>e</sup>Downgraded one level for inconsistency due to high heterogeneity (I<sup>2</sup> = 70%) mainly due to one cross‐over study.<br/><sup>f</sup>Downgraded one level for indirectness. Symptom scales were often invalidated and highly variable across studies, and we chose not to pool most in a meta‐analysis using standard mean differences, as this would lead to a result that would have been much more difficult to interpret.<br/><sup>g</sup>Downgraded one level for imprecision due to small number of participants in the analysis; it was difficult to judge precision due to different scales.<br/><sup>h</sup>Downgraded one level for indirectness as studies in the analysis recruited different populations with regard to severity of asthma, and one study only recruited smokers.<br/><sup>i</sup>Downgraded one level for risk of bias as four studies that we were unable to properly assess for risk of bias were included in this analysis, and we were uncertain of how and when the measurement was taken in some cases.<br/><sup>j</sup>No change in grade: there was uncertainty in several domains across studies, but the two studies carrying most of the weight were well conducted.<br/><sup>k</sup>Downgraded one level for imprecision; eight studies reported the outcomes, but only four studies observed events, leading to very wide confidence intervals that included important benefit and harm of macrolide treatment. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002997-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD002997-sec-0009"></div> <section id="CD002997-sec-0010"> <h3 class="title" id="CD002997-sec-0010">Description of the condition</h3> <p>Asthma is an inflammatory disease of the airways characterised by chronic inflammation, bronchial hyperresponsiveness and paroxysmal attacks of wheezing. It affects people of every age, but frequently the disease occurs in childhood, especially in those who are atopic. It is estimated that asthma may affect between 1% and 18% of the general population, and it represents a significant cause of morbidity and costs for healthcare systems. Furthermore, the control of the disease is difficult to achieve in people with severe asthma, and even in people with milder asthma it may be hampered by poor adherence to treatments and lack of access to healthcare (<a href="./references#CD002997-bbs2-0080" title="Global Initiative for Asthma. Global strategy for asthma management and prevention 2021. ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf (accessed prior to 14 November 2021.">GINA 2021</a>). </p> <p>Different phenotypes of the disease are recognised and under investigation. Current guidelines recommend tailoring asthma treatment according to a stepwise approach, considering severity of symptoms and response to treatment (<a href="./references#CD002997-bbs2-0080" title="Global Initiative for Asthma. Global strategy for asthma management and prevention 2021. ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf (accessed prior to 14 November 2021.">GINA 2021</a>). </p> <p>Recently, the role of short‐acting bronchodilators in intermittent asthma was revised, and a combination of inhaled corticosteroids (ICS) and formoterol as needed is now recommended in people with mild asthma. Persistent asthma is treated with regular ICS, longer‐acting bronchodilators, or both (<a href="./references#CD002997-bbs2-0080" title="Global Initiative for Asthma. Global strategy for asthma management and prevention 2021. ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf (accessed prior to 14 November 2021.">GINA 2021</a>). More recent therapies include anti‐leukotrienes in mild‐to‐moderate asthma, humanised antibodies targeting immunoglobulin E (omalizumab), interleukin (IL)‐5 (mepolizumab, reslizumab, benralizumab), and IL‐4/‐13 (dupilumab), which are currently only recommended in severe asthma with markers of a phenotype likely to respond (e.g. raised blood eosinophils for the anti‐IL‐5 agents) (<a href="./references#CD002997-bbs2-0080" title="Global Initiative for Asthma. Global strategy for asthma management and prevention 2021. ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf (accessed prior to 14 November 2021.">GINA 2021</a>; <a href="./references#CD002997-bbs2-0096" title="OlinJT , WechslerME . Asthma: pathogenesis and novel drugs for treatment. BMJ2014;349:g5517.">Olin 2014</a>). </p> </section> <section id="CD002997-sec-0011"> <h3 class="title" id="CD002997-sec-0011">Description of the intervention</h3> <p>Macrolides are a class of antibiotics that are widely used in the treatment of various infectious diseases, including respiratory tract infections (<a href="./references#CD002997-bbs2-0059" title="Alvarez-ElcoroS , EnzlerMJ . The macrolides: erythromycin, clarithromycin, and azithromycin. Mayo Clinic Proceedings1999;74(6):613-34.">Alvarez‐Elcoro 1999</a>). The first studies on macrolides in people with asthma suggested a steroid‐sparing effect (<a href="./references#CD002997-bbs2-0014" title="NelsonHS , HamilosDL , CorselloPR , LevesqueNV , BuchmeierAD , BuckerBL . A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. American Review of Respiratory Disease1993;147(2):398-404. ">Nelson 1993</a>), while other reports have demonstrated an anti‐inflammatory effect of this class of antibiotics, whereby macrolides seem to decrease bronchial hyperresponsiveness associated with eosinophilic inflammation (<a href="./references#CD002997-bbs2-0001" title="AmayasuH , YashidaS , EbanaS , YamamotoY , NishikawaT , ShojiT , et al. Clarithromycin suppress bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Annals of Allergy, Asthma and Immunology2000;84(6):594-8. ">Amayasu 2000</a>). A host‐directed anti‐inflammatory effects was also postulated (<a href="./references#CD002997-bbs2-0102" title="SpagnoloP , FabbriLM , BushA . Long-term macrolide treatment for chronic respiratory disease. European Respiratory Journal2013;42(1):239-51.">Spagnolo 2013</a>). Macrolides are effective in the long‐term treatment of cystic fibrosis, diffuse panbronchiolitis and chronic obstructive pulmonary disease (COPD), and they are not associated with an increased risk of adverse events (<a href="./references#CD002997-bbs2-0065" title="CaiY , ChaiD , WangR , BaiN , LiangBB , LiuY . Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review. Journal of Antimicrobial Chemotherapy2011;66(5):968-78.">Cai 2011</a>; <a href="./references#CD002997-bbs2-0102" title="SpagnoloP , FabbriLM , BushA . Long-term macrolide treatment for chronic respiratory disease. European Respiratory Journal2013;42(1):239-51.">Spagnolo 2013</a>). </p> <p>However, a potential drawback of longer‐term antibiotic use for asthma is the development of bacterial resistance by strains that normally colonise the airways. Macrolide use in healthy volunteers led to pharyngeal carriage of macrolide‐resistant streptococci (<a href="./references#CD002997-bbs2-0093" title="Malhotra-KumarS , LammensC , CoenenS , vanHerckK , GoossensH . Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet2007;369(9560):482-90.">Malhotra‐Kumar 2007</a>), which is of particular concern for the wider community. Similar concerns were raised by studies in COPD (<a href="./references#CD002997-bbs2-0063" title="BrillSE , LawM , El-EmirE , AllinsonJP , JamesP , MaddoxV , et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax2015;70(10):930-8.">Brill 2015</a>). Furthermore, the potential for arrhythmias due to QTc prolongation, potential ototoxicity and hepatotoxicity from macrolide long‐term use was highlighted in a British Thoracic Society document (<a href="./references#CD002997-bbs2-0064" title="SmithD , Du RandI , AddyCL , CollynsT , HartSP , MitchelmorePJ , et al. British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease. Thorax2020;75:370-404.">BTS 2020</a>). </p> </section> <section id="CD002997-sec-0012"> <h3 class="title" id="CD002997-sec-0012">How the intervention might work</h3> <p>Macrolides have anti‐inflammatory and antimicrobial properties that may improve asthma symptoms in two ways: by reducing airways inflammation directly and by controlling intracellular infection, which may trigger and maintain inflammation (<a href="./references#CD002997-bbs2-0061" title="BlackPN . Anti-inflammatory effects of macrolide antibiotics. European Respiratory Journal1997;10:971-2.">Black 1997</a>; <a href="./references#CD002997-bbs2-0062" title="BlackPN , ScicchitanoR , JenkinsCR , BlasiF , AllegraL , WlodarczykJ , et al. Serological evidence of infection with Chlamidia pneumoniae is related to the severity of asthma. European Respiratory Journal2000;15(2):254-9.">Black 2000</a>; <a href="./references#CD002997-bbs2-0089" title="KawasakiS , TakizawaH , OhtoshiT , TakeuchiN , KohyamaT , NakamuraH , et al. Roxithromycin inhibits cytokine production by and neutrophil attachment to human bronchial epithelial cells in vitro. Antimicrobial Agents and Chemotherapy1998;42(6):1499-502.">Kawasaki 1998</a>). Their anti‐inflammatory potential has been linked to their action on pro‐inflammatory cytokines and chemokines causing inflammation, which was highlighted by the results of the previous versions of this systematic review (<a href="./references#CD002997-bbs2-0107" title="RicheldiL , FerraraG , FabbriLM , GibsonPG . Macrolides for chronic asthma. Cochrane Database of Systematic Reviews2002, Issue 1. Art. No: CD002997. [DOI: 10.1002/14651858.CD002997]">Richeldi 2002</a>; <a href="./references#CD002997-bbs2-0108" title="RicheldiL , FerraraG , FabbriLM , LassersonTJ , GibsonPG . Macrolides for chronic asthma. Cochrane Database of Systematic Reviews2005, Issue 3. Art. No: CD002997. [DOI: 10.1002/14651858.CD002997.pub2]">Richeldi 2005</a>; <a href="./references#CD002997-bbs2-0106" title="KewKM , UndelaK , KotortsiI , FerraraG . Macrolides for chronic asthma. Cochrane Database of Systematic Reviews2015, Issue 9. Art. No: CD002997. [DOI: 10.1002/14651858.CD002997.pub4]">Kew 2015</a>). In vivo and in vitro studies of human and animal models have demonstrated that macrolides suppress the production of cytokines such as ILs and inhibit neutrophil adhesion to epithelial cells, the respiratory burst of neutrophils and the secretion of mucous from human airways (<a href="./references#CD002997-bbs2-0058" title="AdachiT , MotojimaS , HirataA . Eosinophil apoptosis caused by theophylline, glucocorticoids, and macrolides after stimulation with IL-5. Journal of Allergy and Clinical Immunology1996;98(6 Pt 2):S207-15.">Adachi 1996</a>; <a href="./references#CD002997-bbs2-0085" title="HinksT , LevineSJ , BrusselleGG . Treatment options in type-2 low asthma. European Respiratory Journal2012;57(1):2000528.">Hinks 2021</a>; <a href="./references#CD002997-bbs2-0090" title="KonnoS , AsanoK , KurokawaM , IkedaK , OkamotoK , AdachiM . Antiasthmatic activity of a macrolide antibiotic, roxithromycin: analysis of possible mechanisms in vitro and in vivo. International Archives of Allergy and Immunology1994;105(3):308-16.">Konno 1994</a>; <a href="./references#CD002997-bbs2-0091" title="KoyamaT , TakizawaH , KawasakiS , TakamiK , OtoshiT , ItoK . Effects of various drugs on IL-8 production by eosinophils collected from patients with allergic inflammation. Japanese Journal of Antibiotics1998;51(Suppl A):131-3.">Koyama 1998</a>). </p> <p>Older macrolides such as troleandomycin were investigated for a steroid‐sparing effect, related to reduced hepatic glucocorticoid metabolism (<a href="./references#CD002997-bbs2-0014" title="NelsonHS , HamilosDL , CorselloPR , LevesqueNV , BuchmeierAD , BuckerBL . A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. American Review of Respiratory Disease1993;147(2):398-404. ">Nelson 1993</a>). </p> <p>The potential benefit of their antimicrobial action for people with asthma was suggested after observational studies identified intracellular bacterial infection (i.e. <i>Chlamydophila pneumoniae</i> or <i>Mycoplasma pneumoniae</i>) as a possible trigger of bronchial inflammation (<a href="./references#CD002997-bbs2-0092" title="KraftM , CassellGH , HensonJE , WatsonH , WilliamsonJ , MarmionBP , et al. Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma. American Journal of Respiratory and Critical Care Medicine1998;158(3):998-1001.">Kraft 1998</a>). <a href="./references#CD002997-bbs2-0072" title="GencayM , RudigerJJ , TammM , SolérM , PerruchoudAP , RothM . Increased frequency of Chlamydia pneumoniae antibodies in patients with asthma. American Journal of Respiratory and Critical Care Medicine2001;163(5):1097-100.">Gencay 2001</a> subsequently demonstrated that people with asthma had a higher frequency of <i>C pneumoniae</i> antibodies than matched controls. Longitudinal studies showed no clear effect of infection with <i>C pneumoniae</i> on the incidence of asthma, but people who had an infection and developed asthma showed a faster decline in lung function (<a href="./references#CD002997-bbs2-0097" title="PasternackR , HuhtalaH , KarjalainenJ . Chlamydophila (Chlamydia) pneumoniae serology and asthma in adults: a longitudinal analysis. Journal of Allergy and Clinical Immunology2005;116(5):1123-8.">Pasternack 2005</a>). Furthermore, in children with asthma, <i>M pneumoniae</i> detection in respiratory samples was associated with poorer asthma control (<a href="./references#CD002997-bbs2-0105" title="WoodPR , HillVL , BurksML , PetersJI , SinghH , KannanTR , et al. Mycoplasma pneumoniae in children with acute and refractory asthma. Annals of Allergy, Asthma and Immunology2013;110(5):328-334.e1.">Wood 2013</a>). Studies in animal models seem to point to an important role of the infection with <i>C pneumoniae</i> in the early phases of life in the pathogenesis of severe asthma (<a href="./references#CD002997-bbs2-0069" title="EssilfieAT , HorvatJC , KimRY , MayallJR , PinkertonJW , BeckettEL , et al. Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma. Thorax2015;70:458-67.">Essilfie 2015</a>; <a href="./references#CD002997-bbs2-0082" title="HansbroPM , StarkeyMR , MattesJ , HorvatJC . Pulmonary immunity during respiratory infections in early life and the development of severe asthma. Annals of the American Thoracic Society2014;11(Suppl 5):S297-302.">Hansbro 2014</a>). </p> </section> <section id="CD002997-sec-0013"> <h3 class="title" id="CD002997-sec-0013">Why it is important to do this review</h3> <p>Macrolides represent a relatively inexpensive intervention that may improve control of inflammation and clinical outcomes in people with chronic asthma. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002997-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002997-sec-0014"></div> <p>To assess the effects of macrolides compared with placebo for managing chronic asthma.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002997-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002997-sec-0015"></div> <section id="CD002997-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002997-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included parallel and cross‐over randomised controlled trials (RCTs).</p> </section> <section id="CD002997-sec-0018"> <h4 class="title">Types of participants</h4> <p>Children and adults with chronic asthma.</p> </section> <section id="CD002997-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Macrolides, administered for four or more weeks versus placebo. We pooled data from studies comparing different macrolide therapies. </p> </section> <section id="CD002997-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD002997-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD002997-list-0001"> <li> <p>Exacerbations requiring hospitalisation.</p> </li> <li> <p>Severe exacerbations (defined as requiring an emergency department (ED) visits or short‐course of systemic steroids, or both). </p> </li> <li> <p>Asthma symptoms, control and quality of life scores.</p> </li> <li> <p>Asthma medication requirements (need for rescue medications).</p> </li> <li> <p>Lung function, including morning and evening peak expiratory flow (PEF) and forced expiratory volume in one second (FEV<sub>1</sub>). </p> </li> <li> <p>Non‐specific bronchial hyperresponsiveness (to histamine or methacholine).</p> </li> <li> <p>Lowest tolerated oral corticosteroid dose (in people requiring oral corticosteroids at baseline). </p> </li> </ul> </p> </section> <section id="CD002997-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD002997-list-0002"> <li> <p>Number and type of serious adverse events (including mortality).</p> </li> <li> <p>Number of study withdrawals.</p> </li> <li> <p>Eosinophil count in peripheral blood samples, sputum samples or both.</p> </li> <li> <p>Eosinophilic cationic protein (ECP) measurements in serum and sputum.</p> </li> </ul> </p> </section> </section> </section> <section id="CD002997-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD002997-sec-0024"> <h4 class="title">Electronic searches</h4> <p>Search methods used in the previous version of this review are detailed in <a href="./appendices#CD002997-sec-0084">Appendix 1</a>. The previously published version included searches up to April 2015. The search period for this update was April 2015 to 31 March 2021. </p> <p>We searched the Cochrane Airways Trials Register on 31 March 2021. At that time the Register contained studies identified from: </p> <p> <ul id="CD002997-list-0003"> <li> <p>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL), through the Cochrane Register of Studies Online (crso.cochrane.org), all years to Issue 3, 2021; </p> </li> <li> <p>weekly searches of MEDLINE (OvidSP), 1946 to 26 March 2021;</p> </li> <li> <p>weekly searches of Embase (OvidSP), 1974 to week 12 2021;</p> </li> <li> <p>monthly searches of PsycINFO (OvidSP), 1967 to March week 4 2021;</p> </li> <li> <p>monthly searches of CINAHL (EBSCO) (Cumulative Index to Nursing and Allied Health Literature), 1937 to 15 March 2021; </p> </li> <li> <p>monthly searches of AMED (EBSCO) (Allied and Complementary Medicine), all years to 11 March 2021; </p> </li> <li> <p>handsearches of the proceedings of major respiratory conferences.</p> </li> </ul> </p> <p>Studies contained in the Trials Register are identified through search strategies based on the scope of Cochrane Airways. Details of these strategies, as well as a list of handsearched conference proceedings are in <a href="./appendices#CD002997-sec-0085">Appendix 2</a>. See <a href="./appendices#CD002997-sec-0090">Appendix 3</a> for search terms used to identify studies for this review. We did not restrict our search by language or type of publication. </p> <p>We also searched the following trials registries on 31 March 2021:</p> <p> <ul id="CD002997-list-0004"> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="https://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="https://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>). </p> </li> </ul> </p> </section> <section id="CD002997-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We surveyed review articles and bibliographies identified from the primary papers for additional references and RCTs. </p> </section> </section> <section id="CD002997-sec-0026"> <h3 class="title" id="CD002997-sec-0026">Data collection and analysis</h3> <section id="CD002997-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (KU and GF) independently screened the abstracts of articles identified using the search strategy above, retrieving the full text for articles that appeared to fulfil the inclusion criteria. Two review authors (KU and GF) independently reviewed and categorised each article identified as included or excluded. When there was disagreement or doubt, a third review author (KK) assessed the article and helped to reach a consensus. We presented a PRISMA diagram to illustrate the flow of studies through the selection process (<a href="./references#CD002997-bbs2-0094" title="MoherD , LiberatiA , TetzlaffJ , AltmanD . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097]">Moher 2009</a>). </p> </section> <section id="CD002997-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form to collect study characteristics and outcome data. We piloted the form on at least one study in the review. Two review authors (KU and GF) extracted the following study characteristics from included studies, when available. </p> <p> <ul id="CD002997-list-0005"> <li> <p>Methods: study design, total duration of study, details of any run‐in period, number of study centres and location, study setting, withdrawals and date of study. </p> </li> <li> <p>Participants: number, mean age, age range, gender, severity of condition, diagnostic criteria, baseline lung function, smoking history, inclusion criteria and exclusion criteria. </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications and excluded medications.</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported. </p> </li> <li> <p>Notes: funding for trial, and notable conflicts of interest of trial authors.</p> </li> </ul> </p> <p>Two review authors (KU and GF) independently extracted outcome data from included studies. We noted in the <a href="./references#CD002997-sec-0109" title="">Characteristics of included studies</a> table if outcome data were not reported in a usable way. We resolved disagreements by involving a third review author (KK). Two review authors (KK and KU) transferred data into the Review Manager 5 (<a href="./references#CD002997-bbs2-0100" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). Three review authors (KU, LG and GF) double‐checked that data were entered correctly by comparing the data presented in the systematic review with the study reports. </p> </section> <section id="CD002997-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (KK and GF) independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002997-bbs2-0083" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). We resolved disagreements by discussion and by involving another review author (KU). We assessed risk of bias according to the following domains. </p> <p> <ul id="CD002997-list-0006"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ul> </p> <p>Each potential source of bias was graded as high, low or unclear and justified with a quote from the study report in the risk of bias table. We summarised the risk of bias judgements across different studies for each of the domains listed. We considered blinding separately for different key outcomes where necessary (e.g. for unblinded outcome assessment, risk of bias for all‐cause mortality may be very different from for a participant‐reported pain scale). Where information on risk of bias related to unpublished data or correspondence with a trial list, we noted this in the risk of bias table. </p> <p>For treatment effects, we considered the risk of bias for the studies that contributed to that outcome. </p> </section> <section id="CD002997-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as odds ratios (OR), incidence rate data as rate ratio (RaR) and continuous data as mean difference (MD; where studies used the same scales) or standardised mean difference (SMD; where studies used different scales). We entered data presented as a scale with a consistent direction of effect. We narratively described skewed data reported as medians and interquartile ranges. We analysed data from cross‐over trials using generic inverse variance (GIV). We pooled results from cross‐over trials and parallel trials. Where studies presented raw data and adjusted analyses (e.g. accounting for baseline differences), we used the adjusted analyses. </p> <p>We undertook meta‐analyses only where meaningful, that is, if the treatments, participants and the underlying clinical question were similar enough for pooling to make sense and made decisions about this by consensus among review authors. </p> <p>Where a trial reported multiple arms, we included only the relevant arms but reported all arms in the <a href="./references#CD002997-sec-0109" title="">Characteristics of included studies</a> table. If two comparisons (e.g. drug A versus placebo and drug B versus placebo) were combined in the same meta‐analysis, we halved the control group to avoid double‐counting. </p> <p>If change from baseline and endpoint scores were available for continuous data, we used change from baseline unless most studies reported endpoint scores. If a study reported outcomes at multiple time points, we used the end‐of‐study treatment measurement. </p> <p>When both an analysis using only participants who completed the trial and an analysis that imputed data for participants who were randomised but did not provide endpoint data (e.g. last observation carried forward) were available, we used the latter. </p> </section> <section id="CD002997-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>We combined events data using ORs or RaRs (number of participants or number of events) according to which measure would allow us to include the most studies. We used ORs for exacerbations requiring hospitalisation, serious adverse events (including mortality) (Peto OR) and withdrawal. We used RaRs for severe exacerbations (defined as exacerbations requiring ED visits or systemic steroids, or both). For continuous data in cross‐over trials, we entered data using GIV from suitable adjusted analyses to account for the trial's design. </p> </section> <section id="CD002997-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We assessed the potential for bias in each trial as a result of participants dropping out of the intervention prematurely. Where this was thought to introduce serious bias, we removed the studies in a sensitivity analysis. </p> </section> <section id="CD002997-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I<sup>2</sup> statistic to measure heterogeneity among the trials in each analysis. If we identified high heterogeneity (e.g. I<sup>2</sup> greater than 30%), we reported it and performed a sensitivity analysis with a random‐effects model. </p> </section> <section id="CD002997-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We were unable to pool more than 10 trials for any of the primary outcomes, so were unable to examine a funnel plot to explore possible small‐study and publication biases. </p> </section> <section id="CD002997-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We used a fixed‐effect model for all analyses, as we expected limited variation in effects due to differences in study populations and methods. </p> </section> <section id="CD002997-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned subgroup analyses based on serological response or positivity to polymerase chain reaction (PCR) for <i>C pneumoniae</i>. </p> </section> <section id="CD002997-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We performed a sensitivity analysis with a random‐effects model in case of high heterogeneity (I<sup>2</sup> greater than 30%). </p> </section> <section id="CD002997-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>The summary of findings table included the following outcomes: number of exacerbations requiring hospitalisation; severe exacerbations (requiring ED visits or short‐course systemic steroids, or both); asthma symptoms (including symptom scores, asthma control and Asthma Quality of Life Questionnaire (AQLQ)); asthma medication requirements (as reliever); lung function (including morning and evening PEF and FEV<sub>1</sub>); non‐specific bronchial hyperresponsiveness; serious adverse events; withdrawal; blood and sputum eosinophils; and ECP in serum and sputum. </p> <p>We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the certainty of the body of evidence as it related to the studies that contributed data to the meta‐analyses for the prespecified outcomes. Except for serious adverse events, we did not perform GRADE ratings on the secondary outcomes. We used methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002997-bbs2-0083" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>) using GRADEpro software (<a href="./references#CD002997-bbs2-0081" title="GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org (accessed 27 June 2021).">GRADEpro GDT</a>). We justified all decisions to downgrade or upgrade the certainty of the evidence using footnotes and made comments to aid reader's understanding of the review where necessary. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002997-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002997-sec-0039"></div> <section id="CD002997-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD002997-sec-0041"> <h4 class="title">Results of the search</h4> <p>The literature search of previous versions of this review up to April 2015 identified 137 citations. Out of the 38 references identified in the search between 2007 and 2015, duplicate sifting of the titles and abstracts alone identified 33 potentially eligible studies for inclusion in the systematic review. Among them, review authors were concordant in identifying 16 RCTs to be included in the previous update of the systematic review (<a href="./references#CD002997-bbs2-0106" title="KewKM , UndelaK , KotortsiI , FerraraG . Macrolides for chronic asthma. Cochrane Database of Systematic Reviews2015, Issue 9. Art. No: CD002997. [DOI: 10.1002/14651858.CD002997.pub4]">Kew 2015</a>). Six of the 16 RCTs were identified in a previous meta‐analysis (<a href="./references#CD002997-bbs2-0103" title="TongX , GuoT , LiuS , PengS , YanS , YangX , et al. Macrolide antibiotics for treatment of asthma in adults: a meta-analysis of 18 randomized controlled clinical studies. Pulmonary Pharmacology and Therapeutics2015;31:99-108.">Tong 2015</a>); these Chinese trials were only listed in China's biomedical databases. The authors of this review were able to confirm key study characteristics in order to include them, although risk of bias could not be properly assessed. </p> <p>For this updated review, the search extended to March 2021. We identified 55 new references. Seven titles referring to abstracts presented at congresses were duplicates of other studies already included in the review, while one title (<a href="./references#CD002997-bbs2-0073" title="GibsonPG , YangIA , UphamJW , ReynoldsPN , HodgeS , JamesAL , et al. Efficacy of azithromycin in severe asthma from the AMAZES randomised trial. ERJ Open Research2019;5:00056-2019. [DOI: 10.1183/23120541.00056-2019]">Gibson 2019</a>) was a subgroup analysis of another RCT (<a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a>) included in this update, leaving 20 references for screening. We excluded four based on the abstract alone and 13 after screening the full‐text of the original manuscripts, leaving two new studies eligible for inclusion in the systematic review and meta‐analyses (<a href="./references#CD002997-bbs2-0020" title="Wan K-S, Liu Y-C, Huang C-S, Su Y-M. Effects of low-dose clarithromycin added to fluticasone on inflammatory markers and pulmonary function among children with asthma: a randomized clinical trial. Allergy and Rhinology2016;7(3):e131-4. ">Wan 2016</a>; <a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a>). One study is ongoing, no results available. See <a href="./references#CD002997-sec-0109" title="">Characteristics of included studies</a>, <a href="./references#CD002997-sec-0110" title="">Characteristics of excluded studies</a>, and <a href="./references#CD002997-sec-0111" title="">Characteristics of ongoing studies</a> tables. The study flow of the new included studies is presented in <a href="#CD002997-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD002997-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD002997-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD002997-sec-0042"> <h4 class="title">Included studies</h4> <p>We included 25 RCTs (<a href="./references#CD002997-bbs2-0001" title="AmayasuH , YashidaS , EbanaS , YamamotoY , NishikawaT , ShojiT , et al. Clarithromycin suppress bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Annals of Allergy, Asthma and Immunology2000;84(6):594-8. ">Amayasu 2000</a>; <a href="./references#CD002997-bbs2-0002" title="BelotserkovskayaY , SinopalnikovA . Open-trial randomized comparative trial of the efficacy of the azithromycin in the 8 week treatment of mild to moderate asthma. European Respiratory Journal2007;30(Suppl 51):358s. ">Belotserkovskaya 2007</a>; <a href="./references#CD002997-bbs2-0003" title="BlackP , JenkinsCR , ScicchitanoR , BlasiF , AllegraL , MillsG , et al. Randomised, controlled trial of roxithromycin for the treatment of asthma in subjects with serological evidence of infection with Chlamydia pneumoniae. American Journal of Respiratory and Critical Care Medicine2001;164(4):536-41. ">Black 2001</a>; <a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a>; <a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a>; <a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a>; <a href="./references#CD002997-bbs2-0007" title="HahnDL , PlaneMB , MahdiOS , ByrneGI . Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clinical Trials2006;1(2):e11. ">Hahn 2006</a>; <a href="./references#CD002997-bbs2-0008" title="HahnD , GrasmickM , HetzelS . Pragmatic controlled trial of azithromycin for asthma in adults. European Respiratory Journal2011;38:322s. HahnDL , GrasmickM , HetzelS , YaleS . Azithromycin for bronchial asthma in adults: an effectiveness trial. Journal of the American Board of Family Medicine2012;25(4):442-59. ">Hahn 2012</a>; <a href="./references#CD002997-bbs2-0009" title="HeJ , ZhuN , ChenXD . Clinical impacts of azithromycin on lung function and cytokines for asthmatic patients. Fudan University Journal of Medical Science2009;36(6):719-22. ">He 2009</a>; <a href="./references#CD002997-bbs2-0010" title="KamadaAK , HillMR , IkléDN , BrennerAM , SzeflerSJ . Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. Journal of Allergy and Clinical Immunology1993;91(4):873-82. ">Kamada 1993</a>; <a href="./references#CD002997-bbs2-0011" title="KapoorS , BrashierB , UdupaA , PawarR , KodguleR , LimayeS , et al. Therapeutic effect of low dose roxithromycin in chronic stable mild-to-moderate asthma. European Respiratory Journal2010;36(suppl 54):P1176. ">Kapoor 2010</a>; <a href="./references#CD002997-bbs2-0012" title="KostadimaE , TsiodrasS , AlexopoulosEI , KaditisAG , MavrouI , GeorgatouN , et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. European Respiratory Journal2004;23(5):714-7. ">Kostadima 2004</a>; <a href="./references#CD002997-bbs2-0013" title="KraftM , CassellGH , PakJ , MartinRJ . Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest2002;121(6):1782-8. ">Kraft 2002</a>; <a href="./references#CD002997-bbs2-0014" title="NelsonHS , HamilosDL , CorselloPR , LevesqueNV , BuchmeierAD , BuckerBL . A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. American Review of Respiratory Disease1993;147(2):398-404. ">Nelson 1993</a>; <a href="./references#CD002997-bbs2-0015" title="PiacentiniGL , PeroniDG , BodiniA , PigozziR , CostellaS , LoiaconoA , et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy and Asthma Proceedings2007;28(2):194-8. ">Piacentini 2007</a>; <a href="./references#CD002997-bbs2-0016" title="ShojiT , YoshidaS , SakamotoH , HasegawaH , NakagawaH , AmayasuH . Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clinical and Experimental Allergy1999;29(7):950-6. ">Shoji 1999</a>; <a href="./references#CD002997-bbs2-0017" title="SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Respirology2007;12:A120. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25-28; Auckland:Abstract TO13. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Clarithromycin targets neutrophilic airway inflammation in refractory asthma. American Journal of Respiratory and Critical Care Medicine2008;177(2):148-55. ">Simpson 2008</a>; <a href="./references#CD002997-bbs2-0018" title="StrunkRC , BacharierLB , PhillipsBR , SzeflerSJ , ZeigerRS , ChinchilliVM , et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. Journal of Allergy and Clinical Immunology2008;122(6):1138-44.e4. ">Strunk 2008</a>; <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a>; <a href="./references#CD002997-bbs2-0020" title="Wan K-S, Liu Y-C, Huang C-S, Su Y-M. Effects of low-dose clarithromycin added to fluticasone on inflammatory markers and pulmonary function among children with asthma: a randomized clinical trial. Allergy and Rhinology2016;7(3):e131-4. ">Wan 2016</a>; <a href="./references#CD002997-bbs2-0021" title="WangY , ZhangSL , QuY . Effect of clarithromycin on non-eosinophilic refractory asthma [克拉霉素治疗非嗜酸粒细胞型难治性哮喘的疗效分析]. Journal of Clinical Pulmonary Medicine2012;17(11):1948-51. ">Wang 2012</a>; <a href="./references#CD002997-bbs2-0022" title="WangT , PeiFY , SongXP , WangQ . Clinical impacts of low-dose azithromycin on lung function and fraction of exhaled nitric oxide concentration in bronchial asthma [小剂量阿奇霉素对支气管哮喘患者呼出气NO浓度及肺功能的影响]. Medical Innovation China2014;11(9):122-4. ">Wang 2014</a>; <a href="./references#CD002997-bbs2-0023" title="XiaoKA . The study on effect of roxithromycin combined with budesonide in therapy in patients with asthma. Guide of Chinese Medicine2013;11:119-20. ">Xiao 2013</a>; <a href="./references#CD002997-bbs2-0024" title="YanXQ , WuLQ , LinJ , XiaoXD , DaiYR . Clinical study on efficacy of roxithromycin combined with inhaled budesonide dry powder inhalation on asthma [罗红霉素与布地奈德干粉吸入剂联用治疗哮喘的临床研究]. Chinese Journal of Pharmacology and Therapeutics2008;13(2):184-7. ">Yan 2008</a>; <a href="./references#CD002997-bbs2-0025" title="ZhangLY , QianQ . Clinical effect of azithromycin combined with Seretide for asthma. Strait Pharmaceutical Journal2013;25:159-60. ">Zhang 2013</a>). For brief descriptions of the included studies, refer to the <a href="./references#CD002997-sec-0109" title="">Characteristics of included studies</a> table. For a summary of study characteristics and a narrative on the main results of each study, see <a href="#CD002997-tbl-0002">Table 1</a> and <a href="./appendices#CD002997-sec-0094">Appendix 4</a>. </p> <div class="table" id="CD002997-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary characteristics of included studies at baseline</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Design</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Duration (weeks)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Macrolide dose and schedule</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean age (years)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>% Male</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>% on ICS</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>% Predicted FEV<sub>1</sub> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0001" title="AmayasuH , YashidaS , EbanaS , YamamotoY , NishikawaT , ShojiT , et al. Clarithromycin suppress bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Annals of Allergy, Asthma and Immunology2000;84(6):594-8. ">Amayasu 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan and USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clarithromycin 200 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0002" title="BelotserkovskayaY , SinopalnikovA . Open-trial randomized comparative trial of the efficacy of the azithromycin in the 8 week treatment of mild to moderate asthma. European Respiratory Journal2007;30(Suppl 51):358s. ">Belotserkovskaya 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Russia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (unknown dose)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0003" title="BlackP , JenkinsCR , ScicchitanoR , BlasiF , AllegraL , MillsG , et al. Randomised, controlled trial of roxithromycin for the treatment of asthma in subjects with serological evidence of infection with Chlamydia pneumoniae. American Journal of Respiratory and Critical Care Medicine2001;164(4):536-41. ">Black 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multinational</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roxithromycin 150 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Belgium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin 250 mg once daily for 5 days then 3 times per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.0 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin 250 mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin 500 mg 3 times per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0007" title="HahnDL , PlaneMB , MahdiOS , ByrneGI . Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clinical Trials2006;1(2):e11. ">Hahn 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA, Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin 600 mg once daily for 3 days then weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0008" title="HahnD , GrasmickM , HetzelS . Pragmatic controlled trial of azithromycin for asthma in adults. European Respiratory Journal2011;38:322s. HahnDL , GrasmickM , HetzelS , YaleS . Azithromycin for bronchial asthma in adults: an effectiveness trial. Journal of the American Board of Family Medicine2012;25(4):442-59. ">Hahn 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin 600 mg once daily for 3 days then weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0009" title="HeJ , ZhuN , ChenXD . Clinical impacts of azithromycin on lung function and cytokines for asthmatic patients. Fudan University Journal of Medical Science2009;36(6):719-22. ">He 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin 250 mg twice weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0010" title="KamadaAK , HillMR , IkléDN , BrennerAM , SzeflerSJ . Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. Journal of Allergy and Clinical Immunology1993;91(4):873-82. ">Kamada 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Troleandomycin 250 µg once daily + OCS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0011" title="KapoorS , BrashierB , UdupaA , PawarR , KodguleR , LimayeS , et al. Therapeutic effect of low dose roxithromycin in chronic stable mild-to-moderate asthma. European Respiratory Journal2010;36(suppl 54):P1176. ">Kapoor 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roxithromycin 150 mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0012" title="KostadimaE , TsiodrasS , AlexopoulosEI , KaditisAG , MavrouI , GeorgatouN , et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. European Respiratory Journal2004;23(5):714-7. ">Kostadima 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Greece</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clarithromycin 250 mg twice daily or 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0013" title="KraftM , CassellGH , PakJ , MartinRJ . Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest2002;121(6):1782-8. ">Kraft 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clarithromycin 500 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0014" title="NelsonHS , HamilosDL , CorselloPR , LevesqueNV , BuchmeierAD , BuckerBL . A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. American Review of Respiratory Disease1993;147(2):398-404. ">Nelson 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Troleandomycin 250 mg once daily + OCS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0015" title="PiacentiniGL , PeroniDG , BodiniA , PigozziR , CostellaS , LoiaconoA , et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy and Asthma Proceedings2007;28(2):194-8. ">Piacentini 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin 10 mg/kg once daily 3 days per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0016" title="ShojiT , YoshidaS , SakamotoH , HasegawaH , NakagawaH , AmayasuH . Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clinical and Experimental Allergy1999;29(7):950-6. ">Shoji 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roxithromycin 150 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0017" title="SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Respirology2007;12:A120. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25-28; Auckland:Abstract TO13. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Clarithromycin targets neutrophilic airway inflammation in refractory asthma. American Journal of Respiratory and Critical Care Medicine2008;177(2):148-55. ">Simpson 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clarithromycin 500 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0018" title="StrunkRC , BacharierLB , PhillipsBR , SzeflerSJ , ZeigerRS , ChinchilliVM , et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. Journal of Allergy and Clinical Immunology2008;122(6):1138-44.e4. ">Strunk 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin 250 mg or 500 mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clarithromycin 500 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0020" title="Wan K-S, Liu Y-C, Huang C-S, Su Y-M. Effects of low-dose clarithromycin added to fluticasone on inflammatory markers and pulmonary function among children with asthma: a randomized clinical trial. Allergy and Rhinology2016;7(3):e131-4. ">Wan 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Taiwan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clarithromycin 5 mg/kg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0021" title="WangY , ZhangSL , QuY . Effect of clarithromycin on non-eosinophilic refractory asthma [克拉霉素治疗非嗜酸粒细胞型难治性哮喘的疗效分析]. Journal of Clinical Pulmonary Medicine2012;17(11):1948-51. ">Wang 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clarithromycin 500 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0022" title="WangT , PeiFY , SongXP , WangQ . Clinical impacts of low-dose azithromycin on lung function and fraction of exhaled nitric oxide concentration in bronchial asthma [小剂量阿奇霉素对支气管哮喘患者呼出气NO浓度及肺功能的影响]. Medical Innovation China2014;11(9):122-4. ">Wang 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin 250 mg twice weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0023" title="XiaoKA . The study on effect of roxithromycin combined with budesonide in therapy in patients with asthma. Guide of Chinese Medicine2013;11:119-20. ">Xiao 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roxithromycin 150 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0024" title="YanXQ , WuLQ , LinJ , XiaoXD , DaiYR . Clinical study on efficacy of roxithromycin combined with inhaled budesonide dry powder inhalation on asthma [罗红霉素与布地奈德干粉吸入剂联用治疗哮喘的临床研究]. Chinese Journal of Pharmacology and Therapeutics2008;13(2):184-7. ">Yan 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roxithromycin 150 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0025" title="ZhangLY , QianQ . Clinical effect of azithromycin combined with Seretide for asthma. Strait Pharmaceutical Journal2013;25:159-60. ">Zhang 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin 100 mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>C</b> : cross‐over; <b>DB</b> : double‐blind; <b>FEV<sub>1</sub> </b> : forced expiratory volume in one second; <b>ICS</b> : inhaled corticosteroid; <b>NR</b> : not reported; <b>OCS</b> : oral corticosteroids; <b>P</b> : parallel; <b>PC</b> : placebo‐controlled; <b>R</b>: randomised. </p> <p><sup>a</sup>All participants were taking long‐acting beta<sub>2</sub>‐agonist + ICS combination.<br/><sup>b</sup>82.2% were taking long‐acting beta<sub>2</sub>‐agonist + ICS combination.<br/><sup>c</sup>19 participants were not included in the review because they were randomised to a third group who received montelukast. </p> </div> </div> <p>The 25 included studies reported a great variability in type of participants (ranging from intermittent aspirin‐induced asthma to severe asthma), interventions (different type of macrolides, administration scheme and doses in most of the studies) and outcomes recorded. </p> <section id="CD002997-sec-0043"> <h5 class="title">Design</h5> <p>All studies were RCTs using placebo controls, and most were described as double‐blind. There were 22 parallel group studies and three cross‐over studies (<a href="./references#CD002997-bbs2-0001" title="AmayasuH , YashidaS , EbanaS , YamamotoY , NishikawaT , ShojiT , et al. Clarithromycin suppress bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Annals of Allergy, Asthma and Immunology2000;84(6):594-8. ">Amayasu 2000</a>; <a href="./references#CD002997-bbs2-0011" title="KapoorS , BrashierB , UdupaA , PawarR , KodguleR , LimayeS , et al. Therapeutic effect of low dose roxithromycin in chronic stable mild-to-moderate asthma. European Respiratory Journal2010;36(suppl 54):P1176. ">Kapoor 2010</a>; <a href="./references#CD002997-bbs2-0016" title="ShojiT , YoshidaS , SakamotoH , HasegawaH , NakagawaH , AmayasuH . Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clinical and Experimental Allergy1999;29(7):950-6. ">Shoji 1999</a>). Median study duration was 15.2 weeks (range four to 52 weeks). Two studies were reported in the form of abstracts from congresses, with a very limited amount of data available (<a href="./references#CD002997-bbs2-0002" title="BelotserkovskayaY , SinopalnikovA . Open-trial randomized comparative trial of the efficacy of the azithromycin in the 8 week treatment of mild to moderate asthma. European Respiratory Journal2007;30(Suppl 51):358s. ">Belotserkovskaya 2007</a>; <a href="./references#CD002997-bbs2-0011" title="KapoorS , BrashierB , UdupaA , PawarR , KodguleR , LimayeS , et al. Therapeutic effect of low dose roxithromycin in chronic stable mild-to-moderate asthma. European Respiratory Journal2010;36(suppl 54):P1176. ">Kapoor 2010</a>); the results of one new included study could not be used due to very poor reporting (<a href="./references#CD002997-bbs2-0020" title="Wan K-S, Liu Y-C, Huang C-S, Su Y-M. Effects of low-dose clarithromycin added to fluticasone on inflammatory markers and pulmonary function among children with asthma: a randomized clinical trial. Allergy and Rhinology2016;7(3):e131-4. ">Wan 2016</a>), and only basic information was available from six Chinese studies (<a href="./references#CD002997-bbs2-0009" title="HeJ , ZhuN , ChenXD . Clinical impacts of azithromycin on lung function and cytokines for asthmatic patients. Fudan University Journal of Medical Science2009;36(6):719-22. ">He 2009</a>; <a href="./references#CD002997-bbs2-0021" title="WangY , ZhangSL , QuY . Effect of clarithromycin on non-eosinophilic refractory asthma [克拉霉素治疗非嗜酸粒细胞型难治性哮喘的疗效分析]. Journal of Clinical Pulmonary Medicine2012;17(11):1948-51. ">Wang 2012</a>; <a href="./references#CD002997-bbs2-0022" title="WangT , PeiFY , SongXP , WangQ . Clinical impacts of low-dose azithromycin on lung function and fraction of exhaled nitric oxide concentration in bronchial asthma [小剂量阿奇霉素对支气管哮喘患者呼出气NO浓度及肺功能的影响]. Medical Innovation China2014;11(9):122-4. ">Wang 2014</a>; <a href="./references#CD002997-bbs2-0023" title="XiaoKA . The study on effect of roxithromycin combined with budesonide in therapy in patients with asthma. Guide of Chinese Medicine2013;11:119-20. ">Xiao 2013</a>; <a href="./references#CD002997-bbs2-0024" title="YanXQ , WuLQ , LinJ , XiaoXD , DaiYR . Clinical study on efficacy of roxithromycin combined with inhaled budesonide dry powder inhalation on asthma [罗红霉素与布地奈德干粉吸入剂联用治疗哮喘的临床研究]. Chinese Journal of Pharmacology and Therapeutics2008;13(2):184-7. ">Yan 2008</a>; <a href="./references#CD002997-bbs2-0025" title="ZhangLY , QianQ . Clinical effect of azithromycin combined with Seretide for asthma. Strait Pharmaceutical Journal2013;25:159-60. ">Zhang 2013</a>) included in the previous version of this review (<a href="./references#CD002997-bbs2-0106" title="KewKM , UndelaK , KotortsiI , FerraraG . Macrolides for chronic asthma. Cochrane Database of Systematic Reviews2015, Issue 9. Art. No: CD002997. [DOI: 10.1002/14651858.CD002997.pub4]">Kew 2015</a>). </p> </section> <section id="CD002997-sec-0044"> <h5 class="title">Participants</h5> <p>The studies included 1991 participants of whom 1973 were relevant to this review (<a href="./references#CD002997-bbs2-0018" title="StrunkRC , BacharierLB , PhillipsBR , SzeflerSJ , ZeigerRS , ChinchilliVM , et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. Journal of Allergy and Clinical Immunology2008;122(6):1138-44.e4. ">Strunk 2008</a> included a third group of 18 people receiving a treatment that was outside the protocol of this review). All participants had an asthma diagnosis, which was generally established according to the guidelines in use at the time of the studies (<a href="./references#CD002997-bbs2-0060" title="ATS Scientific Assembly on Clinical Problems. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. American Review of Respiratory Disease1987;136(1):225-44.">ATS 1987</a>; <a href="./references#CD002997-bbs2-0074" title="Global Initiative for Asthma. Global strategy for asthma management and prevention (1995 version). ginasthma.org/wp-content/uploads/2019/01/1995-GINA.pdf (accessed 8 April 2015).">GINA 1995</a>; <a href="./references#CD002997-bbs2-0075" title="Global Initiative for Asthma. Global strategy for asthma management and prevention (2002 version). ginasthma.org/wp-content/uploads/2019/01/2002-GINA.pdf (accessed 8 April 2015).">GINA 2002</a>; <a href="./references#CD002997-bbs2-0076" title="Global Initiative for Asthma. Global strategy for asthma management and prevention (2007 update). ginasthma.org/wp-content/uploads/2019/01/2007-GINA.pdf (accessed 8 April 2015).">GINA 2007</a>; <a href="./references#CD002997-bbs2-0077" title="Global Initiative for Asthma. Global strategy for asthma management and prevention (update 2010). ginasthma.org/wp-content/uploads/2019/01/2010-GINA.pdf (accessed 8 April 2015).">GINA 2010</a>; <a href="./references#CD002997-bbs2-0078" title="Global Initiative for Asthma. Global strategy for asthma management and prevention (update 2014). ginasthma.org/wp-content/uploads/2019/01/2014-GINA.pdf (accessed 8 April 2015).">GINA 2014</a>); these are similar to the current international guidelines for what concerns main diagnosis and grading of severity of asthma (<a href="./references#CD002997-bbs2-0080" title="Global Initiative for Asthma. Global strategy for asthma management and prevention 2021. ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf (accessed prior to 14 November 2021.">GINA 2021</a>). </p> <p>Four studies assessed the effects of macrolide treatment in children with asthma (<a href="./references#CD002997-bbs2-0010" title="KamadaAK , HillMR , IkléDN , BrennerAM , SzeflerSJ . Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. Journal of Allergy and Clinical Immunology1993;91(4):873-82. ">Kamada 1993</a>; <a href="./references#CD002997-bbs2-0015" title="PiacentiniGL , PeroniDG , BodiniA , PigozziR , CostellaS , LoiaconoA , et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy and Asthma Proceedings2007;28(2):194-8. ">Piacentini 2007</a>; <a href="./references#CD002997-bbs2-0018" title="StrunkRC , BacharierLB , PhillipsBR , SzeflerSJ , ZeigerRS , ChinchilliVM , et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. Journal of Allergy and Clinical Immunology2008;122(6):1138-44.e4. ">Strunk 2008</a>; <a href="./references#CD002997-bbs2-0020" title="Wan K-S, Liu Y-C, Huang C-S, Su Y-M. Effects of low-dose clarithromycin added to fluticasone on inflammatory markers and pulmonary function among children with asthma: a randomized clinical trial. Allergy and Rhinology2016;7(3):e131-4. ">Wan 2016</a>), and the rest recruited adults with asthma (aged over 18 years). The studies varied according to <a href="./references#CD002997-bbs2-0078" title="Global Initiative for Asthma. Global strategy for asthma management and prevention (update 2014). ginasthma.org/wp-content/uploads/2019/01/2014-GINA.pdf (accessed 8 April 2015).">GINA 2014</a>/<a href="./references#CD002997-bbs2-0079" title="Global Initiative for Asthma. Global strategy for asthma management and prevention 2020. ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf (accessed prior to 20 May 2021).">GINA 2020</a>/<a href="./references#CD002997-bbs2-0080" title="Global Initiative for Asthma. Global strategy for asthma management and prevention 2021. ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf (accessed prior to 14 November 2021.">GINA 2021</a> criteria for asthma severity, and often there was very little information about baseline severity. </p> <p>Most studies included participants with persistent mild‐to‐severe asthma, while one included participants with mild asthma (step 1 according to <a href="./references#CD002997-bbs2-0080" title="Global Initiative for Asthma. Global strategy for asthma management and prevention 2021. ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf (accessed prior to 14 November 2021.">GINA 2021</a>) (<a href="./references#CD002997-bbs2-0001" title="AmayasuH , YashidaS , EbanaS , YamamotoY , NishikawaT , ShojiT , et al. Clarithromycin suppress bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Annals of Allergy, Asthma and Immunology2000;84(6):594-8. ">Amayasu 2000</a>), and one used people with aspirin‐induced intermittent asthma (<a href="./references#CD002997-bbs2-0016" title="ShojiT , YoshidaS , SakamotoH , HasegawaH , NakagawaH , AmayasuH . Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clinical and Experimental Allergy1999;29(7):950-6. ">Shoji 1999</a>). </p> <p>Five studies investigated the role of macrolides in people with evidence of <i>C pneumoniae</i> or <i>M pneumoniae</i> infection, based on serological (<a href="./references#CD002997-bbs2-0003" title="BlackP , JenkinsCR , ScicchitanoR , BlasiF , AllegraL , MillsG , et al. Randomised, controlled trial of roxithromycin for the treatment of asthma in subjects with serological evidence of infection with Chlamydia pneumoniae. American Journal of Respiratory and Critical Care Medicine2001;164(4):536-41. ">Black 2001</a>; <a href="./references#CD002997-bbs2-0007" title="HahnDL , PlaneMB , MahdiOS , ByrneGI . Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clinical Trials2006;1(2):e11. ">Hahn 2006</a>; <a href="./references#CD002997-bbs2-0020" title="Wan K-S, Liu Y-C, Huang C-S, Su Y-M. Effects of low-dose clarithromycin added to fluticasone on inflammatory markers and pulmonary function among children with asthma: a randomized clinical trial. Allergy and Rhinology2016;7(3):e131-4. ">Wan 2016</a>) or molecular (<a href="./references#CD002997-bbs2-0013" title="KraftM , CassellGH , PakJ , MartinRJ . Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest2002;121(6):1782-8. ">Kraft 2002</a>; <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a>) methods. The remaining studies did not investigate the presence of these co‐infections or of other concomitant co‐infections, although we could not confirm this in the non‐English language papers. <a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a> investigated the effect of macrolides in adult smokers with persistent asthma, while <a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a>, <a href="./references#CD002997-bbs2-0017" title="SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Respirology2007;12:A120. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25-28; Auckland:Abstract TO13. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Clarithromycin targets neutrophilic airway inflammation in refractory asthma. American Journal of Respiratory and Critical Care Medicine2008;177(2):148-55. ">Simpson 2008</a>, and <a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a> considered the effect of macrolides in people with eosinophilic and non‐eosinophilic asthma. </p> </section> <section id="CD002997-sec-0045"> <h5 class="title">Interventions</h5> <p>Five studies compared roxithromycin with placebo (<a href="./references#CD002997-bbs2-0003" title="BlackP , JenkinsCR , ScicchitanoR , BlasiF , AllegraL , MillsG , et al. Randomised, controlled trial of roxithromycin for the treatment of asthma in subjects with serological evidence of infection with Chlamydia pneumoniae. American Journal of Respiratory and Critical Care Medicine2001;164(4):536-41. ">Black 2001</a>; <a href="./references#CD002997-bbs2-0011" title="KapoorS , BrashierB , UdupaA , PawarR , KodguleR , LimayeS , et al. Therapeutic effect of low dose roxithromycin in chronic stable mild-to-moderate asthma. European Respiratory Journal2010;36(suppl 54):P1176. ">Kapoor 2010</a>; <a href="./references#CD002997-bbs2-0016" title="ShojiT , YoshidaS , SakamotoH , HasegawaH , NakagawaH , AmayasuH . Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clinical and Experimental Allergy1999;29(7):950-6. ">Shoji 1999</a>; <a href="./references#CD002997-bbs2-0023" title="XiaoKA . The study on effect of roxithromycin combined with budesonide in therapy in patients with asthma. Guide of Chinese Medicine2013;11:119-20. ">Xiao 2013</a>; <a href="./references#CD002997-bbs2-0024" title="YanXQ , WuLQ , LinJ , XiaoXD , DaiYR . Clinical study on efficacy of roxithromycin combined with inhaled budesonide dry powder inhalation on asthma [罗红霉素与布地奈德干粉吸入剂联用治疗哮喘的临床研究]. Chinese Journal of Pharmacology and Therapeutics2008;13(2):184-7. ">Yan 2008</a>); seven studies compared clarithromycin with placebo (<a href="./references#CD002997-bbs2-0001" title="AmayasuH , YashidaS , EbanaS , YamamotoY , NishikawaT , ShojiT , et al. Clarithromycin suppress bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Annals of Allergy, Asthma and Immunology2000;84(6):594-8. ">Amayasu 2000</a>; <a href="./references#CD002997-bbs2-0012" title="KostadimaE , TsiodrasS , AlexopoulosEI , KaditisAG , MavrouI , GeorgatouN , et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. European Respiratory Journal2004;23(5):714-7. ">Kostadima 2004</a>; <a href="./references#CD002997-bbs2-0013" title="KraftM , CassellGH , PakJ , MartinRJ . Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest2002;121(6):1782-8. ">Kraft 2002</a>; <a href="./references#CD002997-bbs2-0017" title="SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Respirology2007;12:A120. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25-28; Auckland:Abstract TO13. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Clarithromycin targets neutrophilic airway inflammation in refractory asthma. American Journal of Respiratory and Critical Care Medicine2008;177(2):148-55. ">Simpson 2008</a>; <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a>; <a href="./references#CD002997-bbs2-0022" title="WangT , PeiFY , SongXP , WangQ . Clinical impacts of low-dose azithromycin on lung function and fraction of exhaled nitric oxide concentration in bronchial asthma [小剂量阿奇霉素对支气管哮喘患者呼出气NO浓度及肺功能的影响]. Medical Innovation China2014;11(9):122-4. ">Wang 2014</a>; <a href="./references#CD002997-bbs2-0020" title="Wan K-S, Liu Y-C, Huang C-S, Su Y-M. Effects of low-dose clarithromycin added to fluticasone on inflammatory markers and pulmonary function among children with asthma: a randomized clinical trial. Allergy and Rhinology2016;7(3):e131-4. ">Wan 2016</a>); 11 studies investigated the effect of azithromycin (<a href="./references#CD002997-bbs2-0002" title="BelotserkovskayaY , SinopalnikovA . Open-trial randomized comparative trial of the efficacy of the azithromycin in the 8 week treatment of mild to moderate asthma. European Respiratory Journal2007;30(Suppl 51):358s. ">Belotserkovskaya 2007</a>; <a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a>; <a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a>; <a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a>; <a href="./references#CD002997-bbs2-0007" title="HahnDL , PlaneMB , MahdiOS , ByrneGI . Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clinical Trials2006;1(2):e11. ">Hahn 2006</a>; <a href="./references#CD002997-bbs2-0008" title="HahnD , GrasmickM , HetzelS . Pragmatic controlled trial of azithromycin for asthma in adults. European Respiratory Journal2011;38:322s. HahnDL , GrasmickM , HetzelS , YaleS . Azithromycin for bronchial asthma in adults: an effectiveness trial. Journal of the American Board of Family Medicine2012;25(4):442-59. ">Hahn 2012</a>; <a href="./references#CD002997-bbs2-0009" title="HeJ , ZhuN , ChenXD . Clinical impacts of azithromycin on lung function and cytokines for asthmatic patients. Fudan University Journal of Medical Science2009;36(6):719-22. ">He 2009</a>; <a href="./references#CD002997-bbs2-0015" title="PiacentiniGL , PeroniDG , BodiniA , PigozziR , CostellaS , LoiaconoA , et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy and Asthma Proceedings2007;28(2):194-8. ">Piacentini 2007</a>; <a href="./references#CD002997-bbs2-0018" title="StrunkRC , BacharierLB , PhillipsBR , SzeflerSJ , ZeigerRS , ChinchilliVM , et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. Journal of Allergy and Clinical Immunology2008;122(6):1138-44.e4. ">Strunk 2008</a>; <a href="./references#CD002997-bbs2-0021" title="WangY , ZhangSL , QuY . Effect of clarithromycin on non-eosinophilic refractory asthma [克拉霉素治疗非嗜酸粒细胞型难治性哮喘的疗效分析]. Journal of Clinical Pulmonary Medicine2012;17(11):1948-51. ">Wang 2012</a>; <a href="./references#CD002997-bbs2-0025" title="ZhangLY , QianQ . Clinical effect of azithromycin combined with Seretide for asthma. Strait Pharmaceutical Journal2013;25:159-60. ">Zhang 2013</a>), and two studies assessed the effects of troleandomycin in addition to oral steroid therapy as part of a steroid‐tapering protocol (<a href="./references#CD002997-bbs2-0010" title="KamadaAK , HillMR , IkléDN , BrennerAM , SzeflerSJ . Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. Journal of Allergy and Clinical Immunology1993;91(4):873-82. ">Kamada 1993</a>; <a href="./references#CD002997-bbs2-0014" title="NelsonHS , HamilosDL , CorselloPR , LevesqueNV , BuchmeierAD , BuckerBL . A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. American Review of Respiratory Disease1993;147(2):398-404. ">Nelson 1993</a>). </p> </section> <section id="CD002997-sec-0046"> <h5 class="title">Outcomes</h5> <p>Six studies did not appear in any of the quantitative syntheses (<a href="./references#CD002997-bbs2-0002" title="BelotserkovskayaY , SinopalnikovA . Open-trial randomized comparative trial of the efficacy of the azithromycin in the 8 week treatment of mild to moderate asthma. European Respiratory Journal2007;30(Suppl 51):358s. ">Belotserkovskaya 2007</a>; <a href="./references#CD002997-bbs2-0003" title="BlackP , JenkinsCR , ScicchitanoR , BlasiF , AllegraL , MillsG , et al. Randomised, controlled trial of roxithromycin for the treatment of asthma in subjects with serological evidence of infection with Chlamydia pneumoniae. American Journal of Respiratory and Critical Care Medicine2001;164(4):536-41. ">Black 2001</a>; <a href="./references#CD002997-bbs2-0011" title="KapoorS , BrashierB , UdupaA , PawarR , KodguleR , LimayeS , et al. Therapeutic effect of low dose roxithromycin in chronic stable mild-to-moderate asthma. European Respiratory Journal2010;36(suppl 54):P1176. ">Kapoor 2010</a>; <a href="./references#CD002997-bbs2-0020" title="Wan K-S, Liu Y-C, Huang C-S, Su Y-M. Effects of low-dose clarithromycin added to fluticasone on inflammatory markers and pulmonary function among children with asthma: a randomized clinical trial. Allergy and Rhinology2016;7(3):e131-4. ">Wan 2016</a>; <a href="./references#CD002997-bbs2-0021" title="WangY , ZhangSL , QuY . Effect of clarithromycin on non-eosinophilic refractory asthma [克拉霉素治疗非嗜酸粒细胞型难治性哮喘的疗效分析]. Journal of Clinical Pulmonary Medicine2012;17(11):1948-51. ">Wang 2012</a>; <a href="./references#CD002997-bbs2-0025" title="ZhangLY , QianQ . Clinical effect of azithromycin combined with Seretide for asthma. Strait Pharmaceutical Journal2013;25:159-60. ">Zhang 2013</a>), and two more only contributed to the bronchial hyperresponsiveness summary of results and withdrawal (<a href="./references#CD002997-bbs2-0015" title="PiacentiniGL , PeroniDG , BodiniA , PigozziR , CostellaS , LoiaconoA , et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy and Asthma Proceedings2007;28(2):194-8. ">Piacentini 2007</a>; <a href="./references#CD002997-bbs2-0017" title="SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Respirology2007;12:A120. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25-28; Auckland:Abstract TO13. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Clarithromycin targets neutrophilic airway inflammation in refractory asthma. American Journal of Respiratory and Critical Care Medicine2008;177(2):148-55. ">Simpson 2008</a>). </p> <p>Two studies reported data on exacerbations requiring hospitalisation (<a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a>; <a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a>), and four on severe exacerbations (defined as exacerbations requiring ED visits or systemic steroids, or both) as an outcome, but the definition of 'severe exacerbation' used in the different studies was variable and sometimes unclear (<a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a>; <a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a>; <a href="./references#CD002997-bbs2-0012" title="KostadimaE , TsiodrasS , AlexopoulosEI , KaditisAG , MavrouI , GeorgatouN , et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. European Respiratory Journal2004;23(5):714-7. ">Kostadima 2004</a>; <a href="./references#CD002997-bbs2-0018" title="StrunkRC , BacharierLB , PhillipsBR , SzeflerSJ , ZeigerRS , ChinchilliVM , et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. Journal of Allergy and Clinical Immunology2008;122(6):1138-44.e4. ">Strunk 2008</a>). The meta‐analysis of <a href="./references#CD002997-bbs2-0103" title="TongX , GuoT , LiuS , PengS , YanS , YangX , et al. Macrolide antibiotics for treatment of asthma in adults: a meta-analysis of 18 randomized controlled clinical studies. Pulmonary Pharmacology and Therapeutics2015;31:99-108.">Tong 2015</a> did not include exacerbations as an outcome but explicitly confirmed that the Chinese studies did not report this outcome either. Data from these studies only contributed to one meta‐analysis (FEV<sub>1</sub>). We narratively summarised data that could not be meta‐analysed for the relevant outcomes. </p> <p>Most studies reported measures of symptoms, asthma control or quality of life, but the analyses were limited by the way data were reported and by the use of different scales. We did not consider a meta‐analysis of all these measures to be valid or the subsequent results to be interpretable in any meaningful way, so we chose only to meta‐analyse those that we knew would be similar. We used SMDs for the 'symptom scale' meta‐analysis, which still made the effect and its precision difficult to interpret. </p> <p>Four studies reported data about change in rescue medication as puffs per day in a way that could be included in meta‐analysis (<a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a>; <a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a>; <a href="./references#CD002997-bbs2-0007" title="HahnDL , PlaneMB , MahdiOS , ByrneGI . Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clinical Trials2006;1(2):e11. ">Hahn 2006</a>; <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a>). </p> <p>Most of the studies reported measures of lung function such as FEV<sub>1</sub> or PEF, but only 10 reported data for FEV<sub>1</sub> (<a href="./references#CD002997-bbs2-0001" title="AmayasuH , YashidaS , EbanaS , YamamotoY , NishikawaT , ShojiT , et al. Clarithromycin suppress bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Annals of Allergy, Asthma and Immunology2000;84(6):594-8. ">Amayasu 2000</a>; <a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a>; <a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a>; <a href="./references#CD002997-bbs2-0009" title="HeJ , ZhuN , ChenXD . Clinical impacts of azithromycin on lung function and cytokines for asthmatic patients. Fudan University Journal of Medical Science2009;36(6):719-22. ">He 2009</a>; <a href="./references#CD002997-bbs2-0013" title="KraftM , CassellGH , PakJ , MartinRJ . Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest2002;121(6):1782-8. ">Kraft 2002</a>; <a href="./references#CD002997-bbs2-0016" title="ShojiT , YoshidaS , SakamotoH , HasegawaH , NakagawaH , AmayasuH . Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clinical and Experimental Allergy1999;29(7):950-6. ">Shoji 1999</a>; <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a>; <a href="./references#CD002997-bbs2-0022" title="WangT , PeiFY , SongXP , WangQ . Clinical impacts of low-dose azithromycin on lung function and fraction of exhaled nitric oxide concentration in bronchial asthma [小剂量阿奇霉素对支气管哮喘患者呼出气NO浓度及肺功能的影响]. Medical Innovation China2014;11(9):122-4. ">Wang 2014</a>; <a href="./references#CD002997-bbs2-0023" title="XiaoKA . The study on effect of roxithromycin combined with budesonide in therapy in patients with asthma. Guide of Chinese Medicine2013;11:119-20. ">Xiao 2013</a>; <a href="./references#CD002997-bbs2-0024" title="YanXQ , WuLQ , LinJ , XiaoXD , DaiYR . Clinical study on efficacy of roxithromycin combined with inhaled budesonide dry powder inhalation on asthma [罗红霉素与布地奈德干粉吸入剂联用治疗哮喘的临床研究]. Chinese Journal of Pharmacology and Therapeutics2008;13(2):184-7. ">Yan 2008</a>), four reported morning PEF (<a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a>; <a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a>; <a href="./references#CD002997-bbs2-0010" title="KamadaAK , HillMR , IkléDN , BrennerAM , SzeflerSJ . Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. Journal of Allergy and Clinical Immunology1993;91(4):873-82. ">Kamada 1993</a>; <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a>), and three reported for evening PEF (<a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a>; <a href="./references#CD002997-bbs2-0010" title="KamadaAK , HillMR , IkléDN , BrennerAM , SzeflerSJ . Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. Journal of Allergy and Clinical Immunology1993;91(4):873-82. ">Kamada 1993</a>; <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a>) that could be pooled. There were some issues with selective reporting that prevented studies from being included in the analyses, such as data only being presented graphically or without a measure of variance (e.g. <a href="./references#CD002997-bbs2-0003" title="BlackP , JenkinsCR , ScicchitanoR , BlasiF , AllegraL , MillsG , et al. Randomised, controlled trial of roxithromycin for the treatment of asthma in subjects with serological evidence of infection with Chlamydia pneumoniae. American Journal of Respiratory and Critical Care Medicine2001;164(4):536-41. ">Black 2001</a>; <a href="./references#CD002997-bbs2-0020" title="Wan K-S, Liu Y-C, Huang C-S, Su Y-M. Effects of low-dose clarithromycin added to fluticasone on inflammatory markers and pulmonary function among children with asthma: a randomized clinical trial. Allergy and Rhinology2016;7(3):e131-4. ">Wan 2016</a>). It was often unclear when the measures were taken (i.e. pre‐ or post‐bronchodilator), but when the information was available, we recorded it in the analysis footnotes. <a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a> reported percentage FEV<sub>1</sub>, but their data could not be combined with the other studies, which reported the outcome in litres. We combined the data made available to us from <a href="./references#CD002997-bbs2-0103" title="TongX , GuoT , LiuS , PengS , YanS , YangX , et al. Macrolide antibiotics for treatment of asthma in adults: a meta-analysis of 18 randomized controlled clinical studies. Pulmonary Pharmacology and Therapeutics2015;31:99-108.">Tong 2015</a> for <a href="./references#CD002997-bbs2-0009" title="HeJ , ZhuN , ChenXD . Clinical impacts of azithromycin on lung function and cytokines for asthmatic patients. Fudan University Journal of Medical Science2009;36(6):719-22. ">He 2009</a>, <a href="./references#CD002997-bbs2-0022" title="WangT , PeiFY , SongXP , WangQ . Clinical impacts of low-dose azithromycin on lung function and fraction of exhaled nitric oxide concentration in bronchial asthma [小剂量阿奇霉素对支气管哮喘患者呼出气NO浓度及肺功能的影响]. Medical Innovation China2014;11(9):122-4. ">Wang 2014</a>, <a href="./references#CD002997-bbs2-0023" title="XiaoKA . The study on effect of roxithromycin combined with budesonide in therapy in patients with asthma. Guide of Chinese Medicine2013;11:119-20. ">Xiao 2013</a>, and <a href="./references#CD002997-bbs2-0024" title="YanXQ , WuLQ , LinJ , XiaoXD , DaiYR . Clinical study on efficacy of roxithromycin combined with inhaled budesonide dry powder inhalation on asthma [罗红霉素与布地奈德干粉吸入剂联用治疗哮喘的临床研究]. Chinese Journal of Pharmacology and Therapeutics2008;13(2):184-7. ">Yan 2008</a>. We were also provided with data for peak flow for <a href="./references#CD002997-bbs2-0022" title="WangT , PeiFY , SongXP , WangQ . Clinical impacts of low-dose azithromycin on lung function and fraction of exhaled nitric oxide concentration in bronchial asthma [小剂量阿奇霉素对支气管哮喘患者呼出气NO浓度及肺功能的影响]. Medical Innovation China2014;11(9):122-4. ">Wang 2014</a>, <a href="./references#CD002997-bbs2-0023" title="XiaoKA . The study on effect of roxithromycin combined with budesonide in therapy in patients with asthma. Guide of Chinese Medicine2013;11:119-20. ">Xiao 2013</a>, and <a href="./references#CD002997-bbs2-0024" title="YanXQ , WuLQ , LinJ , XiaoXD , DaiYR . Clinical study on efficacy of roxithromycin combined with inhaled budesonide dry powder inhalation on asthma [罗红霉素与布地奈德干粉吸入剂联用治疗哮喘的临床研究]. Chinese Journal of Pharmacology and Therapeutics2008;13(2):184-7. ">Yan 2008</a>, but the data were a different order of magnitude to the other studies, and it did not make sense to pool them. </p> <p>Nine studies considered bronchial hyperresponsiveness, but there was variation in the measures used and the way the data were reported, which meant it was not possible to meta‐analyse the data (<a href="./references#CD002997-bbs2-0001" title="AmayasuH , YashidaS , EbanaS , YamamotoY , NishikawaT , ShojiT , et al. Clarithromycin suppress bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Annals of Allergy, Asthma and Immunology2000;84(6):594-8. ">Amayasu 2000</a>; <a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a>; <a href="./references#CD002997-bbs2-0010" title="KamadaAK , HillMR , IkléDN , BrennerAM , SzeflerSJ . Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. Journal of Allergy and Clinical Immunology1993;91(4):873-82. ">Kamada 1993</a>; <a href="./references#CD002997-bbs2-0012" title="KostadimaE , TsiodrasS , AlexopoulosEI , KaditisAG , MavrouI , GeorgatouN , et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. European Respiratory Journal2004;23(5):714-7. ">Kostadima 2004</a>; <a href="./references#CD002997-bbs2-0014" title="NelsonHS , HamilosDL , CorselloPR , LevesqueNV , BuchmeierAD , BuckerBL . A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. American Review of Respiratory Disease1993;147(2):398-404. ">Nelson 1993</a>; <a href="./references#CD002997-bbs2-0015" title="PiacentiniGL , PeroniDG , BodiniA , PigozziR , CostellaS , LoiaconoA , et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy and Asthma Proceedings2007;28(2):194-8. ">Piacentini 2007</a>; <a href="./references#CD002997-bbs2-0016" title="ShojiT , YoshidaS , SakamotoH , HasegawaH , NakagawaH , AmayasuH . Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clinical and Experimental Allergy1999;29(7):950-6. ">Shoji 1999</a>; <a href="./references#CD002997-bbs2-0017" title="SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Respirology2007;12:A120. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25-28; Auckland:Abstract TO13. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Clarithromycin targets neutrophilic airway inflammation in refractory asthma. American Journal of Respiratory and Critical Care Medicine2008;177(2):148-55. ">Simpson 2008</a>; <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a>).  </p> <p>Most studies considered adverse events, but only eight explicitly reported serious adverse events (<a href="./references#CD002997-bbs2-0001" title="AmayasuH , YashidaS , EbanaS , YamamotoY , NishikawaT , ShojiT , et al. Clarithromycin suppress bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Annals of Allergy, Asthma and Immunology2000;84(6):594-8. ">Amayasu 2000</a>; <a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a>; <a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a>; <a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a>; <a href="./references#CD002997-bbs2-0007" title="HahnDL , PlaneMB , MahdiOS , ByrneGI . Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clinical Trials2006;1(2):e11. ">Hahn 2006</a>; <a href="./references#CD002997-bbs2-0008" title="HahnD , GrasmickM , HetzelS . Pragmatic controlled trial of azithromycin for asthma in adults. European Respiratory Journal2011;38:322s. HahnDL , GrasmickM , HetzelS , YaleS . Azithromycin for bronchial asthma in adults: an effectiveness trial. Journal of the American Board of Family Medicine2012;25(4):442-59. ">Hahn 2012</a>; <a href="./references#CD002997-bbs2-0010" title="KamadaAK , HillMR , IkléDN , BrennerAM , SzeflerSJ . Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. Journal of Allergy and Clinical Immunology1993;91(4):873-82. ">Kamada 1993</a>; <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a>). While it was not ideal to include the dichotomous cross‐over data without adjusting them to account for matched pairs, there were no events in <a href="./references#CD002997-bbs2-0001" title="AmayasuH , YashidaS , EbanaS , YamamotoY , NishikawaT , ShojiT , et al. Clarithromycin suppress bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Annals of Allergy, Asthma and Immunology2000;84(6):594-8. ">Amayasu 2000</a>, so it did not contribute to the pooled effect. </p> <p>Ten studies reported study withdrawal (<a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a>; <a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a>; <a href="./references#CD002997-bbs2-0007" title="HahnDL , PlaneMB , MahdiOS , ByrneGI . Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clinical Trials2006;1(2):e11. ">Hahn 2006</a>; <a href="./references#CD002997-bbs2-0008" title="HahnD , GrasmickM , HetzelS . Pragmatic controlled trial of azithromycin for asthma in adults. European Respiratory Journal2011;38:322s. HahnDL , GrasmickM , HetzelS , YaleS . Azithromycin for bronchial asthma in adults: an effectiveness trial. Journal of the American Board of Family Medicine2012;25(4):442-59. ">Hahn 2012</a>; <a href="./references#CD002997-bbs2-0010" title="KamadaAK , HillMR , IkléDN , BrennerAM , SzeflerSJ . Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. Journal of Allergy and Clinical Immunology1993;91(4):873-82. ">Kamada 1993</a>; <a href="./references#CD002997-bbs2-0012" title="KostadimaE , TsiodrasS , AlexopoulosEI , KaditisAG , MavrouI , GeorgatouN , et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. European Respiratory Journal2004;23(5):714-7. ">Kostadima 2004</a>; <a href="./references#CD002997-bbs2-0014" title="NelsonHS , HamilosDL , CorselloPR , LevesqueNV , BuchmeierAD , BuckerBL . A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. American Review of Respiratory Disease1993;147(2):398-404. ">Nelson 1993</a>; <a href="./references#CD002997-bbs2-0017" title="SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Respirology2007;12:A120. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25-28; Auckland:Abstract TO13. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Clarithromycin targets neutrophilic airway inflammation in refractory asthma. American Journal of Respiratory and Critical Care Medicine2008;177(2):148-55. ">Simpson 2008</a>; <a href="./references#CD002997-bbs2-0018" title="StrunkRC , BacharierLB , PhillipsBR , SzeflerSJ , ZeigerRS , ChinchilliVM , et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. Journal of Allergy and Clinical Immunology2008;122(6):1138-44.e4. ">Strunk 2008</a>; <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a>). </p> <p>Eight studies reported the effect of macrolides on markers of inflammation related to asthma activity, but they used different measures, which could not be pooled in one analysis (<a href="./references#CD002997-bbs2-0001" title="AmayasuH , YashidaS , EbanaS , YamamotoY , NishikawaT , ShojiT , et al. Clarithromycin suppress bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Annals of Allergy, Asthma and Immunology2000;84(6):594-8. ">Amayasu 2000</a>; <a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a>; <a href="./references#CD002997-bbs2-0013" title="KraftM , CassellGH , PakJ , MartinRJ . Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest2002;121(6):1782-8. ">Kraft 2002</a>; <a href="./references#CD002997-bbs2-0014" title="NelsonHS , HamilosDL , CorselloPR , LevesqueNV , BuchmeierAD , BuckerBL . A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. American Review of Respiratory Disease1993;147(2):398-404. ">Nelson 1993</a>; <a href="./references#CD002997-bbs2-0015" title="PiacentiniGL , PeroniDG , BodiniA , PigozziR , CostellaS , LoiaconoA , et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy and Asthma Proceedings2007;28(2):194-8. ">Piacentini 2007</a>; <a href="./references#CD002997-bbs2-0016" title="ShojiT , YoshidaS , SakamotoH , HasegawaH , NakagawaH , AmayasuH . Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clinical and Experimental Allergy1999;29(7):950-6. ">Shoji 1999</a>; <a href="./references#CD002997-bbs2-0017" title="SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Respirology2007;12:A120. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25-28; Auckland:Abstract TO13. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Clarithromycin targets neutrophilic airway inflammation in refractory asthma. American Journal of Respiratory and Critical Care Medicine2008;177(2):148-55. ">Simpson 2008</a>; <a href="./references#CD002997-bbs2-0024" title="YanXQ , WuLQ , LinJ , XiaoXD , DaiYR . Clinical study on efficacy of roxithromycin combined with inhaled budesonide dry powder inhalation on asthma [罗红霉素与布地奈德干粉吸入剂联用治疗哮喘的临床研究]. Chinese Journal of Pharmacology and Therapeutics2008;13(2):184-7. ">Yan 2008</a>). There were also some issues with data accuracy or incomplete reporting that reduced our confidence in the reliability of the data. The separate analyses include very small participant numbers, mostly from the two cross‐over studies. </p> <p>Two studies considered the steroid‐sparing effect of macrolides (<a href="./references#CD002997-bbs2-0010" title="KamadaAK , HillMR , IkléDN , BrennerAM , SzeflerSJ . Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. Journal of Allergy and Clinical Immunology1993;91(4):873-82. ">Kamada 1993</a>; <a href="./references#CD002997-bbs2-0014" title="NelsonHS , HamilosDL , CorselloPR , LevesqueNV , BuchmeierAD , BuckerBL . A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. American Review of Respiratory Disease1993;147(2):398-404. ">Nelson 1993</a>). </p> </section> </section> <section id="CD002997-sec-0047"> <h4 class="title">Excluded studies</h4> <p>We excluded 14 studies from the review after viewing the full papers. Reasons for exclusion are reported in the <a href="./references#CD002997-sec-0110" title="">Characteristics of excluded studies</a> table and <a href="#CD002997-fig-0001">Figure 1</a>. </p> <p>Previous versions of this systematic review excluded 17 studies after reading the full papers (<a href="./references#CD002997-bbs2-0106" title="KewKM , UndelaK , KotortsiI , FerraraG . Macrolides for chronic asthma. Cochrane Database of Systematic Reviews2015, Issue 9. Art. No: CD002997. [DOI: 10.1002/14651858.CD002997.pub4]">Kew 2015</a>; <a href="./references#CD002997-bbs2-0108" title="RicheldiL , FerraraG , FabbriLM , LassersonTJ , GibsonPG . Macrolides for chronic asthma. Cochrane Database of Systematic Reviews2005, Issue 3. Art. No: CD002997. [DOI: 10.1002/14651858.CD002997.pub2]">Richeldi 2005</a>), so a total of 31 studies are excluded. </p> </section> <section id="CD002997-sec-0048"> <h4 class="title">Studies awaiting classification</h4> <p>There are no studies awaiting classification.</p> </section> <section id="CD002997-sec-0049"> <h4 class="title">Ongoing studies</h4> <p>We found one ongoing study (<a href="./references#CD002997-bbs2-0057" title="NCT02517099. Preschool wheeze: Inflammation/Infection Guided Management (PrIGMa) [Use of pathological phenotype to determine optimal management for moderate to severe preschool wheeze]. www.clinicaltrials.gov/ct2/show/NCT02517099 (first received 6 August 2015). ">NCT02517099</a>). </p> </section> </section> <section id="CD002997-sec-0050"> <h3 class="title">Risk of bias in included studies</h3> <p>There was considerable uncertainty relating to study methodology due to insufficient reporting in the published reports. This was particularly true for the selection bias domains, but also for blinding of outcome assessment and attrition bias. We had concerns about incomplete and selective reporting of the results for most of the studies and generally considered there to be a high risk for bias because only a few studies reported data in a way that could be pooled in meta‐analysis. Summaries of the risk of bias judgements for each study are presented in <a href="#CD002997-fig-0002">Figure 2</a> and <a href="#CD002997-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD002997-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002997-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD002997-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD002997-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <p>Pharmaceutical industries financed at least five included studies (<a href="./references#CD002997-bbs2-0001" title="AmayasuH , YashidaS , EbanaS , YamamotoY , NishikawaT , ShojiT , et al. Clarithromycin suppress bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Annals of Allergy, Asthma and Immunology2000;84(6):594-8. ">Amayasu 2000</a>; <a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a>; <a href="./references#CD002997-bbs2-0007" title="HahnDL , PlaneMB , MahdiOS , ByrneGI . Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clinical Trials2006;1(2):e11. ">Hahn 2006</a>; <a href="./references#CD002997-bbs2-0008" title="HahnD , GrasmickM , HetzelS . Pragmatic controlled trial of azithromycin for asthma in adults. European Respiratory Journal2011;38:322s. HahnDL , GrasmickM , HetzelS , YaleS . Azithromycin for bronchial asthma in adults: an effectiveness trial. Journal of the American Board of Family Medicine2012;25(4):442-59. ">Hahn 2012</a>; <a href="./references#CD002997-bbs2-0010" title="KamadaAK , HillMR , IkléDN , BrennerAM , SzeflerSJ . Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. Journal of Allergy and Clinical Immunology1993;91(4):873-82. ">Kamada 1993</a>); which could raise the risk of publication bias; this could not be ascertained in the non‐English language papers. The authors of <a href="./references#CD002997-bbs2-0103" title="TongX , GuoT , LiuS , PengS , YanS , YangX , et al. Macrolide antibiotics for treatment of asthma in adults: a meta-analysis of 18 randomized controlled clinical studies. Pulmonary Pharmacology and Therapeutics2015;31:99-108.">Tong 2015</a> provided us with information about study quality for the studies that were not available in English. </p> <section id="CD002997-sec-0051"> <h4 class="title">Allocation</h4> <p>We deemed 13 studies at low risk of bias for random sequence generation, including seven of the English language studies (<a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a>; <a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a>; <a href="./references#CD002997-bbs2-0007" title="HahnDL , PlaneMB , MahdiOS , ByrneGI . Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clinical Trials2006;1(2):e11. ">Hahn 2006</a>; <a href="./references#CD002997-bbs2-0008" title="HahnD , GrasmickM , HetzelS . Pragmatic controlled trial of azithromycin for asthma in adults. European Respiratory Journal2011;38:322s. HahnDL , GrasmickM , HetzelS , YaleS . Azithromycin for bronchial asthma in adults: an effectiveness trial. Journal of the American Board of Family Medicine2012;25(4):442-59. ">Hahn 2012</a>; <a href="./references#CD002997-bbs2-0015" title="PiacentiniGL , PeroniDG , BodiniA , PigozziR , CostellaS , LoiaconoA , et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy and Asthma Proceedings2007;28(2):194-8. ">Piacentini 2007</a>; <a href="./references#CD002997-bbs2-0017" title="SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Respirology2007;12:A120. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25-28; Auckland:Abstract TO13. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Clarithromycin targets neutrophilic airway inflammation in refractory asthma. American Journal of Respiratory and Critical Care Medicine2008;177(2):148-55. ">Simpson 2008</a>; <a href="./references#CD002997-bbs2-0020" title="Wan K-S, Liu Y-C, Huang C-S, Su Y-M. Effects of low-dose clarithromycin added to fluticasone on inflammatory markers and pulmonary function among children with asthma: a randomized clinical trial. Allergy and Rhinology2016;7(3):e131-4. ">Wan 2016</a>) and six in <a href="./references#CD002997-bbs2-0103" title="TongX , GuoT , LiuS , PengS , YanS , YangX , et al. Macrolide antibiotics for treatment of asthma in adults: a meta-analysis of 18 randomized controlled clinical studies. Pulmonary Pharmacology and Therapeutics2015;31:99-108.">Tong 2015</a> (<a href="./references#CD002997-bbs2-0009" title="HeJ , ZhuN , ChenXD . Clinical impacts of azithromycin on lung function and cytokines for asthmatic patients. Fudan University Journal of Medical Science2009;36(6):719-22. ">He 2009</a>; <a href="./references#CD002997-bbs2-0021" title="WangY , ZhangSL , QuY . Effect of clarithromycin on non-eosinophilic refractory asthma [克拉霉素治疗非嗜酸粒细胞型难治性哮喘的疗效分析]. Journal of Clinical Pulmonary Medicine2012;17(11):1948-51. ">Wang 2012</a>; <a href="./references#CD002997-bbs2-0022" title="WangT , PeiFY , SongXP , WangQ . Clinical impacts of low-dose azithromycin on lung function and fraction of exhaled nitric oxide concentration in bronchial asthma [小剂量阿奇霉素对支气管哮喘患者呼出气NO浓度及肺功能的影响]. Medical Innovation China2014;11(9):122-4. ">Wang 2014</a>; <a href="./references#CD002997-bbs2-0023" title="XiaoKA . The study on effect of roxithromycin combined with budesonide in therapy in patients with asthma. Guide of Chinese Medicine2013;11:119-20. ">Xiao 2013</a>; <a href="./references#CD002997-bbs2-0024" title="YanXQ , WuLQ , LinJ , XiaoXD , DaiYR . Clinical study on efficacy of roxithromycin combined with inhaled budesonide dry powder inhalation on asthma [罗红霉素与布地奈德干粉吸入剂联用治疗哮喘的临床研究]. Chinese Journal of Pharmacology and Therapeutics2008;13(2):184-7. ">Yan 2008</a>; <a href="./references#CD002997-bbs2-0025" title="ZhangLY , QianQ . Clinical effect of azithromycin combined with Seretide for asthma. Strait Pharmaceutical Journal2013;25:159-60. ">Zhang 2013</a>). For the rest, the methods for random sequence generation was unclear. </p> <p>Only five studies were at low risk for adequate allocation concealment (<a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a>; <a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a>; <a href="./references#CD002997-bbs2-0007" title="HahnDL , PlaneMB , MahdiOS , ByrneGI . Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clinical Trials2006;1(2):e11. ">Hahn 2006</a>; <a href="./references#CD002997-bbs2-0008" title="HahnD , GrasmickM , HetzelS . Pragmatic controlled trial of azithromycin for asthma in adults. European Respiratory Journal2011;38:322s. HahnDL , GrasmickM , HetzelS , YaleS . Azithromycin for bronchial asthma in adults: an effectiveness trial. Journal of the American Board of Family Medicine2012;25(4):442-59. ">Hahn 2012</a>; <a href="./references#CD002997-bbs2-0020" title="Wan K-S, Liu Y-C, Huang C-S, Su Y-M. Effects of low-dose clarithromycin added to fluticasone on inflammatory markers and pulmonary function among children with asthma: a randomized clinical trial. Allergy and Rhinology2016;7(3):e131-4. ">Wan 2016</a>); the studies from the <a href="./references#CD002997-bbs2-0103" title="TongX , GuoT , LiuS , PengS , YanS , YangX , et al. Macrolide antibiotics for treatment of asthma in adults: a meta-analysis of 18 randomized controlled clinical studies. Pulmonary Pharmacology and Therapeutics2015;31:99-108.">Tong 2015</a> review were not assessed for this criterion because it is not considered in the <a href="./references#CD002997-bbs2-0086" title="JadadA , MooreRA , CarrollD , JenksonC , ReynoldsJM , GavaghanDJ , et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?Controlled Clinical Trials1996;17(1):1-12.">Jadad 1996</a> system, so we had to rate those studies as unclear, and the 14 other studies did not adequately describe the methods used. </p> </section> <section id="CD002997-sec-0052"> <h4 class="title">Blinding</h4> <p>Most studies described as double‐blind and placebo‐controlled contained adequate descriptions of the blinding of participants and personnel, but methods were unclear in nine studies (<a href="./references#CD002997-bbs2-0009" title="HeJ , ZhuN , ChenXD . Clinical impacts of azithromycin on lung function and cytokines for asthmatic patients. Fudan University Journal of Medical Science2009;36(6):719-22. ">He 2009</a>; <a href="./references#CD002997-bbs2-0020" title="Wan K-S, Liu Y-C, Huang C-S, Su Y-M. Effects of low-dose clarithromycin added to fluticasone on inflammatory markers and pulmonary function among children with asthma: a randomized clinical trial. Allergy and Rhinology2016;7(3):e131-4. ">Wan 2016</a>; <a href="./references#CD002997-bbs2-0021" title="WangY , ZhangSL , QuY . Effect of clarithromycin on non-eosinophilic refractory asthma [克拉霉素治疗非嗜酸粒细胞型难治性哮喘的疗效分析]. Journal of Clinical Pulmonary Medicine2012;17(11):1948-51. ">Wang 2012</a>; <a href="./references#CD002997-bbs2-0022" title="WangT , PeiFY , SongXP , WangQ . Clinical impacts of low-dose azithromycin on lung function and fraction of exhaled nitric oxide concentration in bronchial asthma [小剂量阿奇霉素对支气管哮喘患者呼出气NO浓度及肺功能的影响]. Medical Innovation China2014;11(9):122-4. ">Wang 2014</a>; <a href="./references#CD002997-bbs2-0023" title="XiaoKA . The study on effect of roxithromycin combined with budesonide in therapy in patients with asthma. Guide of Chinese Medicine2013;11:119-20. ">Xiao 2013</a>; <a href="./references#CD002997-bbs2-0024" title="YanXQ , WuLQ , LinJ , XiaoXD , DaiYR . Clinical study on efficacy of roxithromycin combined with inhaled budesonide dry powder inhalation on asthma [罗红霉素与布地奈德干粉吸入剂联用治疗哮喘的临床研究]. Chinese Journal of Pharmacology and Therapeutics2008;13(2):184-7. ">Yan 2008</a>; <a href="./references#CD002997-bbs2-0025" title="ZhangLY , QianQ . Clinical effect of azithromycin combined with Seretide for asthma. Strait Pharmaceutical Journal2013;25:159-60. ">Zhang 2013</a>, including two in an abstract form: <a href="./references#CD002997-bbs2-0002" title="BelotserkovskayaY , SinopalnikovA . Open-trial randomized comparative trial of the efficacy of the azithromycin in the 8 week treatment of mild to moderate asthma. European Respiratory Journal2007;30(Suppl 51):358s. ">Belotserkovskaya 2007</a>; <a href="./references#CD002997-bbs2-0011" title="KapoorS , BrashierB , UdupaA , PawarR , KodguleR , LimayeS , et al. Therapeutic effect of low dose roxithromycin in chronic stable mild-to-moderate asthma. European Respiratory Journal2010;36(suppl 54):P1176. ">Kapoor 2010</a>). Blinding of outcome assessment was adequate in seven studies (<a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a>; <a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a>; <a href="./references#CD002997-bbs2-0007" title="HahnDL , PlaneMB , MahdiOS , ByrneGI . Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clinical Trials2006;1(2):e11. ">Hahn 2006</a>; <a href="./references#CD002997-bbs2-0008" title="HahnD , GrasmickM , HetzelS . Pragmatic controlled trial of azithromycin for asthma in adults. European Respiratory Journal2011;38:322s. HahnDL , GrasmickM , HetzelS , YaleS . Azithromycin for bronchial asthma in adults: an effectiveness trial. Journal of the American Board of Family Medicine2012;25(4):442-59. ">Hahn 2012</a>; <a href="./references#CD002997-bbs2-0013" title="KraftM , CassellGH , PakJ , MartinRJ . Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest2002;121(6):1782-8. ">Kraft 2002</a>; <a href="./references#CD002997-bbs2-0015" title="PiacentiniGL , PeroniDG , BodiniA , PigozziR , CostellaS , LoiaconoA , et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy and Asthma Proceedings2007;28(2):194-8. ">Piacentini 2007</a>; <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a>). </p> <p>The same study that we rated high for performance bias also carried a high risk for detection bias (<a href="./references#CD002997-bbs2-0018" title="StrunkRC , BacharierLB , PhillipsBR , SzeflerSJ , ZeigerRS , ChinchilliVM , et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. Journal of Allergy and Clinical Immunology2008;122(6):1138-44.e4. ">Strunk 2008</a>). </p> </section> <section id="CD002997-sec-0053"> <h4 class="title">Incomplete outcome data</h4> <p>Six studies had a high risk of attrition bias (<a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a>; <a href="./references#CD002997-bbs2-0007" title="HahnDL , PlaneMB , MahdiOS , ByrneGI . Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clinical Trials2006;1(2):e11. ">Hahn 2006</a>; <a href="./references#CD002997-bbs2-0008" title="HahnD , GrasmickM , HetzelS . Pragmatic controlled trial of azithromycin for asthma in adults. European Respiratory Journal2011;38:322s. HahnDL , GrasmickM , HetzelS , YaleS . Azithromycin for bronchial asthma in adults: an effectiveness trial. Journal of the American Board of Family Medicine2012;25(4):442-59. ">Hahn 2012</a>; <a href="./references#CD002997-bbs2-0012" title="KostadimaE , TsiodrasS , AlexopoulosEI , KaditisAG , MavrouI , GeorgatouN , et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. European Respiratory Journal2004;23(5):714-7. ">Kostadima 2004</a>; <a href="./references#CD002997-bbs2-0014" title="NelsonHS , HamilosDL , CorselloPR , LevesqueNV , BuchmeierAD , BuckerBL . A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. American Review of Respiratory Disease1993;147(2):398-404. ">Nelson 1993</a>; <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a>), five carried a low risk (<a href="./references#CD002997-bbs2-0003" title="BlackP , JenkinsCR , ScicchitanoR , BlasiF , AllegraL , MillsG , et al. Randomised, controlled trial of roxithromycin for the treatment of asthma in subjects with serological evidence of infection with Chlamydia pneumoniae. American Journal of Respiratory and Critical Care Medicine2001;164(4):536-41. ">Black 2001</a>; <a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a>; <a href="./references#CD002997-bbs2-0013" title="KraftM , CassellGH , PakJ , MartinRJ . Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest2002;121(6):1782-8. ">Kraft 2002</a>; <a href="./references#CD002997-bbs2-0017" title="SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Respirology2007;12:A120. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25-28; Auckland:Abstract TO13. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Clarithromycin targets neutrophilic airway inflammation in refractory asthma. American Journal of Respiratory and Critical Care Medicine2008;177(2):148-55. ">Simpson 2008</a>; <a href="./references#CD002997-bbs2-0018" title="StrunkRC , BacharierLB , PhillipsBR , SzeflerSJ , ZeigerRS , ChinchilliVM , et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. Journal of Allergy and Clinical Immunology2008;122(6):1138-44.e4. ">Strunk 2008</a>), and the risk was unclear for the other 14 studies. </p> </section> <section id="CD002997-sec-0054"> <h4 class="title">Selective reporting</h4> <p>We considered three studies at low risk of bias (<a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a>; <a href="./references#CD002997-bbs2-0007" title="HahnDL , PlaneMB , MahdiOS , ByrneGI . Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clinical Trials2006;1(2):e11. ">Hahn 2006</a>; <a href="./references#CD002997-bbs2-0008" title="HahnD , GrasmickM , HetzelS . Pragmatic controlled trial of azithromycin for asthma in adults. European Respiratory Journal2011;38:322s. HahnDL , GrasmickM , HetzelS , YaleS . Azithromycin for bronchial asthma in adults: an effectiveness trial. Journal of the American Board of Family Medicine2012;25(4):442-59. ">Hahn 2012</a>). We judged eight studies at high risk of selective reporting (<a href="./references#CD002997-bbs2-0002" title="BelotserkovskayaY , SinopalnikovA . Open-trial randomized comparative trial of the efficacy of the azithromycin in the 8 week treatment of mild to moderate asthma. European Respiratory Journal2007;30(Suppl 51):358s. ">Belotserkovskaya 2007</a>; <a href="./references#CD002997-bbs2-0003" title="BlackP , JenkinsCR , ScicchitanoR , BlasiF , AllegraL , MillsG , et al. Randomised, controlled trial of roxithromycin for the treatment of asthma in subjects with serological evidence of infection with Chlamydia pneumoniae. American Journal of Respiratory and Critical Care Medicine2001;164(4):536-41. ">Black 2001</a>; <a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a>; <a href="./references#CD002997-bbs2-0010" title="KamadaAK , HillMR , IkléDN , BrennerAM , SzeflerSJ . Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. Journal of Allergy and Clinical Immunology1993;91(4):873-82. ">Kamada 1993</a>; <a href="./references#CD002997-bbs2-0011" title="KapoorS , BrashierB , UdupaA , PawarR , KodguleR , LimayeS , et al. Therapeutic effect of low dose roxithromycin in chronic stable mild-to-moderate asthma. European Respiratory Journal2010;36(suppl 54):P1176. ">Kapoor 2010</a>; <a href="./references#CD002997-bbs2-0017" title="SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Respirology2007;12:A120. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25-28; Auckland:Abstract TO13. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Clarithromycin targets neutrophilic airway inflammation in refractory asthma. American Journal of Respiratory and Critical Care Medicine2008;177(2):148-55. ">Simpson 2008</a>; <a href="./references#CD002997-bbs2-0018" title="StrunkRC , BacharierLB , PhillipsBR , SzeflerSJ , ZeigerRS , ChinchilliVM , et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. Journal of Allergy and Clinical Immunology2008;122(6):1138-44.e4. ">Strunk 2008</a>; <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a>). This was mostly due to insufficient reporting of numerical data, which meant they could not be pooled in meta‐analysis. We rated 14 studies as unclear for this domain, including the six non‐English language studies, which we could not assess fully. </p> <p>Overall, it is likely that reporting biases had a significant effect on the completeness of the meta‐analyses in this systematic review. </p> </section> <section id="CD002997-sec-0055"> <h4 class="title">Other potential sources of bias</h4> <p>We judged <a href="./references#CD002997-bbs2-0010" title="KamadaAK , HillMR , IkléDN , BrennerAM , SzeflerSJ . Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. Journal of Allergy and Clinical Immunology1993;91(4):873-82. ">Kamada 1993</a> to be at high risk of bias because the report showed significant baseline imbalances between groups, and this may have been an issue in some of the other trials that included very small number of participants. We judged eight studies to be at unclear risk of bias (<a href="./references#CD002997-bbs2-0008" title="HahnD , GrasmickM , HetzelS . Pragmatic controlled trial of azithromycin for asthma in adults. European Respiratory Journal2011;38:322s. HahnDL , GrasmickM , HetzelS , YaleS . Azithromycin for bronchial asthma in adults: an effectiveness trial. Journal of the American Board of Family Medicine2012;25(4):442-59. ">Hahn 2012</a>; <a href="./references#CD002997-bbs2-0009" title="HeJ , ZhuN , ChenXD . Clinical impacts of azithromycin on lung function and cytokines for asthmatic patients. Fudan University Journal of Medical Science2009;36(6):719-22. ">He 2009</a>; <a href="./references#CD002997-bbs2-0011" title="KapoorS , BrashierB , UdupaA , PawarR , KodguleR , LimayeS , et al. Therapeutic effect of low dose roxithromycin in chronic stable mild-to-moderate asthma. European Respiratory Journal2010;36(suppl 54):P1176. ">Kapoor 2010</a>; <a href="./references#CD002997-bbs2-0012" title="KostadimaE , TsiodrasS , AlexopoulosEI , KaditisAG , MavrouI , GeorgatouN , et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. European Respiratory Journal2004;23(5):714-7. ">Kostadima 2004</a>; <a href="./references#CD002997-bbs2-0021" title="WangY , ZhangSL , QuY . Effect of clarithromycin on non-eosinophilic refractory asthma [克拉霉素治疗非嗜酸粒细胞型难治性哮喘的疗效分析]. Journal of Clinical Pulmonary Medicine2012;17(11):1948-51. ">Wang 2012</a>; <a href="./references#CD002997-bbs2-0022" title="WangT , PeiFY , SongXP , WangQ . Clinical impacts of low-dose azithromycin on lung function and fraction of exhaled nitric oxide concentration in bronchial asthma [小剂量阿奇霉素对支气管哮喘患者呼出气NO浓度及肺功能的影响]. Medical Innovation China2014;11(9):122-4. ">Wang 2014</a>; <a href="./references#CD002997-bbs2-0023" title="XiaoKA . The study on effect of roxithromycin combined with budesonide in therapy in patients with asthma. Guide of Chinese Medicine2013;11:119-20. ">Xiao 2013</a>; <a href="./references#CD002997-bbs2-0024" title="YanXQ , WuLQ , LinJ , XiaoXD , DaiYR . Clinical study on efficacy of roxithromycin combined with inhaled budesonide dry powder inhalation on asthma [罗红霉素与布地奈德干粉吸入剂联用治疗哮喘的临床研究]. Chinese Journal of Pharmacology and Therapeutics2008;13(2):184-7. ">Yan 2008</a>; <a href="./references#CD002997-bbs2-0025" title="ZhangLY , QianQ . Clinical effect of azithromycin combined with Seretide for asthma. Strait Pharmaceutical Journal2013;25:159-60. ">Zhang 2013</a>). </p> </section> </section> <section id="CD002997-sec-0056"> <h3 class="title" id="CD002997-sec-0056">Effects of interventions</h3> <p>See: <a href="./full#CD002997-tbl-0001"><b>Summary of findings 1</b> Macrolides compared to placebo for chronic asthma</a> </p> <p>We present the data with the order of outcomes listed in the methods. Evidence certainty was varied. We downgraded most for indirectness due to differences in the study populations and the way outcomes were defined, and for risk of bias due to uncertainty of randomisation procedures and high risk of attrition bias. <a href="./appendices#CD002997-sec-0094">Appendix 4</a> presents a narrative on each study, except for the six that we could not assess fully (<a href="./references#CD002997-bbs2-0009" title="HeJ , ZhuN , ChenXD . Clinical impacts of azithromycin on lung function and cytokines for asthmatic patients. Fudan University Journal of Medical Science2009;36(6):719-22. ">He 2009</a>; <a href="./references#CD002997-bbs2-0021" title="WangY , ZhangSL , QuY . Effect of clarithromycin on non-eosinophilic refractory asthma [克拉霉素治疗非嗜酸粒细胞型难治性哮喘的疗效分析]. Journal of Clinical Pulmonary Medicine2012;17(11):1948-51. ">Wang 2012</a>; <a href="./references#CD002997-bbs2-0022" title="WangT , PeiFY , SongXP , WangQ . Clinical impacts of low-dose azithromycin on lung function and fraction of exhaled nitric oxide concentration in bronchial asthma [小剂量阿奇霉素对支气管哮喘患者呼出气NO浓度及肺功能的影响]. Medical Innovation China2014;11(9):122-4. ">Wang 2014</a>; <a href="./references#CD002997-bbs2-0023" title="XiaoKA . The study on effect of roxithromycin combined with budesonide in therapy in patients with asthma. Guide of Chinese Medicine2013;11:119-20. ">Xiao 2013</a>; <a href="./references#CD002997-bbs2-0024" title="YanXQ , WuLQ , LinJ , XiaoXD , DaiYR . Clinical study on efficacy of roxithromycin combined with inhaled budesonide dry powder inhalation on asthma [罗红霉素与布地奈德干粉吸入剂联用治疗哮喘的临床研究]. Chinese Journal of Pharmacology and Therapeutics2008;13(2):184-7. ">Yan 2008</a>; <a href="./references#CD002997-bbs2-0025" title="ZhangLY , QianQ . Clinical effect of azithromycin combined with Seretide for asthma. Strait Pharmaceutical Journal2013;25:159-60. ">Zhang 2013</a>). </p> <section id="CD002997-sec-0057"> <h4 class="title">Primary outcomes</h4> <section id="CD002997-sec-0058"> <h5 class="title">Exacerbations requiring hospitalisation</h5> <p>Two studies reported exacerbations requiring hospitalisation, with 24 events (four recorded in <a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a>; 20 recorded in <a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a>). The meta‐analysis suggests macrolides make a moderately sized but non‐significant reduction in exacerbation requiring hospitalisation compared to placebo (OR 0.47, 95% CI 0.20 to 1.12; I<sup>2</sup> = 0%; participants = 529; <a href="./references#CD002997-fig-0015" title="">Analysis 1.1</a>; <a href="#CD002997-fig-0004">Figure 4</a>) (95% CI cross the line of zero effect). One study is equivocal and this effect is driven by the larger study. The evidence was of moderate certainty. </p> <div class="figure" id="CD002997-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.1 Exacerbation requiring hospitalisation." data-id="CD002997-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.1 Exacerbation requiring hospitalisation. </p> </div> </div> </div> </section> <section id="CD002997-sec-0059"> <h5 class="title">Severe exacerbations</h5> <p>Four studies reported data on severe exacerbations (defined as exacerbations requiring ED visits or short‐course of systemic steroids, or both) (<a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a>; <a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a>; <a href="./references#CD002997-bbs2-0012" title="KostadimaE , TsiodrasS , AlexopoulosEI , KaditisAG , MavrouI , GeorgatouN , et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. European Respiratory Journal2004;23(5):714-7. ">Kostadima 2004</a>; <a href="./references#CD002997-bbs2-0018" title="StrunkRC , BacharierLB , PhillipsBR , SzeflerSJ , ZeigerRS , ChinchilliVM , et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. Journal of Allergy and Clinical Immunology2008;122(6):1138-44.e4. ">Strunk 2008</a>). The pooled effect of these studies showed a benefit of macrolides over placebo (RaR 0.65, 95% CI 0.53 to 0.80; I<sup>2</sup> = 37%; participants = 640; <a href="./references#CD002997-fig-0016" title="">Analysis 1.2</a>; <a href="#CD002997-fig-0005">Figure 5</a>). The results were mostly driven by the data from <a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a> (weight 81.6%). Apart from this study, the evidence from the other studies was very low quality, being downgraded for indirectness and imprecision. Overall the evidence was of moderate certainty. </p> <div class="figure" id="CD002997-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.2 Severe exacerbations: exacerbations requiring emergency department visits/systemic steroids." data-id="CD002997-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.2 Severe exacerbations: exacerbations requiring emergency department visits/systemic steroids. </p> </div> </div> </div> </section> <section id="CD002997-sec-0060"> <h5 class="title">Asthma symptoms, control and quality of life scores</h5> <p>Symptom scales used across studies varied and were mostly not psychometrically validated. Data from four studies could be combined in meta‐analysis (<a href="./references#CD002997-bbs2-0001" title="AmayasuH , YashidaS , EbanaS , YamamotoY , NishikawaT , ShojiT , et al. Clarithromycin suppress bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Annals of Allergy, Asthma and Immunology2000;84(6):594-8. ">Amayasu 2000</a>; <a href="./references#CD002997-bbs2-0007" title="HahnDL , PlaneMB , MahdiOS , ByrneGI . Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clinical Trials2006;1(2):e11. ">Hahn 2006</a>; <a href="./references#CD002997-bbs2-0008" title="HahnD , GrasmickM , HetzelS . Pragmatic controlled trial of azithromycin for asthma in adults. European Respiratory Journal2011;38:322s. HahnDL , GrasmickM , HetzelS , YaleS . Azithromycin for bronchial asthma in adults: an effectiveness trial. Journal of the American Board of Family Medicine2012;25(4):442-59. ">Hahn 2012</a>; <a href="./references#CD002997-bbs2-0010" title="KamadaAK , HillMR , IkléDN , BrennerAM , SzeflerSJ . Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. Journal of Allergy and Clinical Immunology1993;91(4):873-82. ">Kamada 1993</a>). There was suggestion of a benefit of macrolides compared with placebo (SMD −0.46, 95% CI −0.81 to −0.11; I<sup>2</sup> = 70%; participants = 156; <a href="./references#CD002997-fig-0017" title="">Analysis 1.3</a>; <a href="#CD002997-fig-0006">Figure 6</a>). We downgraded the evidence for high heterogeneity (I<sup>2</sup> = 70%), use of scales that were not psychometrically validated and small numbers in the analysis, meaning the evidence was of very low certainty. </p> <div class="figure" id="CD002997-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.3 Symptom scales." data-id="CD002997-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.3 Symptom scales.</p> </div> </div> </div> <p>Five studies reported measures of asthma control, mostly the Asthma Control Questionnaire (ACQ) (<a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a>; <a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a>; <a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a>; <a href="./references#CD002997-bbs2-0008" title="HahnD , GrasmickM , HetzelS . Pragmatic controlled trial of azithromycin for asthma in adults. European Respiratory Journal2011;38:322s. HahnDL , GrasmickM , HetzelS , YaleS . Azithromycin for bronchial asthma in adults: an effectiveness trial. Journal of the American Board of Family Medicine2012;25(4):442-59. ">Hahn 2012</a>; <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a>). There was a small benefit of macrolide over placebo in reducing symptoms (SMD −0.17, 95% CI −0.31 to −0.03; I<sup>2</sup> = 35%; participants = 773; <a href="./references#CD002997-fig-0018" title="">Analysis 1.4</a>; <a href="#CD002997-fig-0007">Figure 7</a>), although the decrease in the symptom score did not reach the minimal clinically important difference (MCID) (0.5 for the ACQ, <a href="./references#CD002997-bbs2-0088" title="JuniperEF , SvenssonK , MorkAC , StahlE . Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respiratory Medicine2005;99:553-8.">Juniper 2005</a>). We considered the evidence to be low after downgrading for uncertainties with randomisation procedures and different populations with regards to severity of asthma. </p> <div class="figure" id="CD002997-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.4 Asthma Control." data-id="CD002997-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.4 Asthma Control.</p> </div> </div> </div> <p>Six studies reported quality of life measured with the AQLQ (<a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a>; <a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a>; <a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a>; <a href="./references#CD002997-bbs2-0007" title="HahnDL , PlaneMB , MahdiOS , ByrneGI . Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clinical Trials2006;1(2):e11. ">Hahn 2006</a>; <a href="./references#CD002997-bbs2-0008" title="HahnD , GrasmickM , HetzelS . Pragmatic controlled trial of azithromycin for asthma in adults. European Respiratory Journal2011;38:322s. HahnDL , GrasmickM , HetzelS , YaleS . Azithromycin for bronchial asthma in adults: an effectiveness trial. Journal of the American Board of Family Medicine2012;25(4):442-59. ">Hahn 2012</a>; <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a>). There was an improvement of quality of life with macrolides over placebo, but it was under the MCID (MD 0.24, 95% CI 0.12 to 0.35; I<sup>2</sup> = 55%; participants = 802; <a href="./references#CD002997-fig-0019" title="">Analysis 1.5</a>; <a href="#CD002997-fig-0008">Figure 8</a>) (MCID: 0.5; <a href="./references#CD002997-bbs2-0087" title="JuniperEF , GuyattGH , WillanA , GriffithLE . Determining a minimal important change in a disease-specific quality of life questionnaire. Journal of Clinical Epidemiology1994;47(1):81-7.">Juniper 1994</a>). We considered the evidence to be very low certainty after downgrading it for imprecision, uncertainties with randomisation procedures and different populations with regards to severity of asthma. </p> <div class="figure" id="CD002997-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.5 Asthma Quality of Life Questionnaire (AQLQ)." data-id="CD002997-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-08.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.5 Asthma Quality of Life Questionnaire (AQLQ). </p> </div> </div> </div> </section> <section id="CD002997-sec-0061"> <h5 class="title">Need for rescue medications</h5> <p>Four studies reported need for rescue medication (<a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a>; <a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a>; <a href="./references#CD002997-bbs2-0007" title="HahnDL , PlaneMB , MahdiOS , ByrneGI . Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clinical Trials2006;1(2):e11. ">Hahn 2006</a>; <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a>). Analysis indicated macrolides reduced in the need for rescue medications compared to placebo (MD −0.43 puffs per day, 95% CI −0.81 to −0.04; I<sup>2</sup> = 0%; participants = 314; <a href="./references#CD002997-fig-0020" title="">Analysis 1.6</a>; <a href="#CD002997-fig-0009">Figure 9</a>). The evidence was low certainty, being downgraded for uncertainties in the randomisation procedure and indirectness. </p> <div class="figure" id="CD002997-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.6 Rescue medication puffs/day." data-id="CD002997-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-09.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.6 Rescue medication puffs/day. </p> </div> </div> </div> </section> <section id="CD002997-sec-0062"> <h5 class="title">Lung function (morning and evening peak expiratory flow and forced expiratory volume in one second) </h5> <p>Four studies reported morning PEF (<a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a>; <a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a>; <a href="./references#CD002997-bbs2-0010" title="KamadaAK , HillMR , IkléDN , BrennerAM , SzeflerSJ . Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. Journal of Allergy and Clinical Immunology1993;91(4):873-82. ">Kamada 1993</a>; <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a>), and three studies reported evening PEF (<a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a>; <a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a>; <a href="./references#CD002997-bbs2-0010" title="KamadaAK , HillMR , IkléDN , BrennerAM , SzeflerSJ . Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. Journal of Allergy and Clinical Immunology1993;91(4):873-82. ">Kamada 1993</a>; <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a>). The data for morning and evening PEF did not suggest a benefit of macrolide over placebo, and the evidence was very low certainty (morning PEF: MD 1.60 L/minute, 95% CI −10.35 to 13.56; I<sup>2</sup> = 0%; participants = 289; <a href="./references#CD002997-fig-0021" title="">Analysis 1.7</a>; <a href="#CD002997-fig-0010">Figure 10</a>; evening PEF: MD 1.00, 95% CI −13.65 to 15.65; I<sup>2</sup> = 0%; participants = 212; <a href="./references#CD002997-fig-0022" title="">Analysis 1.8</a>; <a href="#CD002997-fig-0011">Figure 11</a>). The evidence for both measures was downgraded due to issues with risk of bias, indirectness and imprecision. </p> <div class="figure" id="CD002997-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.7 Morning PEF (L/minute)." data-id="CD002997-fig-0010" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-10.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.7 Morning PEF (L/minute).</p> </div> </div> </div> <div class="figure" id="CD002997-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.8 Evening PEF (L/minute)." data-id="CD002997-fig-0011" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-11.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.8 Evening PEF (L/minute).</p> </div> </div> </div> <p><a href="./references#CD002997-bbs2-0103" title="TongX , GuoT , LiuS , PengS , YanS , YangX , et al. Macrolide antibiotics for treatment of asthma in adults: a meta-analysis of 18 randomized controlled clinical studies. Pulmonary Pharmacology and Therapeutics2015;31:99-108.">Tong 2015</a> provided data for three additional studies, but it was not clear if they were morning or evening measurements (<a href="./references#CD002997-bbs2-0022" title="WangT , PeiFY , SongXP , WangQ . Clinical impacts of low-dose azithromycin on lung function and fraction of exhaled nitric oxide concentration in bronchial asthma [小剂量阿奇霉素对支气管哮喘患者呼出气NO浓度及肺功能的影响]. Medical Innovation China2014;11(9):122-4. ">Wang 2014</a>; <a href="./references#CD002997-bbs2-0023" title="XiaoKA . The study on effect of roxithromycin combined with budesonide in therapy in patients with asthma. Guide of Chinese Medicine2013;11:119-20. ">Xiao 2013</a>; <a href="./references#CD002997-bbs2-0024" title="YanXQ , WuLQ , LinJ , XiaoXD , DaiYR . Clinical study on efficacy of roxithromycin combined with inhaled budesonide dry powder inhalation on asthma [罗红霉素与布地奈德干粉吸入剂联用治疗哮喘的临床研究]. Chinese Journal of Pharmacology and Therapeutics2008;13(2):184-7. ">Yan 2008</a>). Moreover, the data were in a different order of magnitude to the other studies and had been combined using SMD, so we could not combine them. These three studies showed a benefit of macrolide over placebo, but the method of analysis meant it was difficult to contextualise. </p> <p>Ten studies reported data on FEV<sub>1,</sub> that could be aggregated in a meta‐analysis (<a href="./references#CD002997-bbs2-0001" title="AmayasuH , YashidaS , EbanaS , YamamotoY , NishikawaT , ShojiT , et al. Clarithromycin suppress bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Annals of Allergy, Asthma and Immunology2000;84(6):594-8. ">Amayasu 2000</a>; <a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a>; <a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a>; <a href="./references#CD002997-bbs2-0009" title="HeJ , ZhuN , ChenXD . Clinical impacts of azithromycin on lung function and cytokines for asthmatic patients. Fudan University Journal of Medical Science2009;36(6):719-22. ">He 2009</a>; <a href="./references#CD002997-bbs2-0013" title="KraftM , CassellGH , PakJ , MartinRJ . Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest2002;121(6):1782-8. ">Kraft 2002</a>; <a href="./references#CD002997-bbs2-0016" title="ShojiT , YoshidaS , SakamotoH , HasegawaH , NakagawaH , AmayasuH . Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clinical and Experimental Allergy1999;29(7):950-6. ">Shoji 1999</a>; <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a>; <a href="./references#CD002997-bbs2-0022" title="WangT , PeiFY , SongXP , WangQ . Clinical impacts of low-dose azithromycin on lung function and fraction of exhaled nitric oxide concentration in bronchial asthma [小剂量阿奇霉素对支气管哮喘患者呼出气NO浓度及肺功能的影响]. Medical Innovation China2014;11(9):122-4. ">Wang 2014</a>; <a href="./references#CD002997-bbs2-0023" title="XiaoKA . The study on effect of roxithromycin combined with budesonide in therapy in patients with asthma. Guide of Chinese Medicine2013;11:119-20. ">Xiao 2013</a>; <a href="./references#CD002997-bbs2-0024" title="YanXQ , WuLQ , LinJ , XiaoXD , DaiYR . Clinical study on efficacy of roxithromycin combined with inhaled budesonide dry powder inhalation on asthma [罗红霉素与布地奈德干粉吸入剂联用治疗哮喘的临床研究]. Chinese Journal of Pharmacology and Therapeutics2008;13(2):184-7. ">Yan 2008</a>). There was a benefit of macrolide over placebo on FEV<sub>1</sub> (MD 0.04 L, 95% CI 0 to 0.008; I<sup>2</sup> = 66%; participants = 1046; <a href="./references#CD002997-fig-0023" title="">Analysis 1.9</a>; <a href="#CD002997-fig-0012">Figure 12</a>). The evidence was of low certainty due to indirectness and four studies for which we were unable to properly assess risk of bias. It was not always clear whether the measurement was taken before or after a bronchodilator. </p> <div class="figure" id="CD002997-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.9 FEV1 (L)." data-id="CD002997-fig-0012" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-12.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.9 FEV<sub>1</sub> (L). </p> </div> </div> </div> </section> <section id="CD002997-sec-0063"> <h5 class="title">Non‐specific bronchial hyperresponsiveness</h5> <p>We could not compare the results reported for bronchial hyperresponsiveness in nine studies due to differences in the challenge agent (e.g. methacholine, hypertonic solution) and measurement (histamine provocative concentration causing a 20% (PC<sub>20</sub>) or 15% (PC<sub>15</sub>) drop in FEV<sub>1</sub>, results expressed as log) in the different studies. We present the unpooled data in <a href="./references#CD002997-fig-0024" title="">Analysis 1.10</a>. Three studies reported an effect of macrolides in reducing bronchial hyperresponsiveness compared to placebo (<a href="./references#CD002997-bbs2-0001" title="AmayasuH , YashidaS , EbanaS , YamamotoY , NishikawaT , ShojiT , et al. Clarithromycin suppress bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Annals of Allergy, Asthma and Immunology2000;84(6):594-8. ">Amayasu 2000</a>; <a href="./references#CD002997-bbs2-0012" title="KostadimaE , TsiodrasS , AlexopoulosEI , KaditisAG , MavrouI , GeorgatouN , et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. European Respiratory Journal2004;23(5):714-7. ">Kostadima 2004</a>; <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a>), while six studies reported no effect compared with placebo (<a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a>; <a href="./references#CD002997-bbs2-0010" title="KamadaAK , HillMR , IkléDN , BrennerAM , SzeflerSJ . Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. Journal of Allergy and Clinical Immunology1993;91(4):873-82. ">Kamada 1993</a>; <a href="./references#CD002997-bbs2-0014" title="NelsonHS , HamilosDL , CorselloPR , LevesqueNV , BuchmeierAD , BuckerBL . A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. American Review of Respiratory Disease1993;147(2):398-404. ">Nelson 1993</a>; <a href="./references#CD002997-bbs2-0015" title="PiacentiniGL , PeroniDG , BodiniA , PigozziR , CostellaS , LoiaconoA , et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy and Asthma Proceedings2007;28(2):194-8. ">Piacentini 2007</a>; <a href="./references#CD002997-bbs2-0016" title="ShojiT , YoshidaS , SakamotoH , HasegawaH , NakagawaH , AmayasuH . Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clinical and Experimental Allergy1999;29(7):950-6. ">Shoji 1999</a>; <a href="./references#CD002997-bbs2-0017" title="SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Respirology2007;12:A120. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25-28; Auckland:Abstract TO13. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Clarithromycin targets neutrophilic airway inflammation in refractory asthma. American Journal of Respiratory and Critical Care Medicine2008;177(2):148-55. ">Simpson 2008</a>). </p> </section> <section id="CD002997-sec-0064"> <h5 class="title">Lowest tolerated oral corticosteroid dose (in people requiring oral corticosteroids at baseline) </h5> <p>Most studies either excluded people taking oral corticosteroids or recruited people who did not take them regularly. Two studies that recruited people taking regular oral corticosteroids reported that macrolides had a steroid‐sparing benefit (<a href="./references#CD002997-fig-0025" title="">Analysis 1.11</a>; <a href="#CD002997-fig-0013">Figure 13</a>; <a href="./references#CD002997-bbs2-0010" title="KamadaAK , HillMR , IkléDN , BrennerAM , SzeflerSJ . Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. Journal of Allergy and Clinical Immunology1993;91(4):873-82. ">Kamada 1993</a>; <a href="./references#CD002997-bbs2-0014" title="NelsonHS , HamilosDL , CorselloPR , LevesqueNV , BuchmeierAD , BuckerBL . A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. American Review of Respiratory Disease1993;147(2):398-404. ">Nelson 1993</a>). However, there was a baseline imbalance in corticosteroid dose in <a href="./references#CD002997-bbs2-0014" title="NelsonHS , HamilosDL , CorselloPR , LevesqueNV , BuchmeierAD , BuckerBL . A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. American Review of Respiratory Disease1993;147(2):398-404. ">Nelson 1993</a>, which overstated the difference at endpoint. We chose not to combine the study results because it was unclear if the ways the doses were calculated were sufficiently similar for pooling to make sense. </p> <div class="figure" id="CD002997-fig-0013"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 13</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.11 Oral corticosteroid dose." data-id="CD002997-fig-0013" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-13.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.11 Oral corticosteroid dose. </p> </div> </div> </div> </section> </section> <section id="CD002997-sec-0065"> <h4 class="title">Secondary outcomes</h4> <section id="CD002997-sec-0066"> <h5 class="title">Serious adverse events</h5> <p>In general, macrolides were well tolerated, and there were no recorded deaths due to treatment with macrolides. Eight studies reported SAEs (<a href="./references#CD002997-bbs2-0001" title="AmayasuH , YashidaS , EbanaS , YamamotoY , NishikawaT , ShojiT , et al. Clarithromycin suppress bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Annals of Allergy, Asthma and Immunology2000;84(6):594-8. ">Amayasu 2000</a>; <a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a>; <a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a>; <a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a>; <a href="./references#CD002997-bbs2-0007" title="HahnDL , PlaneMB , MahdiOS , ByrneGI . Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clinical Trials2006;1(2):e11. ">Hahn 2006</a>; <a href="./references#CD002997-bbs2-0008" title="HahnD , GrasmickM , HetzelS . Pragmatic controlled trial of azithromycin for asthma in adults. European Respiratory Journal2011;38:322s. HahnDL , GrasmickM , HetzelS , YaleS . Azithromycin for bronchial asthma in adults: an effectiveness trial. Journal of the American Board of Family Medicine2012;25(4):442-59. ">Hahn 2012</a>; <a href="./references#CD002997-bbs2-0010" title="KamadaAK , HillMR , IkléDN , BrennerAM , SzeflerSJ . Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. Journal of Allergy and Clinical Immunology1993;91(4):873-82. ">Kamada 1993</a>; <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a>). Meta‐analysis found no clear difference in the likelihood of SAEs in the treatment and placebo groups, but the effect was imprecise due to the rarity of events (Peto OR 0.80, 95% CI 0.49 to 1.31; I<sup>2</sup> = 41%; participants = 854; <a href="./references#CD002997-fig-0026" title="">Analysis 1.12</a>; <a href="#CD002997-fig-0014">Figure 14</a>). </p> <div class="figure" id="CD002997-fig-0014"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 14</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.12 Serious adverse events (including mortality)." data-id="CD002997-fig-0014" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-14.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.12 Serious adverse events (including mortality). </p> </div> </div> </div> <p>We rated the evidence to be of low certainty due to very serious imprecision in the estimate, risk of bias issues and possible indirectness. </p> </section> <section id="CD002997-sec-0067"> <h5 class="title">Study withdrawals/dropouts</h5> <p>Ten studies reported withdrawals/dropouts (<a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a>; <a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a>; <a href="./references#CD002997-bbs2-0007" title="HahnDL , PlaneMB , MahdiOS , ByrneGI . Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clinical Trials2006;1(2):e11. ">Hahn 2006</a>; <a href="./references#CD002997-bbs2-0008" title="HahnD , GrasmickM , HetzelS . Pragmatic controlled trial of azithromycin for asthma in adults. European Respiratory Journal2011;38:322s. HahnDL , GrasmickM , HetzelS , YaleS . Azithromycin for bronchial asthma in adults: an effectiveness trial. Journal of the American Board of Family Medicine2012;25(4):442-59. ">Hahn 2012</a>; <a href="./references#CD002997-bbs2-0010" title="KamadaAK , HillMR , IkléDN , BrennerAM , SzeflerSJ . Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. Journal of Allergy and Clinical Immunology1993;91(4):873-82. ">Kamada 1993</a>; <a href="./references#CD002997-bbs2-0012" title="KostadimaE , TsiodrasS , AlexopoulosEI , KaditisAG , MavrouI , GeorgatouN , et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. European Respiratory Journal2004;23(5):714-7. ">Kostadima 2004</a>; <a href="./references#CD002997-bbs2-0014" title="NelsonHS , HamilosDL , CorselloPR , LevesqueNV , BuchmeierAD , BuckerBL . A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. American Review of Respiratory Disease1993;147(2):398-404. ">Nelson 1993</a>; <a href="./references#CD002997-bbs2-0017" title="SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Respirology2007;12:A120. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25-28; Auckland:Abstract TO13. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Clarithromycin targets neutrophilic airway inflammation in refractory asthma. American Journal of Respiratory and Critical Care Medicine2008;177(2):148-55. ">Simpson 2008</a>; <a href="./references#CD002997-bbs2-0018" title="StrunkRC , BacharierLB , PhillipsBR , SzeflerSJ , ZeigerRS , ChinchilliVM , et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. Journal of Allergy and Clinical Immunology2008;122(6):1138-44.e4. ">Strunk 2008</a>; <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a>). Analysis suggested the likelihood of withdrawal from the studies was similar between participants taking macrolide and placebo (OR 1.06, 95% CI 0.76 to 1.48; I<sup>2</sup> = 0%; participants = 984; <a href="./references#CD002997-fig-0027" title="">Analysis 1.13</a>). </p> </section> <section id="CD002997-sec-0068"> <h5 class="title">Eosinophil counts in blood and sputum</h5> <p>One study reported blood eosinophils (<a href="./references#CD002997-bbs2-0024" title="YanXQ , WuLQ , LinJ , XiaoXD , DaiYR . Clinical study on efficacy of roxithromycin combined with inhaled budesonide dry powder inhalation on asthma [罗红霉素与布地奈德干粉吸入剂联用治疗哮喘的临床研究]. Chinese Journal of Pharmacology and Therapeutics2008;13(2):184-7. ">Yan 2008</a>). There was no difference between macrolide and placebo in blood eosinophils, but analysed data were only available as SMD, so we did not enter it with the two existing studies (<a href="./references#CD002997-bbs2-0001" title="AmayasuH , YashidaS , EbanaS , YamamotoY , NishikawaT , ShojiT , et al. Clarithromycin suppress bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Annals of Allergy, Asthma and Immunology2000;84(6):594-8. ">Amayasu 2000</a>; <a href="./references#CD002997-bbs2-0016" title="ShojiT , YoshidaS , SakamotoH , HasegawaH , NakagawaH , AmayasuH . Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clinical and Experimental Allergy1999;29(7):950-6. ">Shoji 1999</a>). A meta‐analysis of these two small cross‐over studies showed a reduction of eosinophils in the blood of people with asthma treated with macrolides (MD −32.16, 95% CI −34.77 to −29.56; I<sup>2</sup> = 12%; participants = 62; <a href="./references#CD002997-fig-0028" title="">Analysis 1.14</a>). <a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a> investigated the effect of macrolides in sputum eosinophils in current smokers with asthma, and found a vastly different result from the two trials previously included in the analysis. The highly significant heterogeneity suggested that there was a data error (I<sup>2</sup> = 97%). For this reason, data for the three studies have been displayed but not pooled (<a href="./references#CD002997-fig-0029" title="">Analysis 1.15</a>). </p> </section> <section id="CD002997-sec-0069"> <h5 class="title">Eosinophil cationic protein in serum and sputum</h5> <p>Two studies reported serum and sputum ECP (<a href="./references#CD002997-bbs2-0001" title="AmayasuH , YashidaS , EbanaS , YamamotoY , NishikawaT , ShojiT , et al. Clarithromycin suppress bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Annals of Allergy, Asthma and Immunology2000;84(6):594-8. ">Amayasu 2000</a>; <a href="./references#CD002997-bbs2-0016" title="ShojiT , YoshidaS , SakamotoH , HasegawaH , NakagawaH , AmayasuH . Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clinical and Experimental Allergy1999;29(7):950-6. ">Shoji 1999</a>). Macrolides appear to reduce the concentration of ECP both in serum and sputum (serum: MD −12.07, 95% CI −14.90 to −9.24; I<sup>2</sup> = 0%; participants = 62; <a href="./references#CD002997-fig-0030" title="">Analysis 1.16</a>; sputum: MD −1.35, 95% CI −1.69 to −1.01; I<sup>2</sup> = 0%; participants = 62; <a href="./references#CD002997-fig-0031" title="">Analysis 1.17</a>). </p> </section> </section> <section id="CD002997-sec-0070"> <h4 class="title">Subgroup analysis</h4> <p>Subgroup analysis based on serological response or positivity to PCR for <i>C pneumoniae</i> was not possible due to the scarcity and heterogeneity of data and methods. </p> </section> <section id="CD002997-sec-0071"> <h4 class="title">Sensitivity analysis</h4> <p>Primary or secondary outcomes with high heterogeneity (I<sup>2</sup> greater than 30%) were taken into the consideration for conducting the sensitivity analysis with a random‐effects model. The outcomes with high heterogeneity that suggested a beneficial effect of macrolide in primary analyses such as severe exacerbations: exacerbations requiring ED visits/systemic steroids (<a href="./references#CD002997-fig-0016" title="">Analysis 1.2</a> versus <a href="./references#CD002997-fig-0032" title="">Analysis 2.1</a>), symptom scales (<a href="./references#CD002997-fig-0017" title="">Analysis 1.3</a> versus <a href="./references#CD002997-fig-0033" title="">Analysis 2.2</a>), asthma control (<a href="./references#CD002997-fig-0018" title="">Analysis 1.4</a> versus <a href="./references#CD002997-fig-0034" title="">Analysis 2.3</a>), AQLQ (<a href="./references#CD002997-fig-0019" title="">Analysis 1.5</a> versus <a href="./references#CD002997-fig-0035" title="">Analysis 2.4</a>), and FEV<sub>1</sub> (<a href="./references#CD002997-fig-0023" title="">Analysis 1.9</a> versus <a href="./references#CD002997-fig-0036" title="">Analysis 2.5</a>) became analyses in which the 95% CIs crossed the line of no effect by changing the model to random‐effects. The reason for the change in effect estimate is decreasing the weighting of large studies such as <a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a> (<a href="./references#CD002997-fig-0032" title="">Analysis 2.1</a>; <a href="./references#CD002997-fig-0034" title="">Analysis 2.3</a>; <a href="./references#CD002997-fig-0035" title="">Analysis 2.4</a>) and <a href="./references#CD002997-bbs2-0008" title="HahnD , GrasmickM , HetzelS . Pragmatic controlled trial of azithromycin for asthma in adults. European Respiratory Journal2011;38:322s. HahnDL , GrasmickM , HetzelS , YaleS . Azithromycin for bronchial asthma in adults: an effectiveness trial. Journal of the American Board of Family Medicine2012;25(4):442-59. ">Hahn 2012</a> (<a href="./references#CD002997-fig-0033" title="">Analysis 2.2</a>) by changing the model to random effects. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002997-sec-0072" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002997-sec-0072"></div> <section id="CD002997-sec-0073"> <h3 class="title" id="CD002997-sec-0073">Summary of main results</h3> <p>Twenty‐five studies, involving 1973 participants given macrolide or placebo, met the inclusion criteria. The certainty of the evidence was generally low due to incomplete reporting of study methodology and clinical data, indirectness of study populations, risk of bias, and imprecision caused by small numbers of participants and events. Most studies reported data from people with persistent or severe asthma, but inclusion criteria, interventions and outcomes were highly variable, and there may have been selective or incomplete reporting. </p> <p>Macrolides led to a moderately sized but non‐significant improvement compared to placebo when this was defined as exacerbations requiring hospital admission (OR 0.47, 95% CI 0.20 to 1.12; I<sup>2</sup> = 0%; studies = 2, participants = 529), but this was driven by one study and the 95% CIs did not exclude the possibility of no effect. Not considering the heterogeneity among the studies, macrolides appeared beneficial compared to placebo for severe exacerbations (defined as requiring ED visits or systemic steroids, or both) (RaR 0.65, 95% CI 0.53 to 0.80; I<sup>2</sup> = 37%; studies = 4, participants = 640), improvement on symptom scales (SMD −0.46, 95% CI −0.81 to −0.11; I<sup>2</sup> = 70%, studies = 4, participants = 136), rescue medication use (MD −0.43 puffs per day, 95% CI −0.81 to −0.04), ACQ (SMD −0.17, 95% CI −0.31 to −0.03) and AQLQ (MD 0.24, 95% CI 0.12 to 0.35), although the variation in ACQ and AQLQ did not reach the MCID (for both scores, MCID = 0.50) (<a href="./references#CD002997-bbs2-0088" title="JuniperEF , SvenssonK , MorkAC , StahlE . Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respiratory Medicine2005;99:553-8.">Juniper 2005</a>; <a href="./references#CD002997-bbs2-0087" title="JuniperEF , GuyattGH , WillanA , GriffithLE . Determining a minimal important change in a disease-specific quality of life questionnaire. Journal of Clinical Epidemiology1994;47(1):81-7.">Juniper 1994</a>). The improvement in FEV<sub>1</sub> (MD 0.04 L, 95% CI 0.03 to 0.08) was very small and of doubtful clinical relevance. There is no agreed MCID for FEV<sub>1</sub> but this is below any likely MCID. The other outcomes such as lung function were of very low quality and did not show a benefit of macrolide treatment (morning PEF: MD 1.60 L/minute, 95% CI −10.35 to 13.56; evening PEF: MD 1.00 L/minute, 95% CI −13.65 to 15.65). Measures of bronchial hyperresponsiveness were too varied to pool, but most studies showed no clear benefit of macrolide over placebo. Two studies with people taking regular oral corticosteroids suggested macrolides may have a steroid‐sparing effect in this population. Macrolides were well tolerated with respect to severe adverse events (Peto OR 0.80, 95% CI 0.49 to 1.31; I<sup>2</sup> = 41%; studies = 8, participants = 854), although less than half of the studies reported the outcome which was approaching 10% in each group. Reporting of specific adverse effects was too patchy across studies to be analysed meaningfully. Number of withdrawals from the study was near to equal in both macrolide and placebo groups (OR 1.06, 95% CI 0.76 to 1.48; I<sup>2</sup> = 0%; studies = 10, participants = 984), and quite high in both group (almost 20%). Biomarkers of asthma activity such as sputum and serum ECP, sputum and serum eosinophils were lower in people treated with macrolides, but this was not associated with clinical benefits. </p> </section> <section id="CD002997-sec-0074"> <h3 class="title" id="CD002997-sec-0074">Overall completeness and applicability of evidence</h3> <p>The available data do not support any generalised use of macrolides in clinical practice to improve clinical outcomes in people with persistent asthma, but we cannot rule out the possibility of benefit due to several shortcomings in the available studies. The potential benefit of macrolides for the wide range of phenotypes and for clinically relevant groups (e.g. smokers) remains to be confirmed. </p> <p>The available data from the 25 RCTs included in the present review are difficult to interpret for several reasons. First, four different types of macrolides were used across the studies (roxithromycin, clarithromycin, azithromycin and troleandomycin), often with differences in dosage and frequency of administration. Second, participants with different severities of asthma were included: the oldest studies included participants who were taking long‐term oral steroids (<a href="./references#CD002997-bbs2-0010" title="KamadaAK , HillMR , IkléDN , BrennerAM , SzeflerSJ . Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. Journal of Allergy and Clinical Immunology1993;91(4):873-82. ">Kamada 1993</a>; <a href="./references#CD002997-bbs2-0014" title="NelsonHS , HamilosDL , CorselloPR , LevesqueNV , BuchmeierAD , BuckerBL . A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. American Review of Respiratory Disease1993;147(2):398-404. ">Nelson 1993</a>), which could reflect a severe population or outdated prescribing practice. One study included people with aspirin‐intolerant asthma (<a href="./references#CD002997-bbs2-0016" title="ShojiT , YoshidaS , SakamotoH , HasegawaH , NakagawaH , AmayasuH . Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clinical and Experimental Allergy1999;29(7):950-6. ">Shoji 1999</a>), one included people with intermittent allergic asthma (<a href="./references#CD002997-bbs2-0001" title="AmayasuH , YashidaS , EbanaS , YamamotoY , NishikawaT , ShojiT , et al. Clarithromycin suppress bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Annals of Allergy, Asthma and Immunology2000;84(6):594-8. ">Amayasu 2000</a>), and another exclusively recruited smokers with asthma (<a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a>); all the other studies enrolled people with mild‐to‐severe persistent asthma, and we could not properly assess the populations of six Chinese studies. Seven studies tested participants for <i>C pneumoniae</i> or <i>M pneumoniae</i> infection, but all with different techniques and very different results (<a href="./references#CD002997-bbs2-0003" title="BlackP , JenkinsCR , ScicchitanoR , BlasiF , AllegraL , MillsG , et al. Randomised, controlled trial of roxithromycin for the treatment of asthma in subjects with serological evidence of infection with Chlamydia pneumoniae. American Journal of Respiratory and Critical Care Medicine2001;164(4):536-41. ">Black 2001</a>; <a href="./references#CD002997-bbs2-0007" title="HahnDL , PlaneMB , MahdiOS , ByrneGI . Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clinical Trials2006;1(2):e11. ">Hahn 2006</a>; <a href="./references#CD002997-bbs2-0013" title="KraftM , CassellGH , PakJ , MartinRJ . Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest2002;121(6):1782-8. ">Kraft 2002</a>; <a href="./references#CD002997-bbs2-0017" title="SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Respirology2007;12:A120. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25-28; Auckland:Abstract TO13. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Clarithromycin targets neutrophilic airway inflammation in refractory asthma. American Journal of Respiratory and Critical Care Medicine2008;177(2):148-55. ">Simpson 2008</a>; <a href="./references#CD002997-bbs2-0018" title="StrunkRC , BacharierLB , PhillipsBR , SzeflerSJ , ZeigerRS , ChinchilliVM , et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. Journal of Allergy and Clinical Immunology2008;122(6):1138-44.e4. ">Strunk 2008</a>; <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a>; <a href="./references#CD002997-bbs2-0020" title="Wan K-S, Liu Y-C, Huang C-S, Su Y-M. Effects of low-dose clarithromycin added to fluticasone on inflammatory markers and pulmonary function among children with asthma: a randomized clinical trial. Allergy and Rhinology2016;7(3):e131-4. ">Wan 2016</a>). The scarcity of data in the primary analyses precluded any meaningful subgroup analyses to assess the possible effect of these factors. Third and perhaps most importantly, the outcomes measured were heterogeneous; reporting of exacerbations and definitions for exacerbations and their severity varied across the studies; asthma symptoms were recorded using a variety of non‐validated scales as well as the ACQ and AQLQ, with a great variability across the studies. Lung function and bronchial hyperresponsiveness were often assessed and reported using different methodologies or parameters. </p> <p>Two studies showing some effect on symptoms and markers of eosinophil inflammation were unusual both in the participants they recruited and in their design. Both were cross‐over studies, one recruited people with allergic intermittent asthma (<a href="./references#CD002997-bbs2-0001" title="AmayasuH , YashidaS , EbanaS , YamamotoY , NishikawaT , ShojiT , et al. Clarithromycin suppress bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Annals of Allergy, Asthma and Immunology2000;84(6):594-8. ">Amayasu 2000</a>), and the other enrolled people whose asthma was aspirin‐induced (<a href="./references#CD002997-bbs2-0016" title="ShojiT , YoshidaS , SakamotoH , HasegawaH , NakagawaH , AmayasuH . Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clinical and Experimental Allergy1999;29(7):950-6. ">Shoji 1999</a>). </p> <p>Only four studies investigated the role of macrolides in children with asthma (<a href="./references#CD002997-bbs2-0010" title="KamadaAK , HillMR , IkléDN , BrennerAM , SzeflerSJ . Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. Journal of Allergy and Clinical Immunology1993;91(4):873-82. ">Kamada 1993</a>; <a href="./references#CD002997-bbs2-0015" title="PiacentiniGL , PeroniDG , BodiniA , PigozziR , CostellaS , LoiaconoA , et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy and Asthma Proceedings2007;28(2):194-8. ">Piacentini 2007</a>; <a href="./references#CD002997-bbs2-0018" title="StrunkRC , BacharierLB , PhillipsBR , SzeflerSJ , ZeigerRS , ChinchilliVM , et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. Journal of Allergy and Clinical Immunology2008;122(6):1138-44.e4. ">Strunk 2008</a>; <a href="./references#CD002997-bbs2-0020" title="Wan K-S, Liu Y-C, Huang C-S, Su Y-M. Effects of low-dose clarithromycin added to fluticasone on inflammatory markers and pulmonary function among children with asthma: a randomized clinical trial. Allergy and Rhinology2016;7(3):e131-4. ">Wan 2016</a>); unfortunately the great variability in the interventions, measurements and outcomes makes any firm conclusion on the role of macrolides in children impossible. <a href="./references#CD002997-bbs2-0010" title="KamadaAK , HillMR , IkléDN , BrennerAM , SzeflerSJ . Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. Journal of Allergy and Clinical Immunology1993;91(4):873-82. ">Kamada 1993</a> suggested a potential role for troleandomycin as steroid‐sparing agent, while <a href="./references#CD002997-bbs2-0018" title="StrunkRC , BacharierLB , PhillipsBR , SzeflerSJ , ZeigerRS , ChinchilliVM , et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. Journal of Allergy and Clinical Immunology2008;122(6):1138-44.e4. ">Strunk 2008</a> seemed instead to exclude any role of macrolides used in this way. </p> <p>Since the last version of this review, two RCTs were published (<a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a>; <a href="./references#CD002997-bbs2-0020" title="Wan K-S, Liu Y-C, Huang C-S, Su Y-M. Effects of low-dose clarithromycin added to fluticasone on inflammatory markers and pulmonary function among children with asthma: a randomized clinical trial. Allergy and Rhinology2016;7(3):e131-4. ">Wan 2016</a>). <a href="./references#CD002997-bbs2-0020" title="Wan K-S, Liu Y-C, Huang C-S, Su Y-M. Effects of low-dose clarithromycin added to fluticasone on inflammatory markers and pulmonary function among children with asthma: a randomized clinical trial. Allergy and Rhinology2016;7(3):e131-4. ">Wan 2016</a> explored the effect of macrolides versus placebo on lung function and eosinophil inflammation (measured as exhaled nitric oxide, peripheral blood eosinophil count and ECP). Unfortunately, the quality of reporting of this study did not allow us to include its results in any meta‐analysis. Nevertheless, the fact that <a href="./references#CD002997-bbs2-0020" title="Wan K-S, Liu Y-C, Huang C-S, Su Y-M. Effects of low-dose clarithromycin added to fluticasone on inflammatory markers and pulmonary function among children with asthma: a randomized clinical trial. Allergy and Rhinology2016;7(3):e131-4. ">Wan 2016</a> included only 58 participants mitigates the impact of the exclusion of its results on the overall conclusions of this review. In contrast, <a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a> was a very well‐designed and conducted study, with a large sample‐size of well‐selected participants, most of them on high‐dose ICS and long‐acting beta‐agonist (LABA)/long‐acting muscarinic antagonists (LAMA), falling in the category severe asthma of the current <a href="./references#CD002997-bbs2-0080" title="Global Initiative for Asthma. Global strategy for asthma management and prevention 2021. ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf (accessed prior to 14 November 2021.">GINA 2021</a> guidelines. A number of biological drugs such as mepolizumab, reslizumab, benralizumab (<a href="./references#CD002997-bbs2-0071" title="FarneHA , WilsonA , PowellC , BaxL , MilanSJ . Anti-IL5 therapies for asthma. Cochrane Database of Systematic Reviews2017, Issue 9. Art. No: CD010834. [DOI: 10.1002/14651858.CD010834.pub3]">Farne 2017</a>) and dupilumab (<a href="./references#CD002997-bbs2-0066" title="CastroM , CorrenJ , PavordID , MasperoJ , WenzelS , RabeKF , et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. New England Journal of Medicine2018;378(26):2486-96.">Castro 2018</a>; <a href="./references#CD002997-bbs2-0098" title="RabeKF , NairP , BrusselleG , MasperoJF , CastroM , SherL , et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. New England Journal of Medicine2018;378(26):2475-85.">Rabe 2018</a>) have entered the market since 2015 and, together with omalizumab (<a href="./references#CD002997-bbs2-0095" title="NormansellR , WalkerS , MilanSJ , WaltersEH , NairP . Omalizumab for asthma in adults and children. Cochrane Database of Systematic Reviews2014, Issue 1. Art. No: CD003559. [DOI: 10.1002/14651858.CD003559.pub4]">Normansell 2014</a>), are routinely used in clinical practice; their use is now recommended in severe eosinophilic asthma (<a href="./references#CD002997-bbs2-0080" title="Global Initiative for Asthma. Global strategy for asthma management and prevention 2021. ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf (accessed prior to 14 November 2021.">GINA 2021</a>). </p> <p>The results of <a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a> and of a subgroup analysis from the same study (<a href="./references#CD002997-bbs2-0073" title="GibsonPG , YangIA , UphamJW , ReynoldsPN , HodgeS , JamesAL , et al. Efficacy of azithromycin in severe asthma from the AMAZES randomised trial. ERJ Open Research2019;5:00056-2019. [DOI: 10.1183/23120541.00056-2019]">Gibson 2019</a>) may indicate that macrolides could be an alternative to biological drugs for severe forms of asthma: that would be valuable especially in low‐income countries, although the potential risk of resistance development would remain a serious caveat to their wide use. </p> <p>Despite all the limitations and considering the heterogeneity, our systematic review and meta‐analysis found no benefit of macrolides over placebo on lung function. As discussed, this does not rule out the possibility for significant benefit or harm of macrolides given the shortcomings of the evidence described above. The results of this review might change if further well‐designed and appropriately powered RCTs are conducted, but at present, the evidence is not promising enough to support further research for a general use of macrolides, while there is a suggestion that research targeted at specific phenotypes (i.e. severe or non‐eosinophilic (or both) asthma) may be warranted. </p> <p>Overall, the use of macrolides for at least four continuous weeks of treatment proved safe, with similar rates of severe adverse events when macrolides were compared with placebo. There were no reported deaths. Unfortunately, this outcome was not consistently reported across the studies, and internationally approved scales such as the Common Terminology Criteria for Adverse Events were not used (<a href="./references#CD002997-bbs2-0067" title="National Cancer Institute. Common Terminology Criteria for Adverse Events v.6. ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm (accessed prior to 14 November 2021).">CTCAE 2020</a>). Therefore, the evidence for this outcome was low. </p> <p>Antibiotic resistance is of increasing concern and only two included studies investigated this (<a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a>; <a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a>). <a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a> reported that 87% of azithromycin‐treated participants were colonised with erythromycin‐resistant streptococci, a statistically significant increase from baseline and in comparison with the placebo group, while <a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a> reported no significant change on the occurrence of resistant strains. </p> <p>These results suggest that spread of resistant strain is a real concern, and any further research should clearly measure and report resistance as an outcome. </p> <p>Alongside this, the case for macrolide therapy contributing to better outcomes in those testing positive for <i>C pneumoniae</i> or <i>M pneumoniae</i> infection was mostly unconvincing (<a href="./references#CD002997-bbs2-0002" title="BelotserkovskayaY , SinopalnikovA . Open-trial randomized comparative trial of the efficacy of the azithromycin in the 8 week treatment of mild to moderate asthma. European Respiratory Journal2007;30(Suppl 51):358s. ">Belotserkovskaya 2007</a>; <a href="./references#CD002997-bbs2-0003" title="BlackP , JenkinsCR , ScicchitanoR , BlasiF , AllegraL , MillsG , et al. Randomised, controlled trial of roxithromycin for the treatment of asthma in subjects with serological evidence of infection with Chlamydia pneumoniae. American Journal of Respiratory and Critical Care Medicine2001;164(4):536-41. ">Black 2001</a>; <a href="./references#CD002997-bbs2-0013" title="KraftM , CassellGH , PakJ , MartinRJ . Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest2002;121(6):1782-8. ">Kraft 2002</a>; <a href="./references#CD002997-bbs2-0018" title="StrunkRC , BacharierLB , PhillipsBR , SzeflerSJ , ZeigerRS , ChinchilliVM , et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. Journal of Allergy and Clinical Immunology2008;122(6):1138-44.e4. ">Strunk 2008</a>; <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a>; <a href="./references#CD002997-bbs2-0020" title="Wan K-S, Liu Y-C, Huang C-S, Su Y-M. Effects of low-dose clarithromycin added to fluticasone on inflammatory markers and pulmonary function among children with asthma: a randomized clinical trial. Allergy and Rhinology2016;7(3):e131-4. ">Wan 2016</a>). The number of participants testing positive was much lower than expected in several studies, and subgroup analyses were often underpowered or post hoc. </p> </section> <section id="CD002997-sec-0075"> <h3 class="title" id="CD002997-sec-0075">Quality of the evidence</h3> <p>The overall certainty of the evidence is low. We had serious concerns about selective or incomplete reporting, under‐reporting or variation of study results; there was uncertainty regarding allocation procedures and blinding of outcome assessment, and all but four trials recruited fewer than 100 people. </p> <p>Few studies reported clinical data well enough to be included in a meta‐analysis. Some studies reported outcomes of interest but not in a format that allowed the data to be combined with other studies, and other studies focused on non‐clinical outcomes when the use of macrolides was being tested to assess their mechanism of action and effect on biomarkers. Most outcomes were also downgraded for indirectness because some studies focused on specific populations, such as smokers or people with asthma of a particular severity, which varied across studies. Inconsistencies in the scales used or description of outcomes also made it difficult to meta‐analyse the data and reduced our confidence in the conclusions that could be drawn. Risk of bias was also an issue across most of the analyses, largely due to uncertainty as a result of insufficient reporting of methodology, but also as a result of failure to prevent or account for high or unbalanced dropout. </p> <p>Evidence for outcomes such as exacerbations requiring hospitalisation and serious adverse events was very imprecise due to the length of the studies and the rarity of this type of events, so it was difficult to reach meaningful conclusions for these outcomes. Several studies excluded people at higher risk of adverse events including prolonged corrected QT interval on electrocardiogram (<a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a>; <a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a>; <a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a>; <a href="./references#CD002997-bbs2-0008" title="HahnD , GrasmickM , HetzelS . Pragmatic controlled trial of azithromycin for asthma in adults. European Respiratory Journal2011;38:322s. HahnDL , GrasmickM , HetzelS , YaleS . Azithromycin for bronchial asthma in adults: an effectiveness trial. Journal of the American Board of Family Medicine2012;25(4):442-59. ">Hahn 2012</a>; <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a>; <a href="./references#CD002997-bbs2-0020" title="Wan K-S, Liu Y-C, Huang C-S, Su Y-M. Effects of low-dose clarithromycin added to fluticasone on inflammatory markers and pulmonary function among children with asthma: a randomized clinical trial. Allergy and Rhinology2016;7(3):e131-4. ">Wan 2016</a>), abnormal liver function tests (<a href="./references#CD002997-bbs2-0003" title="BlackP , JenkinsCR , ScicchitanoR , BlasiF , AllegraL , MillsG , et al. Randomised, controlled trial of roxithromycin for the treatment of asthma in subjects with serological evidence of infection with Chlamydia pneumoniae. American Journal of Respiratory and Critical Care Medicine2001;164(4):536-41. ">Black 2001</a>; <a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a>; <a href="./references#CD002997-bbs2-0008" title="HahnD , GrasmickM , HetzelS . Pragmatic controlled trial of azithromycin for asthma in adults. European Respiratory Journal2011;38:322s. HahnDL , GrasmickM , HetzelS , YaleS . Azithromycin for bronchial asthma in adults: an effectiveness trial. Journal of the American Board of Family Medicine2012;25(4):442-59. ">Hahn 2012</a>; <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a>), and hearing impairment (<a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a>); the effect of excluding these potential participants is uncertain. For other outcomes such as symptoms, quality of life and FEV<sub>1</sub>, the reporting made it difficult for us to assess the amount of variation in scales, properties, time of measurement, etc., and this uncertainty made the data difficult to interpret. </p> </section> <section id="CD002997-sec-0076"> <h3 class="title" id="CD002997-sec-0076">Potential biases in the review process</h3> <p>We did not contact most trial authors to obtain unpublished data or to clarify methodology. Only two of the studies were conducted in the last five years, and 14 were conducted over 10 years ago. We judged that the time taken to contact all authors and the anticipated low response rate due to study age would delay the publication of this update. </p> <p>We found six studies listed in an existing systematic review conducted in China that did not appear in our searches (<a href="./references#CD002997-bbs2-0103" title="TongX , GuoT , LiuS , PengS , YanS , YangX , et al. Macrolide antibiotics for treatment of asthma in adults: a meta-analysis of 18 randomized controlled clinical studies. Pulmonary Pharmacology and Therapeutics2015;31:99-108.">Tong 2015</a>). While we did not limit our searches by language, they did not cover studies that are indexed in non‐English language databases. Since the <a href="./references#CD002997-bbs2-0103" title="TongX , GuoT , LiuS , PengS , YanS , YangX , et al. Macrolide antibiotics for treatment of asthma in adults: a meta-analysis of 18 randomized controlled clinical studies. Pulmonary Pharmacology and Therapeutics2015;31:99-108.">Tong 2015</a> systematic review was published in English, we were able to contact the authors and extract sufficient information to confirm the eligibility of these trials. However, we did not have the resources to personally extract data or assess for risk of bias in these studies, and the information we were able to include were kindly provided by the authors of that systematic review and not directly from the studies themselves. The review authors were able to answer the questions we had about the studies and their outcomes, but these studies could not be assessed as rigorously as the other 19 included studies and we could not be certain that all data relevant to this review were included. </p> <p>The definitions of severe exacerbation, symptom scales and quality of life were not always consistent across studies. This required a significant post‐hoc assessment of which outcomes could be pooled. </p> <p>For peak flow and blood eosinophils, some of these studies could not be pooled with the others because they used a different unit of analysis. In these cases, we reported the results alongside the meta‐analysis results narratively. The main benefit of including these studies is the completeness of the evidence base, and checking study lists of existing meta‐analyses is part of the standard search procedures for Cochrane Reviews. Subtle differences in the methods between our own review and that of <a href="./references#CD002997-bbs2-0103" title="TongX , GuoT , LiuS , PengS , YanS , YangX , et al. Macrolide antibiotics for treatment of asthma in adults: a meta-analysis of 18 randomized controlled clinical studies. Pulmonary Pharmacology and Therapeutics2015;31:99-108.">Tong 2015</a> (e.g. the way data were extracted, application of trial eligibility criteria) may also have introduced a potential bias, meaning we cannot be sure that all studies relevant to our review were identified and analysed in the same way. We considered the overall benefit of inclusion to outweigh the potential biases in light of the help provided to us by Hon Fang and the other authors of that review (<a href="./references#CD002997-bbs2-0070" title="FanH . Macrolides for asthma [personal communication]. Email to: Kayleigh Kew 30 July 2015.">Fan 2015</a>). </p> </section> <section id="CD002997-sec-0077"> <h3 class="title" id="CD002997-sec-0077">Agreements and disagreements with other studies or reviews</h3> <p>Four other meta‐analyses have evaluated the treatment of asthma with long‐term macrolides (<a href="./references#CD002997-bbs2-0084" title="HilesSA , McDonaldVM , GuilherminoM , BruselleGG , GibsonPG . Does maintenance azithromycin reduce asthma exacerbations? An individual participant data meta-analysis. European Respiratory Journal2019;54(5):1901381. [DOI: 10.1183/13993003.01381-2019]">Hiles 2019</a>; <a href="./references#CD002997-bbs2-0099" title="ReiterJ , DemirelN , MendyA , GasanaJ , VieiraER , ColinAA , et al. Macrolides for the long-term management of asthma – a meta-analysis of randomized clinical trials. Allergy2013;68(8):1040-9.">Reiter 2013</a>; <a href="./references#CD002997-bbs2-0103" title="TongX , GuoT , LiuS , PengS , YanS , YangX , et al. Macrolide antibiotics for treatment of asthma in adults: a meta-analysis of 18 randomized controlled clinical studies. Pulmonary Pharmacology and Therapeutics2015;31:99-108.">Tong 2015</a>; <a href="./references#CD002997-bbs2-0104" title="WangX , LuoJ , WangD , LiuB , LiuC . The efficacy and safety of long-term add-on treatment of azithromycin in asthma: a systematic review and meta-analysis. Medicine2019;98(38):e17190.">Wang 2019</a>). There are noticeable differences across the systematic reviews and meta‐analyses in the conclusions drawn, and this is likely a reflection of the choice of outcomes and methods of analysis. In particular, we chose not to pool results where we were uncertain of scale or measurement similarity in order to make the results as clinically meaningful as possible. Furthermore, more subtle differences in the eligibility criteria and the way scores were aggregated are likely to have contributed to differences in the results and conclusions, such as using SMD or MD, fixed or random effects, change from baseline or endpoint scores, merging multiple relevant study arms, etc. These differences entail difficulties with meta‐analysing and interpreting the body of evidence, which is quite heterogeneous. </p> <p>The analysis by <a href="./references#CD002997-bbs2-0099" title="ReiterJ , DemirelN , MendyA , GasanaJ , VieiraER , ColinAA , et al. Macrolides for the long-term management of asthma – a meta-analysis of randomized clinical trials. Allergy2013;68(8):1040-9.">Reiter 2013</a> included 12 RCTs with a minimum treatment duration of three weeks, and reported a positive effect of macrolides on symptoms scores, quality of life, peak flow and bronchial hyperresponsiveness. <a href="./references#CD002997-bbs2-0103" title="TongX , GuoT , LiuS , PengS , YanS , YangX , et al. Macrolide antibiotics for treatment of asthma in adults: a meta-analysis of 18 randomized controlled clinical studies. Pulmonary Pharmacology and Therapeutics2015;31:99-108.">Tong 2015</a> included 18 studies, including the six Chinese studies that were not identified by our search, and it reported a positive effect on several measures of lung function (FEV<sub>1</sub>, PEF and forced vital capacity (FVC)) and airways hyperresponsiveness, but not on other measures of lung function (percentage predicted FEV<sub>1</sub> and percentage predicted FVC), symptoms, or quality of life. <a href="./references#CD002997-bbs2-0104" title="WangX , LuoJ , WangD , LiuB , LiuC . The efficacy and safety of long-term add-on treatment of azithromycin in asthma: a systematic review and meta-analysis. Medicine2019;98(38):e17190.">Wang 2019</a> explored only studies conducted with azithromycin and for at least three weeks of duration. This systematic review and meta‐analysis included eight RCTs, reporting a small but statistically significant increase in FEV<sub>1</sub>, but no change in exacerbation rate, quality of life measures, PEF or fractional exhaled nitric oxide (FeNO) in the treatment group compared to placebo. </p> <p><a href="./references#CD002997-bbs2-0084" title="HilesSA , McDonaldVM , GuilherminoM , BruselleGG , GibsonPG . Does maintenance azithromycin reduce asthma exacerbations? An individual participant data meta-analysis. European Respiratory Journal2019;54(5):1901381. [DOI: 10.1183/13993003.01381-2019]">Hiles 2019</a> performed an individual participant data meta‐analysis of three studies comparing azithromycin (treatment duration of at least eight weeks) versus placebo. The studies had to include data on exacerbations for a follow‐up of at least six months. Exacerbations were defined as need for at least three days of oral corticosteroids or antibiotic course, or visit to the ED, or admission to hospital. Most of the participants included in this meta‐analysis had severe asthma (320/529 participants, 60.5%). The meta‐analysis showed a reduction of exacerbations in this population, and in people an eosinophilic or non‐eosinophilic phenotype. Azithromycin did not have beneficial effects for secondary outcomes such as quality of life, lung function or biomarkers. </p> <p><a href="./references#CD002997-bbs2-0099" title="ReiterJ , DemirelN , MendyA , GasanaJ , VieiraER , ColinAA , et al. Macrolides for the long-term management of asthma – a meta-analysis of randomized clinical trials. Allergy2013;68(8):1040-9.">Reiter 2013</a> and <a href="./references#CD002997-bbs2-0103" title="TongX , GuoT , LiuS , PengS , YanS , YangX , et al. Macrolide antibiotics for treatment of asthma in adults: a meta-analysis of 18 randomized controlled clinical studies. Pulmonary Pharmacology and Therapeutics2015;31:99-108.">Tong 2015</a> did not formally assess exacerbations, either because they were not included as an outcome (<a href="./references#CD002997-bbs2-0103" title="TongX , GuoT , LiuS , PengS , YanS , YangX , et al. Macrolide antibiotics for treatment of asthma in adults: a meta-analysis of 18 randomized controlled clinical studies. Pulmonary Pharmacology and Therapeutics2015;31:99-108.">Tong 2015</a>) or because the data were considered insufficient to do so (<a href="./references#CD002997-bbs2-0099" title="ReiterJ , DemirelN , MendyA , GasanaJ , VieiraER , ColinAA , et al. Macrolides for the long-term management of asthma – a meta-analysis of randomized clinical trials. Allergy2013;68(8):1040-9.">Reiter 2013</a>). <a href="./references#CD002997-bbs2-0104" title="WangX , LuoJ , WangD , LiuB , LiuC . The efficacy and safety of long-term add-on treatment of azithromycin in asthma: a systematic review and meta-analysis. Medicine2019;98(38):e17190.">Wang 2019</a> explored the exacerbation frequency among the studies they included, but they did not report which definition they used for their analysis. Therefore, the results were difficult to contextualise. The results of <a href="./references#CD002997-bbs2-0084" title="HilesSA , McDonaldVM , GuilherminoM , BruselleGG , GibsonPG . Does maintenance azithromycin reduce asthma exacerbations? An individual participant data meta-analysis. European Respiratory Journal2019;54(5):1901381. [DOI: 10.1183/13993003.01381-2019]">Hiles 2019</a> were limited to people with severe asthma, and seem to confirm the findings of our systematic review and meta‐analysis for this specific group of patients. </p> <p>The lack of hospitalisation and exacerbation data is a major shortcoming of the evidence base, considering that reducing the frequency of these events is the main premise of long‐term macrolides treatment. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002997-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD002997-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/full#CD002997-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002997-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/full#CD002997-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD002997-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/full#CD002997-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.1 Exacerbation requiring hospitalisation." data-id="CD002997-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.1 Exacerbation requiring hospitalisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/full#CD002997-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.2 Severe exacerbations: exacerbations requiring emergency department visits/systemic steroids." data-id="CD002997-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.2 Severe exacerbations: exacerbations requiring emergency department visits/systemic steroids. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/full#CD002997-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.3 Symptom scales." data-id="CD002997-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.3 Symptom scales.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/full#CD002997-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.4 Asthma Control." data-id="CD002997-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.4 Asthma Control.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/full#CD002997-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.5 Asthma Quality of Life Questionnaire (AQLQ)." data-id="CD002997-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.5 Asthma Quality of Life Questionnaire (AQLQ). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/full#CD002997-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-FIG-09" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.6 Rescue medication puffs/day." data-id="CD002997-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-FIG-09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.6 Rescue medication puffs/day. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/full#CD002997-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-FIG-10" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.7 Morning PEF (L/minute)." data-id="CD002997-fig-0010" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-FIG-10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.7 Morning PEF (L/minute).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/full#CD002997-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-FIG-11" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.8 Evening PEF (L/minute)." data-id="CD002997-fig-0011" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-FIG-11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.8 Evening PEF (L/minute).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/full#CD002997-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-FIG-12" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.9 FEV1 (L)." data-id="CD002997-fig-0012" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-FIG-12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.9 FEV<sub>1</sub> (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/full#CD002997-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-FIG-13" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.11 Oral corticosteroid dose." data-id="CD002997-fig-0013" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-FIG-13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 13</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.11 Oral corticosteroid dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/full#CD002997-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-FIG-14" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.12 Serious adverse events (including mortality)." data-id="CD002997-fig-0014" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-FIG-14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 14</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Macrolide versus placebo, outcome: 1.12 Serious adverse events (including mortality). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/full#CD002997-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-FIG-14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Macrolide versus placebo, Outcome 1: Exacerbation requiring hospitalisation" data-id="CD002997-fig-0015" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Macrolide versus placebo, Outcome 1: Exacerbation requiring hospitalisation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/references#CD002997-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Macrolide versus placebo, Outcome 2: Severe exacerbations: exacerbations requiring emergency department visits/systemic steroids" data-id="CD002997-fig-0016" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Macrolide versus placebo, Outcome 2: Severe exacerbations: exacerbations requiring emergency department visits/systemic steroids </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/references#CD002997-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Macrolide versus placebo, Outcome 3: Asthma symptom scales" data-id="CD002997-fig-0017" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Macrolide versus placebo, Outcome 3: Asthma symptom scales</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/references#CD002997-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Macrolide versus placebo, Outcome 4: Asthma control" data-id="CD002997-fig-0018" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Macrolide versus placebo, Outcome 4: Asthma control</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/references#CD002997-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Macrolide versus placebo, Outcome 5: Asthma Quality of Life Questionnaire (AQLQ)" data-id="CD002997-fig-0019" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Macrolide versus placebo, Outcome 5: Asthma Quality of Life Questionnaire (AQLQ) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/references#CD002997-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Macrolide versus placebo, Outcome 6: Need for rescue medication puffs/day" data-id="CD002997-fig-0020" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Macrolide versus placebo, Outcome 6: Need for rescue medication puffs/day</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/references#CD002997-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Macrolide versus placebo, Outcome 7: Morning PEF (L/minute)" data-id="CD002997-fig-0021" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Macrolide versus placebo, Outcome 7: Morning PEF (L/minute)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/references#CD002997-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Macrolide versus placebo, Outcome 8: Evening PEF (L/minute)" data-id="CD002997-fig-0022" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Macrolide versus placebo, Outcome 8: Evening PEF (L/minute)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/references#CD002997-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Macrolide versus placebo, Outcome 9: Forced expiratory volume in 1 second (FEV 1; L)" data-id="CD002997-fig-0023" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Macrolide versus placebo, Outcome 9: Forced expiratory volume in 1 second (FEV <sub>1</sub>; L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/references#CD002997-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0024"> <p> <div class="table" id="CD002997-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Bronchial hyperresponsiveness (BHR)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Measure of BHR (units)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Conclusions</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Amayasu 2000</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methacholine challenge test (log PC<sub>20</sub>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clarithromycin: 2.96, standard deviation (SD) 0.57</p> <p>Placebo: 2.60, SD 0.51 (P &lt; 0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clarithromycin significantly reduced BHR in people with allergic intermittent asthma.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Cameron 2013</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methacholine challenge test (log PC<sub>20</sub>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin: 0.20, SD 1.52</p> <p>Placebo: 0.19, SD 1.29 (P &lt; 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No effect of azithromycin in smokers with persistent asthma.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Kamada 1993</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methacholine challenge test (PC<sub>20</sub>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/19 participants completed the test at the beginning and end of the analysis. Data were reported graphically and not included in the main analysis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference at the end of the treatment was recorded among the 3 arms of the study. </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Kostadima 2004</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methacholine challenge test (PC<sub>20</sub>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median before and after the treatment:</p> <p>Clarithromycin 250 mg twice daily: 0.3 mg (interquartile range (IQR) 0.1 to 1) and 1.3 mg (IQR 0.6 to 2) mg (P &lt; 0.001) </p> <p>Clarithromycin 250 mg 3 times daily: 0.4 mg (IQR 0.1 to 0.9) and 2.0 mg (IQR 2.0 to 2.0) (P &lt; 0.001) </p> <p>Placebo: 0.4 mg (IQR 0.1 to 0.9) and 0.3 mg (IQR 0.1 to 0.6) mg (P not significant)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Compared to the baseline, there was a significant increase in the median PC<sub>20</sub> in the 2 macrolide groups but not in the placebo group. </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Nelson 1993</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methacholine challenge test (PC<sub>20</sub>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/27 participants in placebo group and 13/30 participants in troleandomycin group completed the test at the start and end of the study. </p> <p>Troleandomycin: +1.89 mg/mL</p> <p>Placebo: +0.55 mg/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant effect of troleandomycin was recorded in comparisons within and between the study groups. </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Piacentini 2007</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertonic saline challenge (dose–response slope)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin: 2.75, SD 2.12 to 1.42, SD 1.54 (P &lt; 0.02)</p> <p>Placebo: 1.48, SD 1.75 to 1.01, SD 1.38 (P = 0.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The reduction of BHR in the treatment group was driven by the change from the baseline in 3/9 participants. No significant difference observed in a comparison between the groups. Study in children. </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Shoji 1999</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sulpyrine inhalation testing (log PC<sub>20</sub>‐sulpyrine) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Roxithromycin: 1.18, SD 0.40</p> <p>Placebo: 1.15, SD 0.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant improvement of BHR recorded within and between group comparisons.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Simpson 2008</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertonic saline challenge (dose–response slope; DSR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DSR before: 1.8 (IQR 0.6 to 6.4) and after clarithromycin: 1 (IQR 0.5 to 4.2)</p> <p>DSR before: 1 (IQR 0.6 to 3.2) and after placebo: 1 (IQR 0.5 to 3.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant improvement of BHR within and between group comparisons.</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sutherland 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methacholine challenge test (PC<sub>20</sub> doubling dose) </p> <p>Analysis stratified for polymerase chain reaction (PCR) positivity for <i>M pneumoniae</i> or <i>C pneumonia</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Difference between clarithromycin and placebo groups:</p> <p>Irrespective of PCR status: +1.2, SD 0.5 (P = 0.01)</p> <p>In participants with positive PCR status: +0.9, SD 1.8 (P = 0.6)</p> <p>In participants with negative PCR status: +1.2, SD 0.5 (P = 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BHR was significantly improved by clarithromycin compared to placebo in the whole population and in the PCR‐negative groups, but not among the PCR‐positive participants. </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Macrolide versus placebo, Outcome 10: Bronchial hyperresponsiveness (BHR) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/references#CD002997-fig-0024">Navigate to figure in review</a></div> </div> <div class="figure" id="CD002997-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Macrolide versus placebo, Outcome 11: Oral corticosteroid dose" data-id="CD002997-fig-0025" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Macrolide versus placebo, Outcome 11: Oral corticosteroid dose</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/references#CD002997-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Macrolide versus placebo, Outcome 12: Serious adverse events (including mortality)" data-id="CD002997-fig-0026" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Macrolide versus placebo, Outcome 12: Serious adverse events (including mortality) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/references#CD002997-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Macrolide versus placebo, Outcome 13: Withdrawal" data-id="CD002997-fig-0027" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Macrolide versus placebo, Outcome 13: Withdrawal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/references#CD002997-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Macrolide versus placebo, Outcome 14: Blood eosinophils" data-id="CD002997-fig-0028" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Macrolide versus placebo, Outcome 14: Blood eosinophils</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/references#CD002997-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Macrolide versus placebo, Outcome 15: Sputum eosinophils" data-id="CD002997-fig-0029" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Macrolide versus placebo, Outcome 15: Sputum eosinophils</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/references#CD002997-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Macrolide versus placebo, Outcome 16: Eosinophil cationic protein (ECP) in serum" data-id="CD002997-fig-0030" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Macrolide versus placebo, Outcome 16: Eosinophil cationic protein (ECP) in serum </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/references#CD002997-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Macrolide versus placebo, Outcome 17: ECP in sputum" data-id="CD002997-fig-0031" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Macrolide versus placebo, Outcome 17: ECP in sputum</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/references#CD002997-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analysis, Outcome 1: Severe exacerbations: exacerbations requiring emergency department visits/systemic steroids" data-id="CD002997-fig-0032" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analysis, Outcome 1: Severe exacerbations: exacerbations requiring emergency department visits/systemic steroids </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/references#CD002997-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analysis, Outcome 2: Symptom scales" data-id="CD002997-fig-0033" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analysis, Outcome 2: Symptom scales</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/references#CD002997-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analysis, Outcome 3: Asthma control" data-id="CD002997-fig-0034" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analysis, Outcome 3: Asthma control</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/references#CD002997-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analysis, Outcome 4: Asthma Quality of Life Questionnaire (AQLQ)" data-id="CD002997-fig-0035" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analysis, Outcome 4: Asthma Quality of Life Questionnaire (AQLQ) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/references#CD002997-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002997-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/urn:x-wiley:14651858:media:CD002997:CD002997-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analysis, Outcome 5: Forced expiratory volume in 1 second (FEV 1; L)" data-id="CD002997-fig-0036" src="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_t/tCD002997-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analysis, Outcome 5: Forced expiratory volume in 1 second (FEV <sub>1</sub>; L) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/references#CD002997-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/media/CDSR/CD002997/image_n/nCD002997-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD002997-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Macrolides compared to placebo for chronic asthma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Macrolide versus placebo for chronic asthma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with chronic asthma<br/><b>Settings:</b> outpatient<br/><b>Intervention:</b> macrolide </p> <p>Drugs used were clarithromycin, azithromycin, roxithromycin and troleandomycin. Macrolide was given once or twice daily in most studies for 4–52 weeks (median 8 weeks).<br/><b>Comparison:</b> placebo </p> <p>Treatment durations were calculated as weighted means of the studies included in each analysis. </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes<sup>a</sup> </b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed comparator risk**</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Macrolide</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbation requiring hospitalisation</b> </p> <p>Weighted mean study duration: 45 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> <p>(13 to 68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.47</b> </p> <p>(0.20 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>529</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe exacerbations (requiring ED visits or systemic steroids, or both)</b> </p> <p>Number of people having ≥ 1 exacerbations requiring an ED visit or systemic steroids, or both. </p> <p>Classification varied across studies.</p> <p>Weighted mean study duration: 35 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>410 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>311 per 1000<br/>(269 to 357) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rate ratio 0.65</b><br/>(0.53 to 0.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>640<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma symptoms – symptom scales (various scales; lower score = better)</b> </p> <p>Weighted mean study duration: 10 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean change in symptom scales in the intervention group compared to the control group was a reduction; <b>0.46 SD lower</b> (0.81 SD lower to 0.11 SD lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>e,f,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The SMD is a Cohen's effect size and can be interpreted as moderate (&lt; 0.4 = small, 0.40–0.70 = moderate, &gt; 0.70 = large). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma control (Asthma Control Questionnaire)</b> </p> <p>Scored 0–6 (lower scores indicate improvement in asthma control)</p> <p>Weighted mean study duration: 34 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean change in asthma control in the intervention group compared to the mean change in control group was a greater reduction;<b>0.17 SD lower</b> (0.31 SD lower to 0.03 SD lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>773<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>d,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The SMD is a Cohen's effect size and can be interpreted as small.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma quality of life (AQLQ)</b> </p> <p>Scored 1–7 (higher scores indicate improvement in quality of life)</p> <p>Weighted mean study duration: 35 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change on the AQLQ scale in the control group was an increase from baseline; <b>0.31 points higher</b>** </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in AQLQ in the intervention group compared to the mean change in the control group was an increase; <b>0.24 points higher</b> (0.12 higher to 0.35 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>802<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>c,d,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID: 0.5 points</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rescue medication (puffs/day)</b> </p> <p>Weighted mean study duration: 17 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean rescue medication use in the control group was <b>1.08</b> puffs/day** </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in rescue medication puffs/day in the intervention group compared to the mean change in the control group was reduction; <b>0.43 fewer puffs</b> (0.81 fewer to 0.04 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>314<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>d,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (L)</b> </p> <p>Weighted mean study duration: 28 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean FEV<sub>1</sub> in the control group was <b>2.49</b> L** </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> (L) the intervention group compared to the control group was an increase; <b>0.04 L higher</b> (0 L to 0.08 L higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1046<br/>(10 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>h,i,j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Although there is no universally accepted MCID for FEV<sub>1</sub> in asthma, variability within a single testing session can be up to 0.12 L (data from a mixed pool of respiratory patients; <a href="./references#CD002997-bbs2-0068" title="EnrightPL , BeckKC , SherrillDL . Repeatability of spirometry in 18,000 adult patients. American Journal of Respiratory and Critical Care Medicine2004;169:235-8. [DOI: 10.1164/rccm.200204-347OC]">Enright 2004</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>(including mortality)</p> <p>Weighted mean study duration: 16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>93 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 1000<br/>(50 to 118) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.80</b><br/>(0.49 to 1.31) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>854<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>i,k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>**Assumed risk for continuous outcomes were calculated as weighted means of the scores in the control group. Note: <a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a> could not be included in the rescue medication or quality of life calculations because they reported only mean difference between groups; <a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a> was not included in the FEV<sub>1</sub> calculation because it was the only change score; <a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a> was not included in the asthma control or quality of life calculations because it was the only study reporting absolute endpoint scores rather than change from baseline. </p> <p><b>AQLQ:</b> Asthma Quality of Life Questionnaire; <b>CI:</b> confidence interval; <b>ED:</b> emergency department; <b>FEV<sub>1</sub>:</b> forced expiratory volume in one second; <b>MCID:</b> minimal clinically important difference; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>SD:</b> standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE domains: study limitations, consistency of effect, imprecision, indirectness and publication bias. GRADE Working Group grades of evidence (<a href="./references#CD002997-bbs2-0101" title="Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). In: Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Schünemann 2021</a>).<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Two primary outcomes (morning and evening peak expiratory flow) are not presented. Bronchial hyperresponsiveness could not be pooled in a meta‐analysis and is described narratively in the review. Studies did not report lowest tolerated oral corticosteroid dose well and there were no data to analyse.<br/><sup>b</sup>Downgraded one level for indirectness due to differences in the recruited populations and in the criteria used to define 'severe exacerbations'.<br/><sup>c</sup>Downgraded one level for imprecision as among the included studies, one reported an important benefit of macrolide and another possible benefit of placebo.<br/><sup>d</sup>Downgraded one level due to uncertainties with randomisation procedures and high risk of attrition bias in some studies included in the analysis.<br/><sup>e</sup>Downgraded one level for inconsistency due to high heterogeneity (I<sup>2</sup> = 70%) mainly due to one cross‐over study.<br/><sup>f</sup>Downgraded one level for indirectness. Symptom scales were often invalidated and highly variable across studies, and we chose not to pool most in a meta‐analysis using standard mean differences, as this would lead to a result that would have been much more difficult to interpret.<br/><sup>g</sup>Downgraded one level for imprecision due to small number of participants in the analysis; it was difficult to judge precision due to different scales.<br/><sup>h</sup>Downgraded one level for indirectness as studies in the analysis recruited different populations with regard to severity of asthma, and one study only recruited smokers.<br/><sup>i</sup>Downgraded one level for risk of bias as four studies that we were unable to properly assess for risk of bias were included in this analysis, and we were uncertain of how and when the measurement was taken in some cases.<br/><sup>j</sup>No change in grade: there was uncertainty in several domains across studies, but the two studies carrying most of the weight were well conducted.<br/><sup>k</sup>Downgraded one level for imprecision; eight studies reported the outcomes, but only four studies observed events, leading to very wide confidence intervals that included important benefit and harm of macrolide treatment. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Macrolides compared to placebo for chronic asthma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/full#CD002997-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002997-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary characteristics of included studies at baseline</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Design</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Duration (weeks)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Macrolide dose and schedule</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean age (years)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>% Male</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>% on ICS</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>% Predicted FEV<sub>1</sub> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0001" title="AmayasuH , YashidaS , EbanaS , YamamotoY , NishikawaT , ShojiT , et al. Clarithromycin suppress bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Annals of Allergy, Asthma and Immunology2000;84(6):594-8. ">Amayasu 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan and USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clarithromycin 200 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0002" title="BelotserkovskayaY , SinopalnikovA . Open-trial randomized comparative trial of the efficacy of the azithromycin in the 8 week treatment of mild to moderate asthma. European Respiratory Journal2007;30(Suppl 51):358s. ">Belotserkovskaya 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Russia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin (unknown dose)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0003" title="BlackP , JenkinsCR , ScicchitanoR , BlasiF , AllegraL , MillsG , et al. Randomised, controlled trial of roxithromycin for the treatment of asthma in subjects with serological evidence of infection with Chlamydia pneumoniae. American Journal of Respiratory and Critical Care Medicine2001;164(4):536-41. ">Black 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multinational</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roxithromycin 150 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0004" title="BrusselleGG , VandersticheleC , JordensP , DemanR , SlabbynckH , RingoetV , et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax2013;68(4):322-9. ">Brusselle 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Belgium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin 250 mg once daily for 5 days then 3 times per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.0 (median)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0005" title="CameronEJ , ChaudhuriR , MairF , McSharryC , GreenlawN , WeirCJ , et al. Randomised controlled trial of azithromycin in smokers with asthma. European Respiratory Journal2013;42(5):1412-5. ">Cameron 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin 250 mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0006" title="ACTRN12609000197235. The AMAZES study: Asthma and macrolides: the Azithromycin Efficacy and Safety Study [A large-scale, multicentre, double-blind, placebo controlled randomised trial to compare the efficacy (and safety) of the addition of oral low dose azithromycin for 48 weeks with fixed dose maintenance therapy on the incidence of asthma exacerbations and clinical asthma status in people with persistent asthma]. ictrptest.azurewebsites.net/Trial2.aspx?TrialID=ACTRN12609000197235 (first received 20 April 2009). GibsonPG , YangIA , UphamJW , ReynoldsPN , HidgeS , JamesAL , et al. Azithromycin reduces exacerbations in adults with persistent symptomatic eosinophilic asthma. American Journal of Respiratory and Critical Care Medicine2017;195:A4679. GibsonPG , YangIA , UphamPN , HodgeS , JamesAL , JenkinsC , et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet2017;390(10095):659-68. ">Gibson 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin 500 mg 3 times per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0007" title="HahnDL , PlaneMB , MahdiOS , ByrneGI . Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clinical Trials2006;1(2):e11. ">Hahn 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA, Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin 600 mg once daily for 3 days then weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0008" title="HahnD , GrasmickM , HetzelS . Pragmatic controlled trial of azithromycin for asthma in adults. European Respiratory Journal2011;38:322s. HahnDL , GrasmickM , HetzelS , YaleS . Azithromycin for bronchial asthma in adults: an effectiveness trial. Journal of the American Board of Family Medicine2012;25(4):442-59. ">Hahn 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin 600 mg once daily for 3 days then weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0009" title="HeJ , ZhuN , ChenXD . Clinical impacts of azithromycin on lung function and cytokines for asthmatic patients. Fudan University Journal of Medical Science2009;36(6):719-22. ">He 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin 250 mg twice weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0010" title="KamadaAK , HillMR , IkléDN , BrennerAM , SzeflerSJ . Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. Journal of Allergy and Clinical Immunology1993;91(4):873-82. ">Kamada 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Troleandomycin 250 µg once daily + OCS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0011" title="KapoorS , BrashierB , UdupaA , PawarR , KodguleR , LimayeS , et al. Therapeutic effect of low dose roxithromycin in chronic stable mild-to-moderate asthma. European Respiratory Journal2010;36(suppl 54):P1176. ">Kapoor 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roxithromycin 150 mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0012" title="KostadimaE , TsiodrasS , AlexopoulosEI , KaditisAG , MavrouI , GeorgatouN , et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. European Respiratory Journal2004;23(5):714-7. ">Kostadima 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Greece</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clarithromycin 250 mg twice daily or 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0013" title="KraftM , CassellGH , PakJ , MartinRJ . Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest2002;121(6):1782-8. ">Kraft 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clarithromycin 500 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0014" title="NelsonHS , HamilosDL , CorselloPR , LevesqueNV , BuchmeierAD , BuckerBL . A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. American Review of Respiratory Disease1993;147(2):398-404. ">Nelson 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Troleandomycin 250 mg once daily + OCS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0015" title="PiacentiniGL , PeroniDG , BodiniA , PigozziR , CostellaS , LoiaconoA , et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy and Asthma Proceedings2007;28(2):194-8. ">Piacentini 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin 10 mg/kg once daily 3 days per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0016" title="ShojiT , YoshidaS , SakamotoH , HasegawaH , NakagawaH , AmayasuH . Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clinical and Experimental Allergy1999;29(7):950-6. ">Shoji 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roxithromycin 150 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0017" title="SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Respirology2007;12:A120. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Anti-inflammatory effects of clarithromycin in refractory non-eosinophilic asthma. Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25-28; Auckland:Abstract TO13. SimpsonJL , PowellH , BoyleMJ , ScottRJ , GibsonPG . Clarithromycin targets neutrophilic airway inflammation in refractory asthma. American Journal of Respiratory and Critical Care Medicine2008;177(2):148-55. ">Simpson 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clarithromycin 500 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0018" title="StrunkRC , BacharierLB , PhillipsBR , SzeflerSJ , ZeigerRS , ChinchilliVM , et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. Journal of Allergy and Clinical Immunology2008;122(6):1138-44.e4. ">Strunk 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin 250 mg or 500 mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0019" title="SutherlandER , KingTS , IcitovicN , AmeredesBT , BleeckerE , BousheyHA , et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology2010;126(4):747-53. ">Sutherland 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, DB, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clarithromycin 500 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0020" title="Wan K-S, Liu Y-C, Huang C-S, Su Y-M. Effects of low-dose clarithromycin added to fluticasone on inflammatory markers and pulmonary function among children with asthma: a randomized clinical trial. Allergy and Rhinology2016;7(3):e131-4. ">Wan 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Taiwan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clarithromycin 5 mg/kg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0021" title="WangY , ZhangSL , QuY . Effect of clarithromycin on non-eosinophilic refractory asthma [克拉霉素治疗非嗜酸粒细胞型难治性哮喘的疗效分析]. Journal of Clinical Pulmonary Medicine2012;17(11):1948-51. ">Wang 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clarithromycin 500 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0022" title="WangT , PeiFY , SongXP , WangQ . Clinical impacts of low-dose azithromycin on lung function and fraction of exhaled nitric oxide concentration in bronchial asthma [小剂量阿奇霉素对支气管哮喘患者呼出气NO浓度及肺功能的影响]. Medical Innovation China2014;11(9):122-4. ">Wang 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin 250 mg twice weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0023" title="XiaoKA . The study on effect of roxithromycin combined with budesonide in therapy in patients with asthma. Guide of Chinese Medicine2013;11:119-20. ">Xiao 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roxithromycin 150 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0024" title="YanXQ , WuLQ , LinJ , XiaoXD , DaiYR . Clinical study on efficacy of roxithromycin combined with inhaled budesonide dry powder inhalation on asthma [罗红霉素与布地奈德干粉吸入剂联用治疗哮喘的临床研究]. Chinese Journal of Pharmacology and Therapeutics2008;13(2):184-7. ">Yan 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roxithromycin 150 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002997-bbs2-0025" title="ZhangLY , QianQ . Clinical effect of azithromycin combined with Seretide for asthma. Strait Pharmaceutical Journal2013;25:159-60. ">Zhang 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P, R, PC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin 100 mg once daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><b>C</b> : cross‐over; <b>DB</b> : double‐blind; <b>FEV<sub>1</sub> </b> : forced expiratory volume in one second; <b>ICS</b> : inhaled corticosteroid; <b>NR</b> : not reported; <b>OCS</b> : oral corticosteroids; <b>P</b> : parallel; <b>PC</b> : placebo‐controlled; <b>R</b>: randomised. </p> <p><sup>a</sup>All participants were taking long‐acting beta<sub>2</sub>‐agonist + ICS combination.<br/><sup>b</sup>82.2% were taking long‐acting beta<sub>2</sub>‐agonist + ICS combination.<br/><sup>c</sup>19 participants were not included in the review because they were randomised to a third group who received montelukast. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary characteristics of included studies at baseline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/full#CD002997-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002997-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Macrolide versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Exacerbation requiring hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.20, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Severe exacerbations: exacerbations requiring emergency department visits/systemic steroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.53, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Asthma symptom scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐0.81, ‐0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Asthma control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>773</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.31, ‐0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Asthma Quality of Life Questionnaire (AQLQ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>802</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.12, 0.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Need for rescue medication puffs/day <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.43 [‐0.81, ‐0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Morning PEF (L/minute) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [‐10.35, 13.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Evening PEF (L/minute) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [‐13.65, 15.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Forced expiratory volume in 1 second (FEV <sub>1</sub>; L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1046</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.00, 0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Bronchial hyperresponsiveness (BHR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Oral corticosteroid dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Serious adverse events (including mortality) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>854</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.49, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.76, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Blood eosinophils <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐32.16 [‐34.77, ‐29.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Sputum eosinophils <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Eosinophil cationic protein (ECP) in serum <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.07 [‐14.90, ‐9.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 ECP in sputum <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.35 [‐1.69, ‐1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Macrolide versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/references#CD002997-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002997-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Sensitivity analysis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Severe exacerbations: exacerbations requiring emergency department visits/systemic steroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.48, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Symptom scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.58 [‐1.27, 0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Asthma control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>773</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.33, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Asthma Quality of Life Questionnaire (AQLQ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>802</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.06, 0.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Forced expiratory volume in 1 second (FEV <sub>1</sub>; L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐0.01, 0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Sensitivity analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002997.pub5/references#CD002997-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002997.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD002997-note-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD002997-note-0014">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002997-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD002997-note-0013">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD002997-note-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD002997-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD002997-note-0012">Polski</a> </li> <li class="section-language"> <a class="" href="th#CD002997-note-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD002997-note-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD002997-note-0007">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002997\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002997\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002997\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002997\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002997\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002997\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002997\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002997\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002997\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002997\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002997\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002997\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002997\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002997\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002997\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002997\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002997\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002997\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IYhCEbRn&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002997.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002997.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002997.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002997.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002997.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715115644"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002997.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715115648"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002997.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d7f393d0e1bde',t:'MTc0MDcxNTExNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 